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ABSTRACT 
The use of minocycline for the treatment of a broad range of systemic infections and for severe acne has 
been associated with vestibular side effects. The severity of side effects may lead to poor adherence to 
therapy by patients. The use of sustained release formulations of minocycline that display slow 
dissolution of minocycline following administration may be beneficial in reducing the incidence and 
severity of side effects. Therefore, sustained release capsule dosage forms containing 100 mg 
minocycline (base) were manufactured and assessed for use as sustained release oral dosage forms of 
minocycline. 
\ 
Minocycline sustained release capsules were manufactured based on matrix technologies using 
hydroxypropylmethyl cellulose (HPMC) and Compritol® as release retarding polymers. The rate and 
extent of minocycline release from the capsules was evaluated using USP Apparatus 1 and samples were 
analysed using a validated High Performance Liquid Chromatographic (HPLC) method with ultraviolet 
(UV) detection. 
Differences in the rate and extent of minocycline release from formulations manufactured using HPMC 
or Compritol® were influenced by the concentration of polymer used in the formulations. The rate and 
extent of minocycline release was faster and greater when low concentrations of polymer were used in 
formulations. 
The effect of different excipients on the release pattern(s) of minocycline and particularly their potential 
to optimise minocycline release from experimental formulations was investigated. The use of diluents 
such as lactose and microcrystalline cellulose (MCC) revealed that lactose facilitated minocycline release 
when HPMC was used as the polymer matrix. In contrast, the use of lactose as diluent resulted in slower 
release of minocycline from Compritol® based formulations. 
The addition of sodium starch glycolate to HPMC based formulations resulted in slower release of 
minocycline than when no sodium starch glycolate was used. Compritol® based formulations were 
observed to release minocycline faster following addition of sodium starch glycolate and Poloxamer 188 
to experimental formulations. 
In vitro dissolution profiles were compared to a target or reference profile using the difference and 
similarity factors, f1 and {2 , and a one way analysis of variance (ANOVA). In addition, the mechanism of 
minocycline release was elucidated following fitting of dissolution data to the Korsmeyer-Peppas, 
Higuchi and Zero order models. 
Minocycline release kinetics were best described by the Korsmeyer-Peppas model and the values of the 
release exponent, n, revealed that drug release was a result of the combined effects of minocycline 
diffusion through matrices and erosion of the matrices. These in vitro dissolution profiles were better fit 
to the Higuchi model than to the Zero order model. 
Two formulations that displayed a fit to the Zero order model were identified for further studies as 
potential dosage forms for sustained release minocycline. 
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STUDY OBJECTIVES 
Minocycline, a second generation tetracycline antibiotic is prescribed for a broad range of systemic 
infections [1]. In addition, minocycline is used for the management and treatment of severe acne that is 
unresponsive to treatment with other tetracycline antibiotics [ 1]. Chronic use of minocycline is associated 
with vestibular side effects, the severity of which may cause patients to default on treatment [2-4]. The 
incidence and severity of side effects bas been shown to be greater when dissolution of m.inocycline 
following administration is rapid [5]. The vestibular side effects associated with rapid dissolution of the 
API may be reduced by the administration of a sustained release formulation, thereby potentially 
promoting adherence to therapy by the patient. 
The objectives of this study were: 
1. To develop and validate a stability-indicating, simple, sensitive and selective High Performance 
Liquid Chromatographic (HPLC) method with the necessary accuracy and precision for the 
quantitation of minocycline in aqueous solutions and in pharmaceutical dosage forms. 
2. To investigate the use of hydrophilic and lipophilic polymers for the development of minocycline 
(100 mg base) sustained release dosage forms that released at least 80% according to a zero order 
kinetic model for 12 hours. 
3. To assess and evaluate the rate and extent of minocycline release from the formulations using an 
appropriate dissolution method. 
4. To study the dissolution kinetics and release mechanisms of minocycline from manufactured 
capsule dosage forms. 
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CHAPTER ONE 
1 MINOCYCLINE HYDROCHLORIDE 
1.1 INTRODUCTION 
Minocycline is a second generation semi-synthetic tetracycline antibiotic [6,7). Although not the first to 
be discovered, tetracycline is the generic structure for nomenclature purposes in the entire tetracycline 
family [8]. Tetracycline, originally known as terramycin, was named due to the presence of the linearly 
arranged naphthacene ring system that forms the basic chemical and structural makeup of tetracycline 
antibiotics depicted in Figure 1.1 [6]. Structurally, minocycline possesses the perhydronaphthacene 
skeleton characteristic of all tetracyclines but lacks the 6-methyl and 6-hydroxyl substituents and 
possesses a ?-dimethyl substituent as indicted in Figure 1.1 [8]. As a consequence of this difference in 
chemical structure, minocycline has a broader spectrum of activity and better tissue penetration 
characteristics when compared to other tetracycline molecules and which is more than likely due to the 
fact that the lipophilicity of minocycline in the physiological pH range is much more pronounced than 
with other tetracycline analogues [3]. 
N(CH3)2 
OH 
OH 
Tetracycline Minocycline 
Figure 1.1. Chemical structure of tetracycline and minocycline 
Following the discovery and isolation of chlortetracycline, the first tetracycline, from cultures of 
Streptomyces aureofaciens by scientists at Lederle in the late 1940s, and subsequent development of the 
first generation tetracyclines, researchers undertook studies with blocked mutant strains of Streptomyces 
which led to the discovery of demeclocycline in 1956 [6]. Although not chemically useful due to its 
potential to precipitate phototoxic episodes, demeclocyline became an important starting material for the 
manipulation of the tetracycline molecule using semi-synthetic teclmiques resulting in modification at the 
C-6 and C-7 positions leading to the discovery of minocycline by chemists at Cyanamid [6]. 
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Minocycline has similar indications to those of other tetracycline antibiotics, which include the treatment 
of rickettsial, chlamydia! and vibrio infections, brucellosis, chronic bronchitis, acne and mycoplasma and 
spirochaetal infections [9]. Minocycline is administered via the oral or parenteral routes and is usually 
used as the hydrochloride salt. 
1.2 PHYSICO-CHEMICAL PROPERTIES 
1.2.1 Description 
Minocycline hydrochloride is chemically known as 4, 7-bis (dimethlyamino) 1, 4-4a, 5, Sa, 6, 11, 12a-
octahydro-3, 10, 12, -12a-tetrahydroxy-1, 11-dioxo-2-napthacenecarboxamide monohydrochloride and 
by the trivial name 7-dimethylamino-6-demethyl-deoxytetracycline hydrochloride [1 0]. The chemical 
structure ofminocycline hydrochloride is depicted in Figure 1.2. 
CONH 2 
OH 
.HCI 
Figure 1.2. Minocycline hydrochloride [IOJ 
Minocycline hydrochloride occurs as a yellow crystalline powder that is slightly hygroscopic [ 11]. One 
milligram (1 mg) of minocycline hydrochloride contains not less than 890 J.tg and not more than 950 J.tg 
ofminocycline calculated on an anhydrous basis [12]. 
1.2.2 Solubility 
Minocycline hydrochloride is sparingly soluble in water, slightly soluble in alcohol and soluble in 
solutions of alkali hydroxides and carbonates [ 11 ]. It is practically insoluble in chloroform and ether [ 13]. 
A list of the solubilities of minocycline hydrochloride dihydrate in a variety of solvents is shown in Table 
1.1 [10]. 
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Table 1.1. Solubility of minocycline hydrochloride dihydrate in various solvents at 25°C 
Solvent Solubility Solubility 
mg/ml o/ow/v 
Hexane 0.004 0.0004 
Benzene 0.02 0.002 
Chloroform 0.13 0.013 
Ethyl acetate 0.3 0.03 
Methyl ethyl ketone 0.4 0.04 
1-0ctanol 0.5 0.05 
Acetone 0.6 0.06 
Dioxane 0.7 0.07 
!-Butanol 4.4 0.44 
2-Propanol 7 0.7 
Methanol 14 1.4 
Water 16 1.6 
Absolute Ethanol 42 4.2 
1.2.3 Dissociation constant (pKa) 
The apparent dissociation constants of tetracycline antibiotics are quite similar within the class [ 14]. The 
three functional groups associated with each of the reported dissociation constants of tetracycline 
antibiotics and the respective dissociation constants of tetracycline, the parent compound for tetracycline 
antibiotics are depicted in Figure 1.3 [ 15]. 
pKa =3.3 
pKa = 7.7 
Figure 1.3. Dissociation constants of tetracycline 
Minocycline has a second dimethy1amino group located at position C-7 of the tetracycline backbone 
resulting in minocycline having four ionisable groups as depicted in Table 1.2 [16] and an isoelectric 
point of 6.4 [ 17]. 
3 
Chapter 1, Minocycline hydrochloride 
Table 1.2. Dissociation constants of minocycline 
Ionisable groups 
Amine groups 
Hydroxyl groups 
1.2.4 Partition coefficient 
Dissociation constants 
5 and 9.5 
2.8 and 7.8 
The partition coefficient of a compound is a measure of the extent to which that compound is distributed 
between water and a water-immiscible liquid phase as determined by their relative concentrations (weight 
per unit volume) in each of the phases [18]. The partition coefficient is frequently determined in binary 
systems of octanol and water and is expressed as a coefficient (P) or as its logarithim, log P [18]. 
Partition coefficients have been extensively used to infer a correlation of the relative lipophilic 
characteristics of a molecule with its biological properties within a set of congeners [19]. Partition 
coefficient measurements are important for predicting membrane transfer properties, protein binding, 
receptor affinity and pharmacological activity of molecules [ 18]. In drug design and formulation, 
partition coefficient measurements may be used to predict dissolution and partitioning rate of drugs and 
for establishing structure-activity parameters that are involved in the hydrophobic bonding ability of a 
drug [19]. 
Colaizzi and Klink [15] studied the pH-partitioning behaviour of tetracyclines in octanoll buffer system. 
The results of these studies indicated that the zwitterionic form of tetracycline molecules are the most 
lipophilic form of the molecule. Furthermore, the zwitterionic form was found to be present in the highest 
concentration in solutions of between pH 4 and pH 7. The partition coefficients of minocycline observed 
in these studies are summarised in Table 1.3. 
Table 1.3. Apparent Partition coefficients (OctanoU Buffer) of minocycline hydrochloride 
pH 2.1 3.9 5.6 6.6 8.5 
Partition coefficient 0 0.051 1.11 1.48 0.36 
1.2.5 pH of solution 
A 1% (w/v) solution ofminocycline hydrochloride in water has a pH of between 3.5 and 4.5 [20]. 
1.2.6 Melting range 
Differential thermal analysis studies have shown that minocycline hydrochloride exhibits one melting 
and/or decomposition endotherm at 217°C [10]. 
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1.2.7 Infra-red absorption spectrum 
Infrared spectroscopy is a relatively simple, fast and reliable method for assigning a substance to a 
particular class of compounds [21]. Many functional groups in organic compounds exhibit molecular 
vibrations which correspond to absorption bands in defined regions of the infrared spectrum [21]. The 
infrared spectrum of minocycline hydrochloride (Lederle House Standard No. 7 516B-172) in the range of 
4000-700 cm·1 was determined by the K.Br method using a Perkin-Elmer 21 Instrument [10]. The infrared 
spectrum of minocycline and the relevant band assignments are shown below in Figure 1.4 and Table 1.4, 
respectively. 
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Figure 1.4. Infrared spectrum ofMinocycline HC1.2H20 in KBr Pellet 
Table 1.4. Characteristic band assignment of Minocycline HCI.2H20 infrared spectrum 
Wavelength (11) Assignment 
NH2 stretching of2-carboxamido and 12-hydroxy 
1' 
"'50 
2.9 
>2.9-5 Hydrogen bonded phenolic and enolic hydroxyl groups and hydrogen 
atom on protonated dimethylamino group 
6.07 
6.25 
7.7 
8.2 
Carbonyl of 2-carboxamido group 
Conjugated hydrogen bonded ketones and conjugated double bond 
systems 
Hydrogen bonded phenolic and enolic hydroxyl groups and 2-
carboxamindo 
Relatively unbonded phenolic hydroxy groups 
1.2.8 Ultra-violet absorption spectrum 
The use of ultraviolet/visible (UV/ Vis) spectroscopy is valuable for qualitative and quantitative analysis, 
photometric titration, determination of equilibrium and dissociation constants in addition to trace analysis 
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of compounds [21]. Furthermore the usc of UV detection in High Performance Liquid Chromatography 
(HPLC) is well known [21]. In the absence of physico-chemical factors such as for example solubility of 
the compound, the UV absorbance of a substance is proportional to the path length through which the 
radiation passes and the concentration of the substance in solution [22]. 
The ultraviolet absorption spectra of minocycline hydrochloride in solution in methanol, mobile phase 
(methanol: acetonitrile:0.08 M phosphate buffer pH 7.0, 13:17:70v/v/v) and water at a concentration of 
20 !J.g/ml are shown in Figures 1.5, 1.6 and 1.7, respectively. The spectra were generated using a double 
beam Model GBC 916 UV VIS spectrophotometer (GBC Scientific Equipment Pty Ltd, Melbourne, 
Victoria, Australia). The resultant spectra reveal a peak at 253.6nm (methanol), and two peaks at 244.8 
nm and 273.6 nm (mobile phase). The spectrum obtained from water revealed three peaks at wavelengths 
of221.6 run, 248.8 nm and 273.6 nm. 
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Figure 1.5. The ultraviolet spectrum of minocycline hydrochloride in methanol 
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1.2.9 Nuclear magnetic resonance spectrum 
Nuclei such as protons possess a permanent magnetic moment which when placed in an external 
magnetic field takes on well-defined orientations which correspond to distinct energy levels determined 
with respect to direction of the applied magnetic field [22]. A proton magnetic resonance spectrum is 
used to characterise the behaviour of protons with respect to their nuclear and electronic environment 
within a molecule [22]. A chemical (o) shift, expressed in parts per million (ppm), results when there is 
difference between a given sample and reference standard [22]. As a consequence of the magnetic field 
emanating from an adjacent nucleus, signals are frequently split into groups of related peaks that are 
referred to as doublets, triplets or multiplets [22]. 
The proton magnetic resonance spectrum of minocycline hydrochloride in hexadeuterodimethylsulfoxide 
with tetramethyl silane as the internal standard with the corresponding proton assignments observed are 
depicted in Figurel.8 and Table1.5, respectively [10]. 
-. 
Figure 1.8. Proton magnetic resonance spectrum of minocycline HC1.2H20 
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Table 1.5. Proton magnetic resonance spectral assignments of minocycline Hydrochloride 
Proton site 
N(CH3)2 (at C4) 
N(CH3)2 (at C7) 
c4 
Cs 
c9 
CO(NH2) 
Cw-OH 
1.3 SYNTHESIS 
Chemical shifts (ppm) 
2.60 
2.94 
4.34 
7.41 
6.83 
9.05; 9.53 
11.30 
· 1.3.1 Synthetic procedure/pathway 
Multiplicity 
singlet 
singlet 
singlet 
doublet 
doublet 
2 broad singlets 
Minocycline was originally synthetically produced by chemical modification of demeclocycline [6]. Due 
to an increased potential for phototoxicity, demeclocycline has restricted clinical use but was considered 
an important starting material for the manufacture of semi-synthetic derivatives of tetracycline [6]. 
The synthesis of minocycline from demeclocycline (I) is comprised of four main steps and is illustrated 
in Figure 1.9. Initially following catalytic reduction, the acid labile 6-hydroxy group is removed to form 
6a-deoxy-6-demethyl tetracycline, also known as sancycline (II) [6]. The acid stable sancycline is reacted 
with nitration reagents under strong acidic conditions to allow aromatic substitution at positions C-7 and 
C-9 on the D-ring yielding the 7 -nitro (III) and 9-nitro derivatives of sancycline [6]. Hydrogenation of the 
nitro groups yields the 7 -amino (IV) and 9-amino compounds, after which reductive alkylation of the C-7 
amino derivative using formaldehyde in the presence of catalysts yields 7-dimethylamino-6-demethyl-6-
deoxytetracycline, minocycline (V) [6]. 
9 
Cl OH 
CON~ catalytic reduction 
OH 0 
H CON~ 
h~rogenation H 
IV l reductive alkylation/ 
formaldeh~e,catalyst 
N(Cii3)2 N(Ct-1:3}2 
: OH 
H CON~ 
v 
Figure 1.9. Original synthesis of minocycline 
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N(Ct-1:3}2 
OH 
CON~ 
OH 
II 
NG-.1 
t nitration/acid 
N(CH3}2 
OH · 0 OH 
Ill 
KEY 
I demeclocycline 
II sancycline 
Ill ?-nitro sancycline 
IV?-amino sancycline 
V minocycline 
OH 
CON~ 
It is clear that the synthesis of minocycline using the procedure depicted in Figure 1.9 is likely to yield 
both the 7-nitro and 9-nitro tetracycline derivatives, thereby posing challenges. Consequently it is 
necessary to separate the ?-substituted and 9-substituted derivatives to provide an appropriate reactant for 
the synthesis of minocycline. In order for electrophilic substitution to occur in such a way to exclusively 
form the 7-nitro derivative, position 9 must be sterically protected in some way [23]. Bernardi et al. [23] 
reported that 9-alkyl derivatives of 6-demethyl-6-deoxytetracycline, which could revert back to the non-
substituted 6-demethyly-6-deoxytetracycline, could be formed by reacting 6-demethyl-6-
deoxytetracycline with alkylating agents in the presence of a strong acid. By reacting the resulting 9-alkyl 
derivative obtained with anhydrous hydrofluoric acid, methanesulfonic acid or boiling trifluoric acid, the 
non-substituted 6-demethly-6-deoxytetracycline could be regenerated. Bernardi et al. used the above 
concept to synthesise minocycline as summarized in Figure 1.1 0. 
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N(CH:Jf2 
OH 
CON~ 
OH 0 
N0.1 
~ OH 
Ill 
N(CH:Jf2 
dealkylation 
alkylation 
.. 
... 
catalytic 
reduction 
N(C~l-2 
ft OH 
II 
IV 
N(C~)2 
OH 
CON~ 
OH 0 
v ~ 
KEY 
I 6-demethyl-6-deoxytetracycline 
II 9-tert-butyt-6-demethyl-6-deoxytetracycline 
Ill 9-tert-butyt-7-nitro-6-demethyl-6-deoxytetracycline 
IV 7 -am ino-9-tert-butyt-6-dem ethyl-6-deoxytetracycline 
V 9-tert-butyt-7 -d im ethyl am ino-6-dem ethy-6-deoxytetracycline 
~ 7 -dim ethylam ino-6-demethyl-6-deoxytetracycline/m inocycline 
Figure 1.1 0. Stereo-specific synthesis of minocycline 
nitra tion 
reductive 
methylation 
Additional methods for synthesizing minocycline involve the reductive dimethylamination of 7-nitro-6-
demethy-6-deoxytetracycline, 7-[ I ,2-bis( carbobenzyloxy) hydrazino ]-6-demethyl-6-deoxytetracycline or 
7-(4-sulfophenylazo) -6-demethyl-6-deoxytetracycline with formaldehyde [24]. Using any of the 
aforementioned methods, minocycline is isolated from the reaction liquid containing formaldehyde by 
using either dilution or extraction. Both methods involve the use of large volumes of organic solvents 
and often leave residual formaldehyde, which has the potential to form unwanted by-products, 
particularly in aqueous media [24]. Hasegawa eta!. [24] have described a process for synthesising high 
purity minocycline and with a higher yield and less residual formaldehyde after reductive methylation of 
7-amino-6-methyl-6-deoxytetracycline. This process uses a reaction liquid containing minocycline and 
II 
Chapter 1, Minocycline hydrochloride 
formaldehyde that is treated with hydroxylamine or urea and subsequently subjected to an adsorption 
process using non-ionic adsorptive resins onto which minocycline is preferentially adsorbed. 
1.3.2 Structure activity relationship 
All tetracycline antibiotics share the perhydronaphthacene skeleton as depicted in Figure 1.11 [8]. 
Tetracycline is denoted the parent compound for nomenclature purposes [8]. 6-demethyl-6-deoxy-4-
dedimethylaminotetracycline is the simplest known tetracycline that displays some anti bacterial activity, 
although only against Gram-positive bacteria in vitro [8]. A basic functional group at the C-4 position is 
essential to ensure in vivo activity of tetracylines, thus making 6-demethyl-6-deoxytetracycline the 
simplest tetracycline compound to display broad-spectrum activity both in vitro and in vivo [8]. In order 
to ensure broad-spectrum activity, tetracycline antibiotics must contain the two UV -absorbing 
chromophoric groups i.e. the A-ring and BCD-ring systems. Modification (breaking, aromatization, 
extension, blockage) of these components of the structure results in the formation of compounds that lack 
activity or compounds that display weak antibacterial activity and through a mode of action different to 
that of other tetracycline derivatives [8]. 
Figure 1.11. Stereochemistry of tetracyclines (tetracycline) 
Neither the 6-methyl nor the 6-hydroxy substituent is essential for antibacterial activity [8] and 
minocycline lacks both these substituents. The presence of the 6-hydroxy substituent renders 
tetracyclines acid labile and modification of the molecule at the C-6 position may yield 6-
deoxytetracycline derivatives that are acid stable and which have facilitated substitution at the C-7 and/or 
C-9 positions [8) . Substitution with electron withdrawing groups at the C-7 position has also been shown 
to enhance in vitro activity [8). Minocycline possesses a 7-dimethylamino substituent which is protonated 
and therefore electron withdrawing near the surface of bacteria thereby enhancing the in vitro activity of 
the compound [8). 
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With the increase of bacterial resistance to tetracycline antibiotics, so the development of newer semi-
synthetic tetracyclines that exhibit a broader spectrum of activity has commenced [25]. Sum et al. [25] 
synthesised and studied 9-substituted minocycline derivatives for possible enhanced microbial activity. 
Substitution with a tert-butyl-glycylamido side chain at the C-9 position of minocyline, has yielded 
tigecycline the first antibiotic of the glycylcycline class [26]. 
1.4 STABILITY 
1.4.1 Temperature 
Minocycline is stable in the dry-powder state for a three to four year period when stored at 25 oc [10]. 
Solutions of minocycline, as solutions of other tetracyclines, are not stable enough to permit the 
preparation of pre-constituted aqueous solutions as feasible practical dosage forms [ 1 0]. In a study 
conducted to determine the stability of minocycline hydrochloride and rifampicin in intravenous 
solutions, minocycline was found to be stable in both 5% dextrose and 0.9% sodium chloride with its 
initial concentration declining by 8% at 24°C and by 2% at 4°C over a period of seven days [27). 
1.4.2 pH 
The stability of minocycline in solution is affected by pH, with solutions stored at pH 4.2 and 5.2 
maintaining at least 90% of their initial potency following a week of storage at 25 °C. The stability of 
minocycline in solution of different pH is depicted in Figure 1.12 [ 1 0]. 
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Figure 1.12. Stability data for minocycline solutions(% Initial activity retained) 
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1.4.3 Oxidative degradation 
Minocycline is more susceptible to oxidative degradation when compared to other tetracycline antibiotics 
as the D-ring of minocycline contains a substituted p-amino-phenol [10]. Minocycline has been 
associated with cases of pigmentation of the thyroid in patients with a history of chronic minocycline use 
[28]. The pigmentation is thought to be as a result of the oxidation of minocycline by the enzyme thyroid 
peroxidase which is required for thyroid hormone synthesis [28]. Although minocycline-induced thyroid 
hyper-pigmentation has been reported as a rare and harmless side effect, a significant number of patients 
reported to have this side effect have been found to exhibit signs of thyroid cancer [28]. 
1.4.4 Structural rearrangement of tetracycline antibiotics 
Tetracycline antibiotics readily undergo 4-epimerization and the rate of epimerization differs from 
analogue to analogue [10]. The tricarbonyl system of ring A of the tetracycline antibiotics allows 
enolization involving loss of the C-4 hydrogen [29]. Reprotonation of the molecule may occur from the 
top of the enol, regenerating the tetracycline. However reprotonation may also occur from the bottom of 
the molecule resulting in the formation of an inactive 4-epitetracycline as depicted in Figure 1.13 [29]. 
Several methods that have been used to reduce the epimerization of the tetracycline antibiotics have been 
reported [30]. These methods include forming calcium, magnesium or aluminium salts with tetracyclines 
to limit epimer formation when manufacturing is performed at basic pH in non-aqueous solutions. 
Formation of metal complexes under acidic conditions results in the subsequent preparation of a stable 
solid form of the drug. Maintenance of pH at values greater than 6. 0 during processing, avoiding contact 
with conjugates of weak acids, avoiding contact of the reactants with moisture and aqueous based 
solutions and working at low temperatures reduces epimer formation in tetracyclines. 
Base H' 
Base 
Tetracycline 4-Epitetracycline 
Figure 1.13. Epimerization of tetracycline antibiotics 
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1.5 CLINICAL PHARMACOLOGY 
1.5.1 Mode of action 
Minocycline exhibits a similar mode of action as other tetracycline analogues [2] but has proved to have 
a broader spectrum of activity against both aerobic and anaerobic bacteria due to enhanced tissue 
penetration activity as compared to other tetracycline derivatives [3]. 
Tetracyclines are bacteriostatic antibiotic compounds [31] and their anti-microbial activity 1s a 
consequence of bacterial protein biosynthesis inhibition [2] . Tetracycline compounds bind to the 30s 
ribosomal subunit [2] thereby preventing aminoacyl-tRNA binding to the acceptor site of the mRNA-
ribosome complex [32]. This mechanism by which the inhibition of protein synthesis occurs is similar for 
human and bacterial cells; however, bacteria have an energy-dependant active transport process that 
moves tetracyclines against a concentration gradient to produce appreciable intracellular concentrations 
[32,33]. The active transport process confers selectivity to bacterial cells on tetracycline antibiotics [33]. 
Tetracyclines have however, been found to have the potential to interfere with protein synthesis in 
mammalian cells which in tum may impair wound healing or produce catabolism in patients with renal 
failure [31]. 
1.5.2 Spectrum of activity 
Tetracyclines, including minocycline, display their antimicrobial action on Gram-negative bacteria, 
Gram-positive bacteria, anaerobes, intracellular bacteria such as Rickettsiae, Chlamydiae and 
Mycoplasma and on some protozoa [3, 31 ,32,34,]. Tetracyclines exert their antimicrobial effects on 
Gram-negative bacteria including; Escherichia coli, Enterobacter, Klebsiella [2,3,31 ], Hemophilus 
influenza [2,31], Gonococcus, Proteus mirabilis, Meningococcus [31], Vibrio and Campylobacterfetus [2]. 
Minocycline has been found to be effective on some Gram-negative bacteria resistant to other 
tetracyclines. Using disc sensitivity criteria, it was found that 32% of Serratia resistant to other 
tetracyclines was sensitive to minocycline [3). In a study conducted on strains of Neisseria gonorrhoea 
sensitive to penicillin or ampicillin it was determined that minocycline was the most sensitive of the 
tetracyclines with 80% of theN. gonorrhoea inhibited when using concentrations of less than 0.4 11glml 
[2]. At concentrations of less than 2 llg/ml, minocycline was found to completely inhibit Pseudomonas 
non-aeruginosa species in susceptibility tests of these species to aminoglycosides and tetracycline 
antibiotics [2]. Of the tetracycline analogues, minocycline was shown to have the highest activity against 
strains of Legionella with a reported minimum inhibitory concentration (MIC) of 0.25 11g/ml [2]. 
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Minocycline shows activity towards some Gram-positive strains that are resistant to methicillin and other 
tetracycline compounds [35]. Whilst other tetracycline analogues have been shown to inhibit only 50% of 
penicillin-sensitive and penicillin-resistant Staphylococcus aureus, minocycline has been shown to inhibit 
90% of these in vitro [31]. Minocycline was found to exert greater activity against tetracycline-resistant 
strains of Streptococcus pneumoniae [2]. Although there is increasing resistance to tetracycline, studies 
have shown minocycline activity against beta-hemolytic streptococci (Group A, B, C, G) and Clostridium 
perfringes [31]. 
1.5.3 Indications 
Minocycline is categorised as a systemic antibacterial and antiprotozoal as well as a systemic agent for 
the treatment of acne [1]. Tetracyclines (including minocycline) are used in the treatment of rickettsial, 
chlamydia! and vibrio infections, brucellosis, chronic bronchitis and acne [9,36}. Tetracyclines are also 
primarily used to treat urinary tract infections, shigellosis and Lyme disease [36]. 
Minocycline has been specifically indicated for the treatment of severe acne and may be of use in forms 
of acne that are resistant to other tetracycline derivatives [ 1]. Systemic minocycline is indicated for the 
treatment of mycobacterial infections and nocardiosis [ I] . Minocycline is effective in the eradication of 
the asymptomatic carrier state of meningococcal infectious disease in the nasopharynx [I ,3 6]. 
Minocycline may be used as an adjunct for the treatment of amoebic dysentery and periodontitis [37]. 
Minocycline may be used in cases of penicillin allergy to treat bacterial infectious disease, Treponema 
pertenue, Listeria monocytogenes, Fusobacterium fusiforme, Actinomyces israelii and Clostridium 
species [37}. Minocycline may be used as a substitute for the treatment of anthrax when penicillin is 
contraindicated [37}. 
1.5.4 Role of minocycline in neurology 
Animal studies have revealed that minocycline may be effective in alleviating and treating a number of 
neurological disorders [38]. Neurodegenerative diseases exhibit common symptoms that include 
apoptotic cell death and production of neurotoxins by the persistent activation of microglia [38]. 
Experimental neurology has established that minocycline 1mpa1rs microglial activation, 
neuroinflammation and apoptosis [38]. An open label blind study for acute stroke, significantly lowered 
NIH Stroke Scale and modified Rankin Scale, and increased Barthel Index in patients, indicating the 
potential benefit of minocycline in the treatment of acute ischacmic stroke [39]. Minocycline is currently 
used in combination with other conventional therapy for the treatment of multiple sclerosis [39]. Phase II 
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clinical trials in which minocycline in combination with creatine was administered to treat Parkinson's 
disease have demonstrated the absence of significant safety concerns and currently phase IIII pilot studies 
to examine the efficacy of this combination in patients with acute spinal cord injury are underway [39). 
1.5.5 Resistance 
Bacterial resistance to clinically used tetracyclines occurs due to acquired resistance of the organism by 
acquisition of resistant genes [ 40]. Chopra et al. [7] have reported that twenty nine tetracycline resistant 
(tel) and three oxytetracycline resistance (otr) genes have been characterised and details are summarized 
in Table 1.6. The two main biochemical mechanisms by which resistance to tetracyclines can occur are as 
a result of the presence of an efflux system that actively exports tetracyclines from bacterial cells and the 
presence of ribosomal proteins that protect bacterial ribosomes from the effect of tetracyclines [7 ,40]. A 
less important mechanism of resistance to tetracyclines includes enzymatic inactivation of tetracyclines 
rendering them ineffective against the bacteria being treated [7,40]. Efflux genes which are found in both 
Gram-positive and Gram-negative bacteria confer resistance to tetracycline but not to minocycline and 
the glycylcyclines [7]. In contrast, ribosomal protection proteins, which confer a wider spectn1m of 
resistance to tetracyclines except for tel (B), protect the ribosomes from the action of tetracycline as well 
as that of doxycycline and minocycline [7]. 
Table 1.6. Mechanisms of resistance for characterised tet and otr genes (7) 
Mechanism of resistance 
Efflux 
Ribosomal protection 
Enzymatic 
Unknown 
Genes 
tet (A), tet (B), tel (C), tel (D), tet (E), tet (G), tel (H), 
tet (I), tet (J), tet (Z), tet (30), tet (3! ), tel (K), tel (L), 
otr (B), tcr3 , tel P(A), tet (V), tet (Y) 
tet (M), tet (0), tet (S), tel (W), tet (Q), tet (T), tel 
P(B), otr (A) 
tet (X) 
tet (U),otr (C) 
In a study aimed to unravel the genetic basis of resistance in the potentially probiotic strain of 
Lactobacillus plantarum it was revealed that L. Plantarum possessed the let (S) gene that conferred 
resistance to both tetracycline and minocycline with observed MIC values of 512 J.Lg/ml and 256 J.Lg/ml 
for tetracycline and minocycline, respectively [ 41]. The presence of tet(M), tet(O) and tet(S) resistance 
genes, that encoded for both tetracycline and minocycline resistance in Sterptococcus pyogenes, the most 
common cause ofbacterial pharyngitis, has also been reported [42]. 
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The inhibition of R-factor resistant Escherichia coli by tetracyclines, reveal that lipophi lie analogues are 
generally more active against tetracycline-resistant Gram-negative bacteria [ 43]. In a study on 
tetracycline susceptible and resistant Escherichia coli, it was reported that although minocycline and 
tetracycline were exported by the same active efflux system in resistant cells, minocycline entered 
resistant host cells largely via this system 10-20 times more rapidly than tetracycline with the net efflux 
of minocycline being low which may partly be the reason for tetracycline-resistant cells being more 
susceptible to minocycline [ 43]. 
1.5.6 Contraindications 
Minocycline is contraindicated in patients with hypersensitivity to minocycline, other tetracyclines or any 
component of a formulation containing minocycline [44]. The use of minocycline is not recommended 
for patients with renal insufficiency related to hepatotoxicity [ 44]. Concomitant use of minocycline with 
isotretinoin is not recommended as there is an increased risk ofpseudotumor cerebri [37]. 
1.5. 7 Drug interactions 
Minocycline may augment the effects of warfarin [44]. The effect of minocycline is decreased by 
concomitant use with aluminium, calcium, zinc or magnesium antacids, bismuth salts, sodium 
bicarbonate, barbiturates, carbamazepine and hydantoins [44]. The concomitant use of dong quai and St 
John's Wort with minocycline is not recommended as photosensitization reactions may be precipitated 
[44]. 
1.5.8 Adverse reactions 
Reported adverse reactions to minocycline are similar to those displayed by other tetracycline antibiotics 
(9]. The common side-effects of tetracycline antibiotics are usually dose-related and include 
gastrointestinal disturbances such as nausea, vomiting, anorexia and an "unpleasant taste" [31]. 
Tetracyclines may also alter the density of normal microbial flora causing candiadiasis and enterocolitis 
[31]. Tetracycline therapy may also cause phototoxicity and tooth mottling (31]. 
Minocycline and methacycline have been shown to have the least phototoxic reactivity of the tetracycline 
group of antibiotics [3]. However minocycline has been associated with a blue-grey pigmentation of the 
:;kin and pigmentation of acne scars (9]. Minocycline has also been associated with a greyish-brown 
jiscolouration in areas of the skin exposed to the sun that may be due to melanin deposition [20]. Skin 
jiscolouration due to minocycline use resolves slowly after discontinuation of minocycline [20]. 
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Minocycline may precipitate vestibular toxicity in the form of nausea, vomiting, vertigo and ataxia [3 ,31] 
which is more than likely a consequence of its relatively high lipophilicity and which enhances its CNS 
penetration capacity (2]. In a study conducted by Jacobson et al. [4] 86% of subjects treated with 
minocycline experienced vestibular toxicity with 84% displaying toxicity after one or two doses of 100 
mg and 52% of the subjects stopped treatment due to the severity of these effects. A review of30 clinical 
trials in which minocycline was administered for a period of at least 3 days at standard doses to 
ambulatory patients revealed that the frequency of vestibular toxicity was no more than 20% and could 
be severe enough to cause alteration of treatment in one third of the patients or one in fifteen patients 
receiving the drug [3]. Vestibular toxicity symptoms usually occur when maximal serum concentrations 
have been reached and are resolved 48 hours following withdrawal or discontinuation of minocycline [2]. 
1.5.9 High risk groups 
Minocycline is classified as a Category D risk factor in pregnancy. Animal studies have indicated that 
there is a possibility of human foetal risk if the drug is used during pregnancy [ 44]. The use of 
minocycline is not recommended during the second half of a pregnancy since it causes permanent tooth 
discolouration in the foetus (37]. High doses of minocycline may result in fatty infiltration of maternal 
liver [9]. Minocycline is not recommended in lactating mothers as it is excreted in breast milk [9,44]. 
There is evidence to suggest that minocycline may alter milk production and/or composition [37]. Unless 
other drugs are contraindicated or lack effectiveness, minocycline should not be used in children under 
the age of eight years of age, as it may be deposited in growing bones thereby causing growth retardation 
or in teeth causing permanent discolouration [9]. Tetracycline may also cause enamel hypoplasia if used 
in children during the process of tooth development [9]. Hepatotoxicity and the anabolic effects of the 
tetracyclines is likely to occur in elderly or frail patients (9]. 
1.6 PHARMACOKINETICS 
1.6.1 Dosage 
Minocycline can be administered to children over eight years of age at an initial dose of 4mg (base)/ kg 
of body weight and then 2 mg/kg 12 hourly for at least 7 days [9]. Children weighing over 50 kg are 
dosed as recommended for adults [9]. When treating infections in adults, minocycline is administered at 
an initial dose of 200 mg (base), then 100 mg every 12 hours [9,44,45]. For the treatment of acne a 100-
200 mg dose of minocycline is given initially with 50 mg doses used as maintenance doses daily [9]. A 
dose of 100 mg every 12 hours for at least 4 days is the recommended dose for treatment for gonorrhoea, 
and for carriers of Neisseria meningitides a 5 day course is recommended whereas 6 to 8 weeks of 
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therapy is required for treating Mycobacterium marium infections [1). In uncomplicated urethral, 
endocervical or rectal infections caused by Chlamydia trachomatis, 100 mg doses are given twice daily 
for at least 7 days [ 1). The maximum amount of minocycline given on a daily basis should not exceed 
400 mg/24 hr [44). 
1.6.2 Absorption 
The absorption of minocycline from the gastrointestinal tract (GIT) is rapid and virtually complete 
following oral administration [2). An oral dose of 200 mg followed by 100 mg doses every twelve hours 
is reported to produce plasma concentrations of between 2 and 4 ~-tg/ml [20). The absorption of 
minocycline is not significantly affected if administered with food or moderate amounts of milk [20]. In a 
study conducted by Leyden [ 46] to determine the effect of milk, food and iron on the absorption of 
minocycline and tetracycline, it was observed that although the absorption of minocycline was less 
affected by concurrent administration with food and milk, there was 27% inhibition of minocycline 
absorption with milk and 13% inhibition of minocycline absorption with food. The absorption of 
minocycline and tetracycline was significantly decreased following administration with iron with 77% 
inhibition of minocycline and 81% inhibition of tetracycline absorption. 
1.6.3 Distribution 
Minocycline is widely distributed in body tissues and fluids due to its high lipid solubility relative to 
other tetracycline derivatives [20). In a pharrnacokinetic study on minocycline in man, peak serum 
concentrations after a single oral dose of minocycline were achieved more rapidly than with doxycycline, 
methacycline and demethylchlortetracycline with the absorption half-time of minocycline determined to 
be less than one hour and approximately 95% of the maximum serum concentration being attained by the 
first sampling time of one hour [ 4 7]. The penetration of mioocycline into the cerebrospinal fluid is better 
than that observed for doxycycline [47}. Minocycline is approximately 75% bound to plasma proteins 
[20]. A decrease in tissue binding may result in an increase in tissue distribution of the drug. When used 
in patients with renal failure there is an apparent trend towards increased tissue distribution of 
minocycline [50). 
1.6.4 Metabolism 
Minocycline has been demonstrated to be the first tetracycline antibiotic to undergo metabolism in man 
and this is most likely due to its lipophilicity and the presence of an additional dimethylamino group, 
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which might specifically be affected by metabolising enzymes and systems [ 48]. Three major metabolites 
of minocycline have been isolated, namely: 9-hydroxyminocycline, a hydroxylation product, N7-
demethylminocycline and N4-demethylminocycline [51]. The metabolic products of minocycline are 
depicted in Figure 1.14. The relatively low recovery (30.9%) of microbiologically active minocycline at 
the end of a 72-96 hour interval following a single oral dose indicates that minocycline is partially 
metabolised to inactive substances [ 49]. 
X 
9-Hydroxyminocycline 
N7-Demethylminocycline 
N4-Demethylminocycline 
X 
OH 
H 
H 
Figure 1.14. Degradation products of minocycline 
1.6.5 Elimination 
OH 
CONH2 
y z 
The plasma half-life of minocycline has been reported to be between 11- 26 hours (20]. Approximately 5-
10% of administered minocycline is excreted unchanged in the urine [9,20). Following oral 
administration the renal clearance ofrninocycline between 6 and 12 hours was found to be 9 ml/min [47]. 
Following a single intravenous dose or repeated oral doses of minocycline to patients with different 
degrees of renal impairment the observed clearance of minocycline from the circulation appeared to be 
independent of renal function [50]. Up to 34 % of administered minocycline is excreted in the faeces 
[20]. 
1.7 CONCLUSIONS 
The structural modifications of the tetracycline backbone, to form minocyc!ine have produced a molecule 
that has unique properties within the tetracycline group of antibiotics. Specifically, the substitution on 
position C-7 of the tetracycline molecule with a dimethylamino group, which can be ionized, has 
produced a molecule that has a higher isoelectric point than its congeners. The isoelectric point of 
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minocycline at which the zwitterionic form is neutral coincides with physiological pH. Due to its higher 
lipophilicity at physiological pH, minocycline penetrates cells more readily than other tetracycline 
antibiotics thereby increasing its spectrum of activity. 
Although minocycline has a relatively long plasma half-life of 11-26 hours, modified-release 
pharmaceutical dosage forms may be essential in reducing the incidence and/or severity of the adverse 
events, particularly the vestibular adverse effects associated with minocycline, in order to optimise 
minocycline therapy particularly for long-term therapy such as for acne. Some formulation methods may 
expose the active component to extreme conditions such as high temperature or extremes of pH. An 
understanding of the stability of the active drug is therefore critical for one to ensure that the integrity of 
the drug is maintained during the formulation process. 
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2 THE DEVELOPMENT AND VALIDATION OF AN HPLC METHOD FOR THE 
ANALYSIS OF MINOCYCLINE 
I 2.1 INTRODUCTION 
2.1.1 Overview 
The analysis ofminocycline has been performed using capillary zone electrophoresis [49], densitometric 
thin layer chromatography [50] and spectrophotometric methods in which oxidative and diazo-coupling 
reactions have been applied [51]. These methods have several shortcomings including cost and inherent 
complexity and require the use of equipment that is not routinely available in all laboratories. High 
performance liquid chromatography (HPLC) has also been used for the quantitation of minocycline in 
biological fluids such as plasma [1 6,52-54], saliva [53] and serum [55]. Several HPLC methods for the 
quantitation of minocycline are used for the simultaneous analysis of minocycline in the presence of 
other antibiotics [ 45,56]. An improved liquid chromatographic method for the determination of 
minocycline has been used for the analysis of raw material but not for the evaluation of formulations 
[57]. Perusal of the literature reveals a paucity of information pertaining to the use of stability indicating 
HPLC methods for the quantitation of minocycline in dosage forms. The objective of this study was to 
develop a simple, precise and accurate stability indicating reversed-phase HPLC method for the 
quantitation of minocycline in pharmaceutical dosage forms. 
2.1.2 Principles of HPLC 
High perfom1ance liquid chromatography (HPLC) has been referred to by other terminology including 
high pressure LC, high speed LC or high efficiency LC and is used as a separative and analytical 
technique in the pharmaceutical industry [58]. Liquid chromatography is a similar technique to gas 
chromatography (GC) and refers to any chromatographic method in which the mobile phase used for a 
separation is a liquid as opposed to a gas .as is the case in GC [59]. Liquid chromatography has allowed a 
wider application in analysis than GC as it is suitable for the analysis of compounds that are not volatile, 
are thermally unstable and that may decompose under the conditions of separation applied in GC [59}. 
The separation of samples that are difficult to isolate using GC is more readily achieved using LC as the 
technique uses two chromatographic phases for selective interaction with the analyte(s) of interest, and 
offers a greater variety of stationary phases and lower separation temperatures. In addition, a variety of 
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detectors that have limited use in GC can be used in LC and sample recovery is relatively easily 
achievable [59] . HPLC has several advantages over other liquid chromatographic methods, which include 
the fact that HPLC columns are reusable without regeneration, resolution in HPLC is better, 
reproducibility is superior as HPLC is less dependent on the skill of the operator, the instrumentation of 
HPLC lends itself to automation and quantitation, analysis times are generally shorter and preparative LC 
is possible on a much larger scale [58]. 
The separation of compounds of interest in HPLC occurs as a result of the differential migration of 
analytes along the HPLC column [59]. Differential migration results from the equilibrium distribution of 
the different compounds between the stationary phase and the mobile phase [59]. Compounds that 
interact preferentially with the stationary phase, move through the column slowly and have longer 
retention times whereas those that interact with the mobile phase move through the column more rapidly 
and have shorter retention times [59]. Differential migration is dependent on factors that influence the 
distribution of compounds between the mobile and stationary phases and include the composition of 
mobile phase, composition of the stationary phase and the separation temperature [59]. 
Three retention mechanisms/models in HPLC have been mathematically described by Kazakevich [60] 
in HPLC viz., the partitioning model, the adsorption model and the adsorption-partitioning retention 
mechanism. 
[n the partitioning mechanism of retention, Kazakevich [60] proposes that the analyte is distributed 
Jetween a mobile and stationary phase and that there is instant equilibrium of the analyte between these 
:wo phases. At the molecular level, the partitioning mechanism entails a process in which a solute-sized 
;avity is created in the organic phase after which there is transfer of a solu~e molecule from the aqueous 
'base into the organic phase and followed by closing of the cavity created by the solute molecule in the 
Lqueous phase [61]. A weakness of the partitioning mechanism of retention is that the model assumes 
hat the two phases are mutually insoluble, which may not always be the case [61]. 
"he adsorption mechanism for retention has been argued by some to be the better logical mechanism to 
xplain the retention characteristics of a compound in HPLC, as stationary phase material is normally 
omposed of a solid porous matter with an associated high surface area and that is impermeable to both 
nalyte and eluant molecules [60]. In the adsorption model, adsorption occurs at the solid-liquid interface 
1here the solute molecules migrate from the liquid phase to the adsorptive layer where they displace 
hysically adsorbed molecules of solvent [61]. 
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The third mechanism of retention in HPLC is essentially a combination of both the partitioning and the 
adsorption models of retention in which overall retention is a consequence of superimposition of two 
consecutive processes [60]. The first process involves the partitioning of analyte molecules from the bulk 
eluant onto the adsorbed eluant layer and the second stage involves the adsorption of an analyte onto the 
surface of the stationary phase or column packing matter [60]. 
HPLC can be divided into four main modes depending on the stationary phase used. These include 
liquid-liquid chromatography in which the stationary phase is a liquid, liquid-solid chromatography in 
which the stationary phase is solid, ion-exchange chromatography in which the stationary phase contains 
fixed ionic groups associated with counter ions of opposite charge and size-exclusion (gel) 
chromatography in which the stationary phase is composed of a material with pores of a specific stze 
[58]. 
Modification of liquid-liquid chromatography (LLC) gave rise to bonded phase chromatography (BPC) 
in which an organic stationary phase is chemically bound to a support, instead of being held mechanically 
as in liquid phase in liquid-liquid chromatography [59]. BPC columns are the most widely used columns 
as the chemically bound stationary phase cannot be easily removed or lost during use as is the case with 
LLC [59]. BPC is further divided into normal phase BPC in which polar packing materials are used and 
reversed-phase BPC in which relatively non-polar stationary phases such as C8 or C18 hydrocarbons are 
used in conjunction with polar mobile phases for the separation of a wide range of solutes of lower 
polarity [59]. 
The original use of reversed-phase BPC columns was for the separation of non-polar compounds such as 
hydrocarbons (59]. However, reversed-phase BPC columns have been applied and continue to be used 
for pharmaceutical and drug analysis in biological fluids, for nucleic acid and nucleosides, in agriculture 
as well as for characterizing oligomeric mixtures of compounds [59]. 
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2.2 LITERATURE REVIEW 
Several HPLC methods have been used for the analysis of minocycline. A summary of the methods 
published in the literature for the analysis of minocycline is shown in Table 2.1. The majority of these 
methods have used ultraviolet (UV) detection for the determination of minocycline in biological matrices 
and have been conducted at low pH. 
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Table 2.1. High Performance Liquid Chromatographic Analysis ofMinocycline 
Column 
Nucleosil"", C8 (250x4 mm 
LD.; 5 ~m) 
Symmetry ShieldsiiJ RP 8 
(150x4.6 mm I.D.; 3.5 ~m) 
Zorbax , RX-CR 
( 150x4.6mm I.D.) 
~-Bondapak"', C18 
(250x30mm) 
XTerra® RP-18 (250x4.6 
mm I.D.; 5~-tm) 
Vydac , C8 (250x4.6 nun 
I.D.; 5~tm) 
Sample Matrix 
plasma, saliva 
plasma 
plasma 
tissue, serum 
Drug substance 
IV solution 
Metaphase-Crest-Pak-ODS® Drug substance 
(250x4.0 mm I.D.; 5~-tm) 
Nucleosi!IJ!· 5-CN (125x4.0- plasma 
mml.D.) 
j.t-Bondapakti, C18 (300x4.6 
mm I.D.; 10 J.lm) 
Bulk powders 
phamaceuticals 
Mobile Phase Composition Detection 
Acetonitrile:methanol:distilled water:O.J% UV-350nm 
trifluoroacetic acid (25:2:72.9:0.1, v/v; 
pH= 1.76) 
Acetonitrile:methanol:O.Ol M KH2 P04 UV-350nm 
(5:20:72.1, v/v) with 0.03 mM Na2 EDT A 
and 60% HC104, pH=2.5 
Acetonitrile:water:TFA (80.0: 19.9:0.1) Mass spectrometry 
methanol UV-350nm 
Acetonitrile:tetrabutylammonium hydrogen UV-280nm 
sulphate (pH=6.5):0.2 M ethylene 
diaminetetraacetic acid (pH=6.5);water 
(20:20:20:40; v/v/v/v) 
22% acetonitrile in 50 mM K2HP04 UV-254nm 
(pH=6.5) 
Tetrabutylammonium hydrogensulphate UV-248nm 
(0.025 M):methanol:acetonitrile (96:2:2) 
(pH=3.0) 
methanol and 20 mMperchloric acid/4 mM UV-350nm 
triethylamine in water (20:80, v/v; pH 
approx. 2) 
KH2P04 (pH=2.5; 0.05 M):acetonitrile 
(84: 16, v/v) 
Amperometric 
detection-1.2 V 
Flow rate Reference 
0.9 mVmin [53] 
0.8 mVmin [62] 
I ml/min [54] 
I mllmin [55] 
I m.l/min [57] 
1 mi./min [27] 
1.5 ml/ml [45] 
1 ml/min [52] 
1 ml/min [56] 
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2.3 EXPERIMENTAL 
2.3.1 Reagents 
Minocycline hydrochloride was purchased from Sigma-Aldrich (Johannesburg, Gauteng, South 
Africa). The potency was established as 903 J..lg minocycline/mg. Methanol (UV cut-off 215nm) 
and Acetonitrile (UV cut-off 200nm) were purchased from Rornil-SpS® (Waterbeach, 
Cambridge, UK). Potassium dihydrogen phosphate and sodium hydroxide pellets were purchased 
from Associated Chemical Enterprises (Southdale, Gauteng, South Africa). Polished HPLC grade 
water was prepared by reverse osmosis using a Milli-RO® 15 Water Purification System 
(Millipore Co., Bedford, MA, USA) that consisted of a Super-C carbon cartridge, two Ion-X ion 
exchange cartridges and an Organex-Q cartridge. The HPLC water was filtered through a 0.22 
J..tm Millipak® 40 sterile filter prior to use. Cyclimycin®-50 and Cyclimycin®-100 (Pharrnacare 
Limited, Port Elizabeth, South Africa) capsules containing minocycline hydrochloride equivalent 
to 50 mg and 100 mg minocycline respectively, were purchased from a local pharmacy (Alpha 
Pharrn, South Africa). All reagents used were at least of analytical grade and were used as 
received. 
2.3.2 Preparation of stock solutions 
A stock solution of rninocycline hydrochloride was freshly prepared before each analytical run by 
accurately weighing 25.0 mg of minocycline hydrochloride in a 50 ml A-grade volumetric flask 
and dissolving in mobile phase. The concentration of the resultant solution was 500 J..tg/ml. 
Standard solutions of 5, 10, 20, 60, 100 and 140 J..tg/ml were prepared by serial dilutions of the 
stock solution. The stock solution of the internal standard, doxycycline hyclate, was freshly 
prepared before each analytical run by accurately weighing 12.5 mg of doxycycline hyclate in a 
50 ml A-grade volumetric flask and dissolving in mobile phase. 
2.3.3 Preparation of buffer solutions 
Buffer solutions of concentrations 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 rnM were prepared 
by accurately weighing appropriate amounts of potassium dihydrogen phosphate into 1 L A-grade 
volumetric flasks and making up to volume with HPLC grade water. The pH of the solutions was 
adjusted to the required pH using 1.0 M NaOH. 1.0 M NaOH was made by accurately weighing 
4.0 g of sodium hydroxide pellets into a 100 ml A-grade volumetric flask and making up to 
volume with HPLC grade water. 
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2.3.4 Preparation of mobile phase 
Mobile phase was prepared by adding the required volume of HPLC-grade acetonitrile and 
methanol and buffer to a glass Duran® Schott solvent mixing bottle (Schott Duran GmbH, 
Hattenbergstrasse, Germany). The mixture was allowed to equilibrate to room temperature and 
the mobile phase was filtered through a 0.45 !.liD Millipore® HVLP filter (Millipore, Bedford, 
MA, USA) and degassed under vacuum using a Model A-2S Eyela Aspirator (Rikakikai Co., Ltd, 
Tokyo, Japan) prior to use. The mobile phase was freshly prepared daily and not recycled during 
analyses. 
2.3.5 HPLC system 
The modular HPLC system was comprised of a Spectra-Physics, Spectra Series PlOO pump 
(Spectra-Physics, San Jose, CA, USA), a Waters WISP 710B Autosamper (Waters 
Chromatography Division, Milford, MA, USA), a LINEAR™ UVIS 200 detector (Linear 
Instrwnents Co., Irvine, CA, USA) and a Spectra Physics, SP 4290 Integrator (Spectra-Physics, 
San Jose, CA, USA). Separation was achieved on a Phenomenex'~> (Torrance, CA, USA) Prodigya- 5 
11m ODS, 150 x 4.60 (i.d.) mm column. 
2.4 METHOD DEVELOPMENT AND OPTIMISATION 
2.4.1 Introduction 
HPLC method development should follow a simple and systematic approach with each 
experiment contributing to an appropriate final result [63). Prior to selecting the initial conditions 
for method development, it is important to know the physicochemical properties of the analyte 
including the chemical structure, molecular weight, pKa values, UV spectrum, solubility in 
addition to the concentration range to be studied (63). Two approaches to HPLC method 
development have been noted, viz., the theoretical approach or the empirical approach [63). 
When using the theoretical approach, an analyst matches the "chemistry" of the analyte to HPLC 
conditions based on past experience and/or based on literature data, whereas when using the 
second approach, the analyst proceeds directly to the chromatographic procedure without paying 
attention to the "chemistry" of the analyte [63]. 
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Samples for HPLC analysis may be classified as being "special" or "regular", the latter being 
composed of small molecules (<2000 Da) (63]. "Regular" samples may be divided further into 
neutral or ionic samples [63). The initial conditions recommended for the analysis of ionic 
samples are shown in Table 2.2 [63). 
Table 2.2. Recommended experimental conditions for the HPLC separation of ionic samples 
Separation variable 
Column 
Dimensions (length, ID) 
Particle size 
Stationary phase 
Mobile Phase 
Solvents A and B 
%B 
Buffer 
Temperature 
Flow rate 
Sample size 
Initial choice 
15 x 0.46 em 
5J..Lm 
Cs or C1s 
Buffer-acetonitrile 
80-100% 
25 mM potassium phosphate, 2.0<pH>3.0 
35-45 oc 
1.5-2.0 mllmin 
<25 J..Ll 
The initial conditions used for the method development for minocycline in pharmaceutical dosage 
forms were based on the physicochemical properties of minocycline hydrochloride in addition to 
data obtained from the literature [27]. 
2.4.2 Column selection 
A stable highly efficient column is essential when developing a rugged, reproducible analytical 
method [63]. It is important that the analyst has an understanding of the column description and 
selectivity and the factors that influence this selectivity prior to selecting the column for use in 
method development. Manufacturers describe reversed-phase HPLC columns in terms of their 
ligand, particle pore diameter and silica type [ 64]. 
Three main column-packing particle types have been described for use in HPLC and these are 
totally porous microspheres, micro-pellicular particles or perfusion particles [63]. Totally porous 
microspheres come in a variety of diameters, pore sizes and surface area and are most commonly 
used in HPLC [63]. Porous microsphere particles may be prepared from silica, alumina, ion · 
exchange material or chemically bonded phases [58]. Although smaller porous particles facilitate 
faster separations for HPLC, particle sizes of 5 f..Lm are usually recommended as this particle size 
offers an excellent compromise in terms of column efficiency, back pressure and lifetime [63). 
Usually, totally porous particles with pore diameters of 7-12 nm are required for separation of 
small molecules whereas pore sizes larger than 15 nm are required for the separation of molecules 
30 
Chapter 2, HPLC method for the analysis ofminocycline 
larger than 10 000 Da with a goal of rapid solute diffusion within the pores whilst retaining 
column efficiency [63]. 
Silica-based particles are the most popularly used column materials as they offer several 
advantages compared to other packing materials. Silica-based packing materials are available in a 
variety of different particles and pore sizes and can be applied to the analysis of small and large 
molecules [63]. Silica-based materials are mechanically strong and are therefore durable and 
column packing is reproducible when using spherical particles. Silica-based packings are 
compatible with water and most organic solvents allowing for the alteration of column selectivity 
through use of different mobile phases [63]. 
Although silica-based packing materials offer several advantages they are not without their 
disadvantages. At high pH silica packing material may be solubilised leading to collapse of 
HPLC columns [63]. In a study to provide insight into the use of silica-based bonded-phase 
column packing materials in aqueous mobile phase of high pH, Kirkland et.al. [65] identified 
three factors affecting the rate of silica support degradation, viz., organic modifier used in the 
mobile phase, silica support type and type of silane bonded phase. The study yielded the 
following conclusions: 
• Densely bonded monomeric dimethyl-C18 ligands protect the silica support from 
dissolution better than bulky diisopropyl- and diisobutyl-substituted silanes. 
• Failure of silica-based columns at high pH results from loss of silica support and not from 
the hydrolysis ofthe Si-0-Si siloxane bond ofthe bonded silane. 
• The nature of the bonded C 18 stationary phase (monomeric or polymeric) does not 
significantly influence column degradation at high pH. 
• The rate of silica dissolution is a function of the nature of the porous silica support with 
the most stable columns prepared by use of consolidating silica sols. 
• The more highly purified, less acidic Type B silica dissolves more rapidly than the less 
pure Type A which dissolves more slowly and is more stable at high pH. 
• Acetonitrile as the organic modifier often prolongs column life at high pH as compared to 
methanol. 
A further disadvantage of silica-based columns is observed during chromatographic analysis of 
basic and weakly basic compounds. Analysis of these materials results in the development of 
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chromatographic separations in which asymmetrical peak shapes, low column efficiencies, poor 
reproducibility and longer retention times than expected may be observed as a result of the strong 
interaction between the analyte of interest and the silica support of the stationary phase [66]. 
Silica based stationary phases that are used for chromatographic separations have been ranked 
according to their desirability for the separation of acidic or basic compounds [63]. Type A silica 
refers to the older, lower purity, more acidic silica that may be used for the separation of non-
ionisable compounds whereas the newer, highly purified lower acidity materials that are 
recommended for the separation ofionisable compounds are referred to as Type B silica [63]. In a 
study in which the acidity of residual silanol groups in HPLC columns with different silica 
supports was studied [66], the highest degree of silanol acidity was observed for non end-capped 
columns based on older, lower purity silica. Conversely, the lowest degree of silanol acidity was 
observed for end-capped columns, in which the stationary phase was bonded to a new generation 
packing material based on silicon-inorganic hybrid and which had a lower silanol activity 
allowing use of the material over an extended pH range. 
The most widely used reversed-phase columns are those with surface-reacted organosilanes 
manufactured by one of three processes vtz., reaction of surface silanols with 
chlorodimethylsilane, reaction of surface silanols with trifunctional silane or reaction of surface 
silanols with trifunctional alkoxysilane [63]. The most commonly used process to produce 
stationary phases is the former, in which mono functional chlorodimethylsilanes are reacted with 
surface silanol groups to yield a variety of alkyl and substituted alkyl silicas such as n-
octadecylsilane (ODS/C18) bonded-phase materials [63]. Since a significant portion of the surface 
does not react in all reactions, some manufacturers have used a process called "end-capping" to 
ensure complete reaction of the silica support surfaces occurs in order to minimize any potential 
and unwanted interactions of residual silanol groups with solutes to be separated [63]. 
Although stainless steel columns are recommended for most HPLC applications, glass and plastic 
columns may be used for solutes that have undesirable interactions with steel [63]. Columns with 
soft outer polymer shells and compression-fitting column types are also commercially available 
[63]. Columns in which the stationary phases are of particle size 3-10 J..Lill and with internal 
diameters (i.d.) 0.3-0.46 em may be used for most HPLC applications [63]. 
The selectivity of reversed-phase columns has been characterized by models such as the 
hydrophobic-subtraction model (64]. Five main factors have been found to influence the 
selectivity of reversed-phase HPLC columns using the hydrophobic subtraction model and 
include: 
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1. Hydrophobicity (H) 
11. Steric resistance (S*) to insertion of bulky solute molecules into the stationary 
phase 
111. Column hydrogen-bond acidity (A), mainly attributable to non-ionized silanols 
1v. Column hydrogen-bond basicity (B), hypothesized to result in some columns 
from adsorbed water in the stationary phase 
v. Column cation-exchange (C) activity due to ionized silanols which varies with 
mobile phase pH 
A Phenomenex® (Torrance, CA, USA) Prodigy 5 ~-tm ODS, 150 x 4.60 (i.d.) mm column was 
selected for the HPLC separation to be developed in these studies. 
The performance of the column was assessed based on the theoretical plate number (N) using the 
equations 2.1 and 2 .2. The Center for Drug Evaluation and Research (CDER) recommends the 
use of columns with at least 2 000 theoretical plates for pharmaceutical applications [67]. 
Where, 
N =column plate number 
tR = band retention time 
W = baseline width 
w 'l,= bandwidth at half peak height. 
2.4.3 UV detection 
Equation 2.1 
Equation 2.2 
Methods of detection used in conjunction with HPLC for the analysis of minocycline include the 
use of ultraviolet (UV), universal, fluorescence, electrochemical detection and mass spectrometric 
detection [63]. UV detection is the most widely used form of detection in most HPLC method 
development techniques and is applied to the determination of most compounds that have UV 
absorptivity [63]. 
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In UV detection methods, absorbance (A) is determined by the concentration (C) of the analyte, 
the molar absorptivity (c) of the analyte and the flow cell length (Lrc) as shown by Beer's Law 
shown in Equation 2.3[63]. 
A= C E Lfc Equation 2.3 
UV detection at long wavelengths of 350 run has been used for detection of minocycline in 
biological fluids whereas shorter wavelengths have been used for detection of minocycline in 
non-biological matrices [27,45,57]. UV detection at a wavelength of254 run was applied in these 
studies. 
2.4.4 Choice of internal standard 
The response of a detector to a compound is measured by determining the peak height or peak 
area of the signal generated in response to the presence of an analyte [ 63]. The use of an internal 
standard is widely applied in HPLC in order to compensate for minor variations in separation 
parameters that affect peak height or area. Such parameters include sample-size fluctuations or 
variable recoveries of compounds of interest [59]. The construction of calibration curves using an 
internal standard requires that the internal standard be added at a constant concentration to 
calibration standards after which the compound to internal standard peak height or area is plotted 
against the concentration of the compound of interest [59]. Suitable internal standards are 
generally similar in structure to the analyte of interest, are usually chemically similar to the 
compound of interest and have similar solubilities and detection responses to the analyte [59]. 
Doxycycline, also a congener of tetracycline was used at a concentration of 125 j.lg/ml as the 
internal standard in these studies. 
2.4.5 Mobile phase selection 
The properties of the stationary phase depend on the type and concentration of organic modifier 
used in the mobile phase [68]. Variation of the composition of a mobile phase results in 
significant changes in the characteristics of the stationary phase and therefore the chemical 
environment the solute is exposed to when in contact with the stationary phase thereby resulting 
in changes in the retention time of the analyte [68]. 
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The pH of the eluant is an important factor to consider in the HPLC analysis of ionisable 
compounds. The pH of an eluant affects the degree of ionisation of the analyte and residual 
silanols present on the surface of the stationary phase ultimately influencing the interaction 
between the analyte and the stationary phase and therefore the retention characteristics of the 
analytes [69]. It is important to buffer mobile phases to maintain a constant pH during analysis of 
ionisable compounds in order to ensure reproducible and robust analyses are conducted [69]. 
The preferred buffers for reversed-phase HPLC analyses must be able to control pH to between a 
pH range of 2-8 and permit the transmittance of light at or below 220 nm to allow low-UV 
detection, in a concentration range of 10-50 mM as higher concentrations may pose solubility 
problems when using large volumes of organic modifiers [63]. Phosphate buffers are marginally 
soluble in solutions that contain high concentrations of organic modifiers and are suitable for use 
in the pH ranges of2.1-3.1 and 6.2-8.2 [63]. Potassium dihydrogen phosphate was selected as the 
buffer of choice for this particular method as the pH of the buffer was 7.0. 
The initial selection of the mobile phase composition was based on a previously reported method 
[27] and was optimized with respect to buffer and organic modifier composition as shown in 
Table 2.3. 
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Table 2.3. Mobile phase selection 
Mobile phase composition Retention time Peak shape 
(min) 
Organic phase Phosphate buffer 
(%v/v) 
MeOH MeCN %v/v, pH Doxy Mino 
molarity 
20 80, 0.08M 7.0 4.4 8.8 Mino peak sharp and well resolved. Doxy peak 
sharp but not adequately resolved 
25 75, 0.08M 7.0 2.4 4.6 As above 
22 78, 0.08M 7.0 2.8 5.9 As above 
40 60, 0.08M 7.0 5.2 10.0 Both peaks sharp and adequately resolved but 
could be sharper 
40 60, 0.08M 6.4 5.1 8.2 Mino peak sharp and well resolve. Doxy peak 
sharp but not adequately resolved 
45 55, 0.08M 7.0 3.5 6.7 As above 
35 5 60, 0.08M 6.4 4.8 8.0 As above 
30 10 60, 0.08M 7.0 4.3 8.2 Both peaks sharp and adequately resolved but 
doxy peak could be better resolved 
35 5 60, 0.08M 7.0 4.3 8.7 As above 
15 15 70, 0.08M 7.0 4.6 9.6 Both peaks sharp and adequately resolved but 
could be sharper 
12 18 70, 0.08M 7.0 3.9 7.6 Both peaks sharp and adequately resolved 
13 17 70, 0.08M 7.0 4.1 8.2 Both peaks sharp and adequately resolved 
2.4.5.1 Effect of organic modifier 
It was desired that the retention times of minocycline and the internal standard be longer than 
four minutes in order to avoid interference by the solvent front and to elute in not more than ten 
minutes so that routine analysis is relatively quick. Acetonitrile at a concentration of 20% v/v 
was selected as the first choice of organic modifier based on a published method [27]. Although, 
the peak shape and retention time of minocycline was optimised at this concentration, 
doxycycline was inadequately resolved. At concentrations of acetonitrile greater than 20% v/v, 
the peak shape of doxycycline improved to a small degree and the peak eluted close to the solvent 
front. The use of methanol as an organic modifier was therefore investigated. Increasing the 
concentration of methanol resulted in better peak shapes but with unacceptably short retention 
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times. The addition of methanol and acetonitrile as organic modifiers to the mobile phase offered 
the best compromise in terms of optimal peak shape and retention time and a representative 
chromatogram is shown in Figure 2.1. 
A 
mlnocycline 
doxycycline 
2 4 6 8 10 12 
Tlme(mlns) 
B 
minocycllne 
doxycycline 
2 4 6 8 10 12 
Time (mlna) 
c 
minocycline 
doxycycline 
2 4 6 8 10 12 14 
Tlme(mlns) 
Figure 2.1. Typical chromatograms of doxycycline (125 IJ.g/ml) and minocycline (100 IJ.g/ml) obtained 
with: A- Acetonitrile (17% v/v) and methanol (13% v/v) as organic modifiers, B-Acctonitrile (22% v/v) as 
organic modifier and C-methanol (40% v/v) as organic modifier in 70% v/v KH2P04 (80 mM, pH=7) 
2.4.5.2 Effect of buffer molarity 
The effect of buffer molarity on chromatography was investigated over the range 10 rnM to 100 
rnM for potassium dihydrogen phosphate buffers. No significant difference in peak shape and 
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retention time was observed for minocycline, however as the molarity was increased more 
symmetrical and sharper peaks were observed for the internal standard as shown in Figure 2 .2. A 
buffer molarity of 80 mM was therefore used for further optimization of the method. 
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Figure 2.2. The effect of buffer molarity on the separation of minocycline and doxycycline using 70 % v/v 
KH2P04 (pH=7, A-30 mM, B-50 mM and C-80 mM): 17% v/v MeCN: 13% MeOH 
2.4.5.3 Effect of buffer pH 
The analysis of minocycline has been performed chromatographically at acidic [45,52,53,56,62] 
and neutral [27,57] pH. The effect of pH on the retention characteristics of minocycline and 
doxycycline was investigated over the pH range 2 to 7. At low pH values, in acidic conditions, 
minocycline and doxycycline peaks were inadequately resolved from each other and the peak 
shape of doxycycline was distorted. The retention times of minocycline and doxycycline 
increased and resolution of the two peaks improved with an increase in the pH. A neutral pH of 7 
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was selected for use as peak shape, retention time and resolution of the peaks were optimal at this 
pH. 
2.4.6 Mobile phase selected 
The mobile phase selected for further optimization and validation for the HPLC analysis of 
minocycline was comprised of 70% v/v potassium hydrogen phosphate buffer (pH 7, 80 mM), 
17% v/v acetonitrile and 13% v/v methanol. Peak shapes were assessed by calculating the peak 
asymmetry factor As using Equation 2.4. Peaks of acceptable symmetry have As values of 0.95-1.1 
although values of up to 1.4 are acceptable [63]. The Center for Drug Evaluation and Research 
(CDER) recommends that capacity factor (k'), which should be greater than 2, be calculated [67]. 
The capacity factor was calculated using Equation 2.5 [67]. A typical chromatogram and the 
typical peak specifications achieved using this mobile phase are shown in Figure 2.3 and Table 
2.4. 
Where, 
Where, 
B As=-
A 
B = the width of the peak to the tailing edge at 10% of the peak height 
A = the width of the peak to the leading edge at 10% of the peak 
k ' = (tR-to) 
to 
tR =elution time of non-retained components 
t0 = elution time of analyte 
Equation 2.4 
Equation 2.5 
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Figure 2.3. Typical chromatogram of the separation of minocycline (4.1 min) and doxycycline (8.1 min) in 
mobile phase 
Table 2.4. Peak specifications for typical chromatogram of the separation of minocycline and doxycycline 
Capacity factor 
Peak symmetry factor 
Retention time (min) 
Minocycline 
5.6 
1.1 
8.2 
Doxycycline 
2.8 
1.2 
4.1 
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2.4.7 Chromatographic conditions 
The chromatographic conditions selected for the method to be validated are summarised in Table 
2.5. 
Table 2.5. Chromatographic conditions 
Column Phenomenex® (Torrance, CA, USA) Prodigy 5 11m ODS, 150 x 4.60 (i.d.) rom 
Pump Spectra-Physics, SPECTRA SERJES PlOO pump (Spectra-Physics, San Jose, CA, 
Injector 
Detector 
Detection wavelength 
Sensitivity 
Recorder 
Integrator speed 
Flow rate 
Injection volume 
Temperature 
Column pressure 
Mobile phase composition 
2.4.8 Conclusions 
USA) 
Waters WISP 71 OB Autosamper (Waters Chromatography Division, Milford, MA, 
USA) 
LINEAR™ UVIS 200 detector (Linear Instruments Co., Irvine, CA, USA) 
254 run 
0.2AUFS 
Spectra Physics, SP 4290 Integrator (Spectra-Physics, San Jose, CA, USA) 
2.5 mm/min 
1.5 ml/min 
20 Jll 
Ambient, 22 °C 
1800-2000 psi 
MeOH:MeCN:80 mM KH2P04 buffer pH 7.0; (13:17:70,v/v/v) 
Using a theoretical approach to HPLC method development [63] a method for the analysis of 
minocycline in pharmaceutical formulations has been developed by optimising the composition 
of organic modifiers, buffer molarity and pH buffer. The developed HPLC method displays 
adequate resolution and has suitable run times of 4.1 and 8.2 minutes for doxycycline (internal 
standard) and minocycline allowing for its further application in these studies. 
41 
Chapter 2, HPLC method for the analysis ofminocycline 
2.5 METHOD VALIDATION 
2.5.1 Introduction 
The validation of an analytical procedure is the process by which it is established by laboratory 
studies, that the procedure has the performance characteristics to meet the requirements for the 
intended analytical application [70]. Parameters typically investigated in the early stages of 
validation studies include specificity, linearity, accuracy and precision with stability studies and 
ruggedness being conducted at a later stage in the validation procedure [63]. Bodies such as the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) [71], The Center for Drug Evaluation and Research 
(CDER) [67] and the United States Pharmacopoeial Convention [70] have established guidelines 
or standard procedures for analytical method validation. 
2.5.2 Linearity and Range 
The linearity of an analytical method is the ability of a method to elicit test results that are 
directly proportional to the analyte concentration within a given range [72]. The range of an 
analytical method is the inclusive interval between the upper and the lower levels of analyte 
concentration for which it has been demonstrated that the analytical method has a suitable level of 
precision, accuracy and linearity [71]. 
Linearity is initially analysed visually by determining whether a plot of signals as a function of 
analyte concentration appear to have a linear relationship [71 ]. If a linear relationship is observed, 
test results should be evaluated by use of an appropriate statistical method such as calculation of a 
regression line by the least squares method [71]. The ICH recommends that linearity be 
established using a minimum of five concentrations. A method is generally accepted as being 
linear if the regression coefficient (r) is greater than or equal to 0.999. Table 2.6 summarises the 
validation ranges recommended by the FDA, USP and ICH for validation studies [73]. 
Table 2.6. Recommended validation ranges for linearity studies 
Analysis categories 
Assay specifications for release 
Assay specifications for check 
Content uniformity tests 
Assay of a preservative in a stability study 
Determination of a degradant in a stability study 
Recommended validation range(%) 
80-120 
80-120 
70-1 30 
40-120 
0-20 
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Linearity was evaluated usmg six calibration solutions (n=6) with concentrations ranging 
between 5-140 J.Lg/ml. The peak height ratio of minocycline and internal standard was plotted 
against concentration to produce a calibration curve. The method was linear over the 
concentration range 5-140 f,lg/ml, with a representative linear equation ofy = 0.0107x- 0.0005 
and a regression coefficient (r value) of 0.9999. A typical calibration curve is shown in Figure 
2.4. 
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Figure 2.4. Typical calibration curve for minocycline hydrochloride in the concentration range 5-140 
!Jglml (n=6) 
2.5.3 Precision 
The precision of an analytical method expresses the degree of agreement of a series of 
measurements resulting from multiple sampling of the same homogenous sample under the 
prescribed conditions [70].The precision of an analytical method is generally expressed as the 
variation, standard deviation or the coefficient of variation (relative standard deviation) of a 
statistically significant number of samples [71, 72, 72). The ICH considers precision at three 
levels: repeatability, intem1ediate precision and reproducibility. 
2.5.3.1 Repeatability 
The repeatability, also termed intra-assay precision expresses the prectswn of the analytical 
method over a short time interval under the same operating conditions, i.e. in the same laboratory 
by the same analyst with the same equipment [70,71]. The ICH recommends that repeatability be 
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assessed using a minimum of nine determinations covering the range of the analytical method or 
using at least six determinations at 100% of the test concentration. For an assay method 
repeatability should exhibit a % RSD of :'5 2 % [73]. 
Replicate analysis (n=6) of samples at low, medium and high concentrations i.e. 10, 60 and 140 
J..Lg/ml were performed to assess the intra-assay precision or repeatability of the method. The 
%RSD values for repeatability were less than 2% and are summarized in Table 2.7. 
Table 2.7. Intra-day precision for minocycline hydrochloride in the concentration range 0-140 1-1g/ml 
Concentration (1-lg/ml) 
10 
60 
140 
Peak/Height Ratio (n=6) 
0.1153 
0.7372 
1.6403 
2.5.3.2 Intermediate precision 
Standard deviation 
0.0012 
0.0055 
0.0098 
%RSD 
1.08 
0.74 
0.59 
Intermediate precision also know as ruggedness expresses the precision of an analytical method 
when the method is subject to within-laboratory variations, i.e. when the method is applied by a 
different analyst, used on different days or used on different equipment [70]. The use of 
experimental design to monitor effects, if any, of individual variables is encouraged [72]. Tight, 
but realistic, system suitability specifications should be set as intermediate precision of an 
analytical method can be partly assured by good system suitability specifications [67]. 
Replicate analysis (n=6) of concentrations of 10, 60 and 140 J..Lg/ml were performed on three 
different days to assess the inter-day or intermediate precision of the method. The % RSD values 
for precision were Jess than 2% for all determinations and are summarized in Table 2.8 thereby 
indicating that the method is precise. 
Table 2.8. Inter-day precision for minocycline hydrochloride in the concentration range 0-140 1-lg/ml 
Concentration (p.g/ml) 
10 
60 
140 
Peak/Height Ratio (n=6) 
0.1148 
0.7451 
1.6683 
2.5.3.3 Reproducibility 
Standard deviation 
0.0013 
0.0099 
0.0292 
%RSD 
1.12 
1.33 
1.74 
Reproducibility of an analytical method refers to the use of the procedure in different laboratories 
as in collaborative studies [70, 71] and is usually applied to standardization of a methodology 
[71]. The determination of reproducibility focuses more on the bias of experimental results and 
not on the difference in precision of the results alone [73]. Although "statistical equivalence" is 
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normally used as a method to determine reproducibility, the use of "analytical equivalence" in 
which a range of acceptable results is set for use to judge acceptability of the results, prior to the 
application of the method in different laboratories, is a more practical approach [73]. The FDA 
does not expect reproducibility data if intermediate precision has been established [67] hence 
reproducibility was not performed in these studies. 
2.5.4 Accuracy 
The accuracy of an analytical method expresses the closeness of an experimental value to that of 
the true value or that of an accepted reference standard [70,71]. The ICH guidelines recommend 
that accuracy be established across the specified range of the analytical procedure with a 
minimum of nine determinations covering the specified range or a minimum of six 
determinations at 100% of the test concentration [71]. The FDA recommends that accuracy be 
determined at 80, 100 and 120% levels of label claim for drug substance and drug product 
analytical methods [67]. 
Shabir [73] highlighted four techniques used to determine accuracy. The first technique requires a 
sample of known concentration to be analysed and the measured value is then compared to the 
known true value. The second approach involves comparing test results from the analytical 
method being validated to a value obtained by a well characterised method that has been found to 
be accurate. The third technique is based on the recovery ofknown amounts ofanalyte following 
spiking of blank matrices with the analyte and the fourth technique for determining accuracy is 
used in cases where a blank matrix cannot be obtained and involves the determination of recovery 
of the spiked analyte following addition of a standard quantity of analyte to the matrix. 
The FDA recommends that the acceptance criteria for accuracy be 100 ± 2% at each 
concentration studied over the range 80-120% of the target concentration [73]. The extent of 
deviation from the true value may also be determined as percent bias (% bias). The limit for 
percent bias for our lab was set at 5%. The accuracy of the analytical method was determined at 
low, medium and high concentrations i.e. 10, 60 and 140 J..Lg/ml. The percent bias was less than 
5% for all solutions tested and the results are summarised in Table 2.9. 
Table 2.9. Accuracy for minocycline hydrochloride in the concentration range 0-140 p.g/ml 
Concentration (J..Lg/ml) Determined concentration % RSD % Recovery % Bias 
/ml 
10 9.53 0.21 95.3 4.7 
60 57.8 0.30 96.33 3.7 
140 144.5 1.28 103.2 3.2 
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2.5.5 Limits of quantitation (LOQ) and detection (LOD) 
The LOQ of an analytical method for quantitative analyses is used to establish the lowest level of 
a compound in a matrix that can be determined with the requisite precision and accuracy. The 
determination of LOQ is normally required when an assessment of impurities in bulk material or 
degradation products in the finished pharmaceutical product are required to be reported [70, 71]. 
The limit of detection (LOD), a characteristic of limit tests [70], is the amount of analyte that can 
be detected, but not necessarily quantitated using the analytical method under the stated 
conditions [70,71]. 
The ICH highlights three approaches to determine the LOQ and LOD of a method and these are 
summarized in Table 2.10. 
Table 2.10. Approaches for determining LOD and LOQ (adapted from [74)) 
Approach 
Visual evaluation 
Signal to noise ratio 
Standard deviation of the response 
( o)* and the slope (S) 
Limit of detection 
Minimum level detectable 
3:1 or 2:1 
3.3 X o/S 
Limit of quantitation 
Minimum level quantifiable 
10:1 
10 X o/S 
*Standard deviation of the blank, residual standard deviation of the calibration line, or standard 
deviation of the intercept 
The first approach is based on a visual evaluation and is used with non-instrumental methods but 
may also be applied to instrumental methods. Using this approach, samples with known 
concentrations of analyte are used to esta~lish the minimum amount of a detectable analyte 
(LOD) and the minimum amount that can be quantitated with acceptable precision and accuracy 
(LOQ). The second approach makes use of the signal to noise ratio method and is applicable 
only to analytical methods that exhibit baseline noise and makes use of the analysis of samples 
with known amounts of analyte and then comparing their response to that of blank samples that 
have been prepared and analysed in the same way. Using the signal to noise ratio method, a signal 
to noise ratio of 2: 1 or 3: 1 is considered suitable for establishing the LOD and a signal to noise 
ratio of 10:1 is considered appropriate for identification of the LOQ. The third approach used to 
determine LOD and LOQ is based on the standard deviation of response and the slope (S) 
obtained from the calibration curve of the analyte, with the LOQ and LOD determined using 
Equations 2.6 and 2.7. 
LOD = 3.3u 
s 
Equation 2.6 
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LOQ = lOCT 
s 
Equation 2.7 
The estimate of cr may be established by one of two methods: 
1. Using the standard deviation of the response of an appropriate number of blank samples 
or 
2. Construction of calibration curves using samples of the analyte in the concentration range 
ofLOQ and LOD. cr can be estimated from the residual standard deviation of a regression 
line or from the standard deviation of y-intercepts of regression lines generated for these 
studies. 
Caution should be taken when using the signal to noise ratio method to ensure that baseline noise 
is not interpreted as extraneous peaks, as undulations may be observed at the void volume if the 
diluents of the samples are different from, or are in different proportions to the solvents used in 
the mobile phase [ 67]. 
The limit of quantitation (LOQ) may also be determined, from precision studies by analysing 
samples with decreasing concentration of the analyte until a specified limit of relative standard 
deviation between the samples is reached; with the concentration at which the limit is reached 
being deemed the LOQ [74]. As the degree of scatter at low concentrations is considerably 
higher, a larger number of samples should be analysed using this method [74]. 
The LOQ has been observed to be more dependent on the equipment used, specific conditions of 
an analytical method and the method of calculation than any other validation parameter [74]. The 
FDA has recommended that there be assurance that the detection and quantitation limits be 
achievable with the test method each time when using low concentrations, in particular with UV 
detectors that exhibit a loss of sensitivity on ageing. In a nine month experiment to determine the 
LOQ using five LC-systems, large differences were observed in the value of the LOQ depending 
on the system used, the method used to calculate the LOQ as well as in repeated analysis for the 
same sample [74]. The LOQ is important when analytical procedures are to be transferred and for 
the determination of impurities. When required for these purposes the requirements of the method 
used for the determination of the LOQ must be taken into consideration [74]. A reliable 
quantification limit should be three standard deviations away from the specification limit [74]. 
The limits of quantitation (LOQ) and detection (LOD) were determined based on the signal to 
noise ratio of the method. The concentrations that produced signal to noise ratios of 10: 1 and 3: 1 
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were the LOQ and LOD respectively. The LOQ was found to be 5.0 f.!g/ml with an associated 
%RSD of 4.42%, whereas the LOD was found to be 2.5 flg/ml. 
2.5.6 Specificity and selectivity 
The terms specificity and selectivity are often used interchangeably, however specificity is used 
to denote the response of a method for a single analyte and selectivity denotes a method that 
provides a response for a number of analytes that may or may not be distinguished from each 
other [72]. Application of these definitions implies that the term selectivity would be more 
appropriate for chromatographic methods; however the term specificity is used to denote the 
ability of a method to accurately measure the analyte response in the presence of all potential 
sample components, as indicated by both the USP and ICH Guidelines [72] . 
For chromatographic methods, specificity may be demonstrated by a sufficient separation of all 
substances present. In contrast to the determination of impurities, where each peak is required to 
be adequately resolved, for assays an appropriate separation requires that the main peak be 
separated from any potential impurity, placebo or degradant peaks which need not themselves be 
separated from each other [74]. Care should be taken when using stress testing to demonstrate 
specificity, that over degradation be avoided as this would result in secondary or higher order 
degradants which are of no practical relevance being present and separated [74]. It is 
recommended that samples be exposed to stress conditions that are sufficient to degrade the 
analyte to between 80 and 90% of the original purity [73]. 
2.5. 7 Stress studies 
Stability testing of drug substances and products provides evidence on how the quality of the drug 
substance or the product varies with time following exposure to different environmental factors 
such as temperature, humidity and light (75]. Stress testing, which depends on the nature of the 
drug substance or the type of drug product involved, gives an indication of the degradation 
pathway and the intrinsic stability of a molecule and validates the stability-indicating power of an 
analytical procedure that is developed and used [75]. Although the ICH Guideline for Stability 
Testing of New Drug Substances and Products [75] leaves the approach to conducting stress 
studies to the discretion of the scientist, it specifies that stress studies should be conducted to 
include the effect of temperature, humidity, oxidation, photolysis and hydrolysis over a wide 
range of pH values. Stress studies were performed to determine if the analytical method 
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developed for the determination of minocycline in pharmaceutical dosage forms was stability-
indicating and specific under the conditions described. 
2.5. 7.1 Photostability studies 
The ICH recommends that exposure to light be an integral part of stress testing of 
pharmaceuticals [7 6]. It is important to distinguish the effects of light and those of temperature by 
monitoring temperature or by using a dark sample reference solution [76]. The light sources that 
are acceptable for use in photostability studies should be designed to produce an output similar to 
that of D 65, an internationally recognised standard for outdoor daylight or ID 65, an indoor 
indirect daylight standard emission [76]. Light sources that can be used for photostability studies 
include artificial daylight fluorescence, lamps combining visible and ultraviolet output and xenon 
or metal halide lamps [76]. During light induced stress, the drug being tested should be subjected 
to light exposure of at least 1.2 million lux hours and an integrated near ultraviolet energy of not 
less than 200 Watt hours/square meter [76]. A 10 ml aliquot of 100 )!g/ml solution of 
minocycline hydrochloride in a clear volumetric flask and a control (1 0 ml of a 100 )!g/ml 
solution of minocycline protected from light) were exposed to direct natural daylight for six hours 
after which the samples were analysed using the developed HPLC method. 
2.5. 7.2 Temperature stress studies 
The ICH guidelines [75] suggest that temperature stress studies be conducted at 10 oc increments 
above the temperatures used for accelerated stability testing (e.g. 50 °C, 60 oc etc.). For the 
purposes of our studies it was necessary to determine if minocycline would degrade at 80 °C, and 
if so, whether the degradation product would be resolved from the minocycline peak using the 
analytical method developed in our laboratory. A solution of 100 )!g/ml minocycline 
hydrochloride was prepared as previously described in Section 2.3.2 and heated and maintained at 
80°C in a water bath (Laboratory Thermal Equipment, A Searle Company, Greenfield, Oldham, 
United Kingdom) for two hours and cooled before analysis by HPLC 
2.5. 7.3 Acid degradation studies 
Bakshi and Singh have suggested that the hydrolytic degradation of a new drug be studied in 
acidic and alkaline conditions by refluxing the drug in 0.1 M 1-ICl/NaOH for eight hours [77]. 
Forced degradation studies ofminocycline in acidic conditions have been studied for the stability-
indicating nature of an HPTLC method for minocycline by refluxing minocycline in 2.0 M HCl 
for two hours at 80 oc [50]. A 5 ml aliquot of a solution of 0.1 M HCl was added to 5 ml of 200 
)!g/ml solution of minocycline hydrochloride to produce a solution of final concentration of 100 
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f.Lg/ml. The solution was heated and maintained at 80 °C for two hours in a water bath as 
previously described and analysed by HPLC. 
2.5. 7.4 Oxidation studies 
In a review of the development and validation of stability-indicating assays [77], Bakshi and 
Singh suggest the use of hydrogen peroxide in the concentration range of 3-30% to establish the 
presence of oxidative degradation products. A 2 ml aliquot of 3% v/v hydrogen peroxide solution 
was added to 8 ml of 120 f.Lg/ml solution of minocycline hydrochloride to produce a 96 f.Lg/ml 
solution of minocycline hydrochloride. The solution was stored in the dark for 30 minutes after 
which it was analysed by HPLC. 
2.5. 7.5 Alkali degradation studies 
A 5 rnl aliquot of a solution of 0.1 M NaOH was added to 5 ml of 200 f.lg/rnl solution of 
minocycline hydrochloride to produce a solution with a resultant concentration of 100 J.lg/ml. The 
solution was heated and maintained at 80°C for two hours in a water bath as previously described. 
After cooling, the solution was analysed using HPLC. 
2.5. 7.6 Results and discussion 
As shown in Figure 2.5 (Chromatogram A), no significant degradation of minocycline was 
observed following six hours of exposure to sunlight. 
An additional peak that was fully resolved from that of rninocycline was observed after heating a 
solution of rninocycline at 80°C for two hours. The resultant chromatogram is shown in Figure 
2.5 (Chromatogram B). 
After heating a solution of minocycline in acidic medium, a degradation peak was observed to 
elute earlier than minocycline (Figure 2.5, Chromatogram C) indicating the instability of 
minocycline under acid conditions. 
Following exposure to hydrogen peroxide for 30 minutes, an additional peak, an oxidative 
degradant of minocycline, was observed on the chromatogram, as shown in Figure 2.5 
(Chromatogram D) confirming the oxidative instability of minocycline reported in Chapter 1, 
Section 1.4.3 and in a published monograph [1 0]. 
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As shown in Figure 2.5 (Chromatogram E) evidence of degradation products was observed 
indicating that more than one degradation product is formed when minocycline in exposed to 
alkali conditions. 
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Figure 2.5. Typical chromatograms showing degradation of minocycline after exposure to A-light for 6 
hr, B-water at 80 •c for 2 hr, C-0.1 M HCL at 80 •c for 2hr, D-H202 for 30 min and E-0.1 M NaOH at 80 
•c for 2 hr (Refer to Figure 2.3 for chromatogram of untreated minocycline solution) 
52 
Chapter 2, HPLC method for the analysis ofminocycline 
2.6 ASSAY OF CYCLIMYCIN®-50 AND CYCLIMYCIN®-100 CAPSULES 
Samples for assay were prepared based on the monograph for minocycline hydrochloride capsule 
analysis in the USP [70]. Minocycline hydrochloride powder was removed from 20 capsules and 
an amount of powder equivalent to the contents of one capsule was removed and dissolved in 
HPLC grade water with sonication for ten minutes in a 100 ml volumetric flask. A l ml aliquot of 
this solution was filtered through a Millipore Millex-HV Hydrophilic PVDF filter (0.45 flm) and 
diluted with 5 ml of a 250 flg/ml doxycycline hyclate solution. The solution was made up to 10 
ml with mobile phase and analysed using the previously described method in Table 2.5 . The 
analysis revealed that an average of 52.3 mg and 106.8 mg of minocycline were present in the 
Cyclimycin®-50 and Cyclimycin®-100 capsules, respectively. 
Table 2.11. Results for analysis of commercially available Cyclimycin®-50 and Cyclimycin®-1 00 
Minocycline Brand 
Cyclimycin®-50 
Cyclimycin ®-I 00 
Expected amount 
(mg) 
50 
100 
2.7 CONCLUSIONS 
Determined amount (Mean± SD) Percentage Recovery 
(mg) 
52.3 ± 1.610 104.6% 
I 06.8 ± 1.283 I 06.8% 
A reversed-phase HPLC method reported in this chapter has been developed and validated for the 
analysis of minocycline in pharmaceutical dosage forms. The method is simple, linear, and 
selective and has the necessary accuracy precision and is stability indicating. The method was 
successfully applied to the analysis of commercially available formulations containing 
minocycline. The method is also suitable for the evaluation of sustained release and novel dosage 
forms that will be developed in formulation studies. Perusal of the literature indicates that the 
developed HPLC method is the first stability indicating HPLC method reported for 
minocycline in pharmaceutical dosage forms. 
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3 FORMULATION DEVELOPMENT AND ASSESSMENT OF MINOCYCLINE 
SUSTAINED -RELEASE CAPSULE DOSAGE FORMS 
3.1 INTRODUCTION 
Immediate release dosage forms of minocycline described in the BP and USP are tablets and 
capsules. Furthermore a suspension is listed in the USP. In addition the BP describes prolonged-
release minocycline capsules designed to release the minocycline over a period of several hours. 
This chapter presents an overview of the formulation development and assessment of 
minocycline sustained release capsule dosage forms based on matrix technologies. 
3.2 ORAL MODIFIED-RELEASE DRUG DELIVERY SYSTEMS 
Oral drug delivery is the preferred and most convenient route of drug administration [78]. As a 
result, most research efforts in searching for new medicines has focused on the discovery of 
orally active drug substances [78]. Several newly discovered drug entities have limitations 
associated with poor physicochemical or pharmacokinetic properties, which, even after lead 
optimization display low oral bioavailability with the result of sub-optimal plasma drug 
concentration-time profiles [78]. In recent years, the focus has been to develop novel drug 
delivery systems, with modified-release oral systems holding the major market share [79]. 
Modified-release formulation technologies provide a means of optimizing drug bioavailability as 
well as plasma concentration-time profiles for drugs with this limitation [78]. Modified-release 
formulations offer advantages over immediate release formulations including better efficacy for 
treating chronic conditions, a reduction in side-effects as well as better patient adherence due to 
the simplification of dosing schedules [79]. The administration of a drug in a modified-release 
oral dosage form may enhance the pharmacodynamic profile of a drug compared with 
administering the drug as a conventional immediate release product [78]. 
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Although several varieties of modified-release formulations have been cited in literature, the 
majority of modified-release oral dosage formulations are based on one of three technologies, 
viz., matrix systems, reservoir systems and osmotic systems [79]. 
3.2.1 Matrix systems 
Monolithic matrix systems for modified drug delivery are grouped into two main categories, 
those in which a drug is dispersed in a water soluble polymeric matrix and conversely those in 
which the drug is dispersed in a water insoluble polymeric material [80]. 
Soluble matrix systems, which make up the majority of oral modified drug delivery systems [81], 
are comprised mainly of hydrophilic colloids that slowly dissolve on contact with water thereby 
allowing sustained release of the drug [80]. On initial contact with water, the hydrophilic colloid 
swells to form a hydrated matrix layer allowing further diffusion of water into the matrix device 
[80]. The drug dispersed in the matrix then diffuses through the hydrated polymer layer and the 
rate of diffusion of the drug is controlled by the polymeric material [80]. As the outer hydrated 
matrix layer becomes more dilute, the polymer erodes and the rate of erosion is dependent on the 
specific type ofhydrophilic colloid used to manufacture the dosage form [80]. Insoluble drugs are 
released from the matrix by erosion and subsequently dissolution of the drug occurs in the 
dissolution medium [80]. Constant drug release from swellable, soluble matrices may be achieved 
when the swelling and eroding fronts of the polymer are synchronized [80]. 
Drug release from hydrophilic matrix devices may be influenced by the physicochemical 
properties of the gel layer [82], the aqueous solubility of a drug dispersed in the device and the 
mechanical attrition of the matrix in an aqueous environment [80]. 
Hydrophilic colloids that have been used to manufacture swellable matrix devices include pH 
insensitive polymers such as high viscosity grades of hydroxypropyl methyl cellulose (HPMC) 
and poly (ethylene oxide), as well as pH sensitive polymers such as Carbopol'~>, xanthan gum and 
guar gum [81]. 
Insoluble matrix systems are usually manufactured using lipid matrices that contain drug particles 
dispersed in that insoluble matrix [80]. The drug is released from these delivery systems by 
diffusion through fluid filled pores following dissolution in fluid that penetrates the matrix [80]. 
The rate of drug release from these matrix systems is dependent on the rate of diffusion of the 
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drug through the fluid filled pores [80,83]. Excipients commonly used to manufacture insoluble 
matrix devices include hydrophobic polymers such as ethyl cellulose, polyvinyl acetate and 
various waxes [80]. The rate of drug release from these systems can be modified by changing the 
porosity and tortuosity of the device [80]. 
A schematic representation of the process of drug release from diffusion-based and erosion-
controlled matrix systems is depicted in Figure 3.1 and Figure 3.2, respectively. 
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Figure 3.1. Schematic representation of drug release from a diffusion-based matrix system adapted from 
[80] 
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Figure 3.2. Schematic representation of drug release from an erosion controlled matrix system adapted 
from [80] 
3.2.2 Reservoir systems 
Reservoir or membrane-controlled drug delivery devices are one of two types of diffusion-
controlled systems [83]. Reservoir controlled systems are comprised of a drug core encased by a 
membrane usually manufactured from a water insoluble polymeric material which is the rate 
controlling element of the system and through which the drug must diffuse to be liberated. A 
schematic representation of the process is shown in Figure 3.3 [83]. 
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Figure 3.3. Schematic representation of diffusion control of drug release from a reservoir device adapted 
from (83} 
The microencapsulation of drug particles and press coating of whole tablets or particles using 
materials such as hardened gelatin, methyl and ethyl celluloses, polyhydroxymethacrylate, 
hydroxypropyl celluloses, polyvinylacetate and some waxes are two methods commonly used to 
manufacture reservoir devices [84]. The release of drug from a reservoir device involves drug 
partitioning into the membrane surrounding the reservoir and exchanging the drug with the fluid 
surrounding the device [84]. Subsequently additional drug enters the membrane, diffuses to the 
periphery of the membrane and then exchange with the surrounding medium occurs [83]. The 
release of drug from such systems is governed by Fick's first law of diffusion that is expressed 
mathematically in Equation 3.1 [83,84]: 
Where, 
J = 
J = -D dC,/dx Equation 3.1 
The flux of a drug across a membrane in the direction of decreasing 
concentration (amount/area-time) 
The diffusion coefficient of a drug in a membrane (area/time) 
The rate of change in concentration of a drug over a distance x 
Drug release from reservoir devices follows zero-order release kinetics if a constant area, 
diffusional path length, concentration and diffusion coefficient are maintained in the device [83]. 
Important factors to be considered when formulating reservoir devices to ensure constant drug 
release are the ratio of polymers making up the coating and the thickness of the rate-controlling 
membrane and in the case of microencapsulation, the method of formulating reservoir devices 
and the hardness ofthe wall of the microcapsule [83]. 
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3.2.3 Osmotic systems 
Osmotically controlled drug delivery systems use osmotic pressure as the driving force for drug 
release [79]. The first described osmotically controlled oral delivery system which formed the 
basis of the Oros® system [78] was the Elementary Osmotic Pump (EOP) (85]. The EOP 
consisted of an osmotic core containing the drug, surrounded by a semi-permeable membrane 
with a delivery orifice and the device is illustrated in Figure 3.4 [85]. 
Osmotic delivery orifice 
' Osmotic core comainimz 
Semi-permeable membrane drug -
Figure 3.4. Schematic representation of the elementary osmotic pump [85) 
On exposure to the aqueous environment of the contents of the gastro-intestinal tract, the 
osmogenic core draws water into the device at a rate determined by the permeability of the 
membrane to water as well as the osmotic pressure of the core to form a saturated solution inside 
the device [85,86]. As the membrane is inflexible the increase in fluid volume in the device, due 
to water uptake results in the development of hydrostatic pressure inside the device that is 
relieved by the flow of saturated solution of equal volume to the water uptake, out of the orifice 
on the device [86]. The release of drug in solution continues at a constant rate for as long as 
excess solid drug is present in the device but declines parabolically towards no release once the 
concentration of the solution in the device falls below the saturation concentration for the drug 
[85]. 
The release of drugs from EOP and other osmotically driven systems is determined by four main 
factors viz., the solubility of the drug, osmotic pressure in the device, the size of the delivery 
orifice and the characteristics of the semi-permeable membrane surrounding the device [79,86]. 
The rate of drug release from these devices is directly proportional to the aqueous solubility of 
drug contained within the core [79]. However since the release of drugs from EOP devices 
declines as solid drug in the core is depleted, highly soluble drugs are not ideal candidates for use 
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in EOP systems as prolonged constant release cannot be maintained [78]. Poorly soluble drugs on 
the other hand fail to generate sufficient hydrostatic pressure to ensure drug release, leaving only 
moderately soluble drugs as the suitable candidates for inclusion in EOP systems [78]. A number 
of formulation approaches have been used to deliver drugs having extremes of solubility [79]. 
The release of drugs from an osmotically driven device is directly proportional to the osmotic 
pressure of the saturated core formulation, with addition of osmotic agents or osmagents to core 
formulations resulting in faster drug release [79,86]. The size of the delivery orifice in these 
devices should be within a specified size range to control the release of the drug from these 
devices (79]. The delivery orifice should be smaller than the maximum permitted size (Amax) to 
minimize solute diffusion through the orifice and be larger than the minimum permitted value 
(Am;,) to minimize hydrostatic pressure in the device that would otherwise affect the development 
of zero-order release rates [86]. The rate of release of drugs is determined by the type and nature 
of membrane polymer, thickness ofthe membrane and the presence of other additives [79]. 
Push-pull osmotic pump systems (PPOP) were designed to overcome the limitations of delivering 
poorly water soluble drugs in EOP devices [87]. PPOP systems consist of two layers which may 
be separated by an elastic diaphragm, surrounded by a semi-permeable membrane. One 
compartment contains the drug and is connected to the outside environment through an orifice 
whilst the lower compartment which lacks a delivery orifice contains a polymeric osmotic agent 
and a schematic representation ofthe device is shown in Figure 3.5 [86]. 
Semi-penn•able 
membrane Drug Ja}er DeJJver: orifice 
Figure 3.5. Schematic representation of the push-pull osmotic pump before and during operation [86] 
Following exposure to an aqueous environment the drug and polymer layers take up water. 
However, as the polymer compartment lacks an orifice, it expands pushing the diaphragm 
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towards and into the drug compartment causing a suspension or dispersion of the drug to be 
released from that compartment as depicted in Figure 3.5 [86]. 
Waterman et al. [88] have developed a single-layer oval-shaped osmotic controlled-release tablet 
for the delivery of poorly soluble drugs, that is comprised of a hydroxyethylcellulose, a poorly 
soluble drug and sugar as an osmagent in the core and that delivers high doses of low solubility 
drugs through an outlet in the coating at one end of the tablet. 
The concept of drug delivery using EOP and PPOP technologies may be combined to achieve 
patterned release of a drug to produce pulse, ascending and delayed release profiles [78]. Slow 
hydrating placebo layers which are released from the device, before a pharmaceutically active 
agent, due to influx of water into the device may be used for the controlled-onset extended release 
and capsule-shaped osmotically driven tablets that are multilayered and that may be used to 
achieve ascending and pulsed delivery profiles [78]. 
The use of osmotically driven systems offers three specific advantages over other modified 
release systems [85]. The primary advantage is that the delivery of drugs can be designed to 
follow zero-order kinetics as the fraction of drug delivered at zero-order can be predicted from 
the solubility of the drug and the core density. A second advantage is that drug release from 
osmotically driven systems is independent of the pH of the environment, the agitation of the 
environment and the size of the delivery portal for orifices within the specified size range. A final 
advantage of drug release from osmotically driven systems is that significant in vitro in vivo 
correlations are normally achieved [78]. 
3.3 MINOCYCLINE MODIFIED-RELEASE DOSAGE FORMS 
Although minocycline has a relatively long half-life (Section 1.6.5 vide infra) conventional 
dosage forms and traditional delayed release dosage forms containing minocycline require 
frequent dosing (every six or twelve hours) on a daily basis resulting in variations in plasma 
concentrations throughout the course of treatment and ultimately poor patient adherence [89 ,90]. 
Therefore the development of a dosage form for minocycline for once-a-day dosing may provide 
therapeutic benefits and enhanced adherence [89]. 
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A European patent, application number 90115881.6 [89] describes compositions for oral liquid, 
capsule or tablet dosage forms of minocycline that provide at least minimum therapeutic levels 
of minocycline in a human subject for approximately 24 hours. The formulation compositions of 
the dosage forms as described in the patent are composed of a two pulse administration system in 
which the initial loading dose component, provides a flrst pulse which releases drug and permits 
up to 100% absorption in the stomach and a secondary loading component proving a second pulse 
which is released and absorbed up to 100% in the duodenum and upper part of the small intestine. 
An international patent, application number PCTIIB2004/002366, describes compositions for 
minocycline for hard gelatine capsules, soft gelatine capsules, sachet or tablets . .The patent 
describes a non-spheronized, multiparticulate modified release composition that is comprised of a 
core and a pH sensitive coating that that may be rapidly or completely eroded in a medium of pH 
in the range of about 4.0- 7.5 and that releases 95-100% of minocycline after 120 minutes when 
tested in vitro. 
Although rapid dissolution is believed to be essential for the effectiveness of orally delivered 
tetracycline antibiotics the dissolution rate of minocycline can affect the occurrence and severity 
of vestibular side effects that is associated with rninocycline therapy [ 5]. The rapid dissolution of 
minocycline is associated with a higher incidence and greater severity of vestibular effects 
suggesting that a decrease in the dissolution rate of minocycline may reduce the incidence and 
severity of such side effects [5]. Although the development of slowly dissolving dosage forms 
was progressive in reducing adverse effects associated with minocycline therapy there remains a 
need for treatments for acne that have fewer side effects than observed with the use of 
conventional rninocycline dosage forms [91]. 
A US patent, patent number 5,908,838 (Solodyn®) [5] describes formulations ofminocycline with 
slower dissolution rates than observed with immediate release capsules. The patent describes the 
preferred dissolution rate of minocycline and suggests that dosage forms that release 15% of the 
payload in the first 15 minutes, 35% within 30 minutes, 50% within 45 minutes and 80% within 
60 minutes as being suitable. An international patent, application number PCT/US2007 /008086 
[91] describes compositions for once-daily administration "4-hour" formulations of minocycline 
with or without a loading dose. The formulations are comprised of minocycline, one or more slow 
dissolving carriers and one or more fast dissolving carriers and that releases approximately 90% 
of the minocycline in the dosage form within a range of four - six hours. The formulations have 
been shown to provide similar or better efficacy for the treatment of acne with a reduced 
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incidence of at least one adverse effect as compared to the twice-daily administration of 
Minocin® immediate-release minocycline hydrochloride capsules. 
3.4 PHARMACEUTICAL CAPSULES 
Pharmaceutically, the term capsule describes oral dosage forms consisting of a container, usually 
made of gelatin filled with a medicament [92]. Capsules may be classified as "hard" or "soft" 
capsules [92]. Hard capsules are comprised of two semi-closed cylindrical pieces in which the 
longer piece, the "body" is filled and fitted into a shorter piece, the "cap" that has a larger 
diameter [92]. Soft gelatin capsules are one-piece capsules that may come in a variety of shapes 
[92]. The use of pharmaceutical capsules dates back to the early 191h century with the first 
recorded patent in 1834 belonging to Messieurs Dublanc and Mothers [93]. The elongated shape 
of capsules makes capsules easier to swallow as the tongue reflexively lines up the capsule end-
on further simplifying the ease with which they can be swallowed [93]. 
3.4.1 Two-piece Hard Capsules 
3.4.1.1 Manufacture of hard gelatin capsules 
The manufacturing process of two-piece bard capsules may be summarized into seven steps as 
listed [93]: 
1. Preparation of a gelatin stock solution 
11. Capsule formation 
111. Drying of capsules 
IV. Capsule removal and assembly 
v. Capsule sorting 
vi. Capsule printing 
vii. Capsule packing and stor.age 
The first step in the manufacture of two-piece hard capsules involves the production of a viscous 
30-40% w/w stock solution of gelatin. The stock solution is made by dissolving gelatin that meets 
the required specifications of the manufacturer, in demineralised water at 60-70°C. On maturation 
of the stock solution, aliquots are withdrawn to which additives such as colourants and surface 
tension modifiers are added so as to meet the requirements of each capsule-forming machine. As 
the thickness of capsules is dependent on the viscosity of the gelatin solution, the viscosity of the 
gelatin solution is adjusted before the gelatin is supplied to the machine. 
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Capsules are formed on stainless steel moulds called "pins", which are designed to produce the 
required shape for the formation of capsule bodies and caps. The gelatin solution is placed into 
jacketed, stirred containers called "dip pans" or "dip pots" which maintain the required 
temperature of the gelatin solution using heat controls. The "pins" are then lowered into the 
gelatin solution and the quantity of gelatin retained on the pins and the pattern of "run-off' is 
governed by the viscosity of the gelatin solution. The gelatin is set on the pins by passing the 
material through a stream of cool air. The capsules are then dried by passing the pins through a 
series of drying kilns in which the temperature and humidity is controlled in order to strike a 
balance between drying of the capsules until they are robust enough to withstand handling and 
not over drying them to a state in which they are brittle. 
The dried capsules are removed from the pins using a set of metal jaws, which are placed around 
each pin. The capsules that are formed are longer than the required length and have to be cut to 
length before joining the bodies and caps together. The capsules are then checked to ensure that 
they are the appropriate length for the required size and to ensure that the diameters of the caps 
and bodies are suitable to ensure that they seal once closed after filling. Capsules with defects, 
such as thin areas, bubbles, poorly cut edges, splits or holes are discarded. 
Capsules that are of appropriate quality are then marked/printed using edible pharmaceutical 
grade ink, in different designs for ease of identification. Capsules are then stored for use at 
appropriate temperatures and relative humidities (RH) that are, ideally between 10-30°C and 70% 
RH, respectively. 
3.4.1.2 Capsule properties 
The moisture content of hard gelatin capsules on receipt from the manufacturer, is required to be 
between 13-16% w/w [93,94]. Hard gelatin capsule stability is particularly sensitive to moisture 
content and concentrations of moisture below 10% w/w result in brittle capsules that fracture on 
handling whereas moisture levels greater than 18% w/w result in capsules that soften and become 
distorted in shape [93]. The change in moisture content of hard gelatin capsules can be monitored 
by a change in diameter of the components of a capsule, with an observed change of 0.5% in 
diameter for each 1% change in moisture content in the range of 13-16% w/w water content 
[93]. Heat absorption, moisture content and tensile strength of capsules exposed to different 
conditions of humidity have been simultaneously measured and found to be affected by the type 
of gelatin, the overall composition of the capsule as well as the presence of colourants [93]. The 
stiffness of a gelatine capsule shell has with time been found to be influenced by the water 
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content and the excipients used in the capsule shell and fill formulations. The optimal 
performance of capsules during machine-filling is attained when capsules are filled at relative 
humidity conditions ofbetween 45-55% RH [94]. 
The solubility of gelatin, which influences the disintegration of hard gelatin capsule shells is 
affected by temperature [93]. Gelatin is insoluble at 31 °C, is readily soluble in biological fluids at 
body temperature and a 30% change in dissolution rate of gelatin in the temperature range of 35-
39°C has been observed [95]. The disintegration of hard gelatin capsule shells is influenced by 
the hydrophilicity and hydrophobicity of fill materials in addition to the dissolution medium used 
in testing [93]. 
Hard capsules are not air tight and gases may penetrate the capsule through the gap between the 
capsule cap and body, a phenomenon that poses a potential stability concern for compounds 
susceptible to oxidation [93]. The use of air tight containers significantly reduces this problem 
[93]. It is important to ensure that hard gelatin capsule formulations are stored appropriately as 
hard gelatin capsules subjected to the ICH-accelerated storage conditions of 40°C/ 75% RH for 
six months, have shown significant changes in the dissolution rate of the fill material that has 
been attributed to a cross-linking reaction of the gelatin [93]. 
3.4.1.3 Capsule sizes 
Two-piece hard gelatin capsules are commercially available in eight different sizes with 
associated fill volumes that are summarised in Table 3.1 [92]. Sizes larger than 0 are rarely used 
to treat humans as their large size make swallowing difficult [17]. Small sized capsules, in 
particular those as small as size 5 are rarely used due to difficulties encountered with automated 
filling of these [92). 
Table 3.1. Sizes of commercially available capsules [92] 
Capsule size 
Volume (ml) 
000 
1.37 
00 
0.95 
0 
0.68 
3.4.2 Alternatives to hard gelatin capsules 
1 
0 .50 
2 
0.37 
3 
0.30 
4 
0.21 
5 
0.13 
Although the majority of two-piece hard capsules are made from gelatin, hydroxypropyl cellulose 
and potato starch have been used to manufacture two-piece capsules that overcome some 
limitations ofhard gelatin capsules. 
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3.4.2.1 Hydroxypropyl methylcellulose (HPMC) capsules 
Two-piece HPMC capsules have been developed as alternatives to hard gelatin capsules and have 
been commercially available for over two decades [96]. The moisture content of HPMC capsules 
is less than that of hard gelatin capsules and ranges between 4-7% w/w [93]. As a consequence of 
this lower moisture content, HPMC capsules are more suitable for formulations containing drugs 
that exhibit tendencies to degrade in water [97]. The effect of moisture content on HPMC 
capsules is less pronounced than in hard gelatine capsules and at levels of 1% w/w, HPMC 
capsules are not brittle [93). Although the dissolution of HPMC capsules is approximately three 
times slower than that of hard gelatin capsules in the temperature range of 35-39°C, the 
dissolution ofHPMC capsules is unaffected by temperature changes ofbetween 10-55°C [93]. 
HPMC capsules offer several advantages over hard gelatin capsules including the fact that they 
are made from plant derived material rendering them suitable for use in patients with special 
religious and/or dietary requirements [98]. HPMC, unlike gelatin, lacks chemically reactive 
groups, which decreases its potential to undergo cross linking reactions over longer periods of 
storage [97]. In addition HPMC capsules are more suitable for enteric coating as they have a 
rough surface as compared to hard gelatin capsules, which provides for better adhesion of the 
coating material to the capsule surface [99]. HPMC capsules have also been observed to have a 
significantly less pronounced oesophageal sticking tendency in vitro, as compared to hard gelatin 
capsules [97]. 
3.4.2.2 Starch capsules 
Starch capsules are made from starch derived from potatos using injection moulding technology 
as a method of manufacture and represent a direct alternative to hard gelatin capsules for drug 
delivery [1 00). Hard shell starch capsules consist of a body and a cap that are sealed immediately 
after filling the capsule body by applying a hydroa1coholic solution to the inner section of the cap 
prior to its being placed on the capsule body [1 00). Hard shell starch capsules are officially 
recognised in the United Stated Pharmacopeia and National Formulary as a suitable alternative to 
gelatine capsules [I 00). 
Starch capsules are supplied in five different sizes viz., 0, 1, 2, 3 and 4, all with the same cap size 
[I 00). Starch capsules have a high quality surface finish as they lack a "lip seal" as observed with 
hard gelatin capsules [100]. Starch capsules are odourless and rigid and display similar 
dissolution characteristics to hard gelatin capsules [I 00). 
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Starch capsules offer several advantages over hard gelatin capsules, which include pH-
independent dissolution characteristics and better stability as any moisture content in the capsules 
shells is bound to the starch [100]. The smooth finish of starch capsules makes them tamper-
evident as well as renders them more suitable for enteric coating after filling [ 1 00]. Furthermore, 
starch capsules are produced from a non-animal source which makes them suitable for patients 
with beef allergies and religious preferences. 
3.4.3 Capsule Fill Materials 
3.4.3.1 Solids for capsule filling 
An increased demand for encapsulated products from the mid 1900's led to the development of 
automated filling machines for ensuring uniform filling of solid materials into two-piece hard 
gelatine capsules [ 1 01]. Modem capsule filling machines are based on two types of automated 
systems viz., dosator nozzle or tamp-filling machines [93]. The operation of dosator nozzle 
machines involves lowering into a powder bed to permit powder to enter a dosing tube following 
which the powder is compressed prior to injection into a capsule body [93]. The operation of 
tamp-filling machines relies on pins pushing through a powder bed so that a unit dose is 
transferred into a dosing disc after which this dose is ej ected into a capsule body [ 1 02]. It is 
therefore important to understand and optimize powder flow properties to ensure efficient capsule 
filling and more importantly accurate dosing of fill materials into capsules. 
Solid materials and powders exhibit an inherent resistance to the differential movement between 
particles when subjected to external stresses such as blending [92]. The magnitude of resistance 
to particle movement is affected by the surface properties of materials, particle size distribution, 
shape and geometry of particles in addition to any electrostatic charges that may be induced as a 
function of the manufacturing process [92]. Powders suitable for filling into capsules should 
display good flow properties, even packing densities, similar particle size distribution and should 
be non-cohesive which will prevent sticking to metallic parts of capsule filling machines [93]. A 
large number of fine particless, i.e. more than 20% of particles of a blend with a diameter of 50 
11m or less, has been associated with poor flow of powders whilst coarse powders with the 
majority of particles being larger in diameter than 150 11m have been shown to display excellent 
flow properties [93]. Optimal powder flow and packing properties for capsule filling can be 
accurately determined by determination of flow parameters using Carr's compressibility index, 
Hausner's ratio in addition to the angle ofrepose, use ofKawakita's equation and Jenike's flow 
factor [ 1 03]. 
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The use of coated pellets for capsule filling has received recognition for use as sustained release 
formulations, which may offer advantages over monolithic dosage forms, such as tablets, in that 
the risk of dose dumping is significantly reduced [ 104]. The effect of pellet shape, pellet size 
distribution and pellet shape for capsule filling has been investigated using a three-dimensional 
computer simulation (Monte-Carlo) technique [104]. Rowe et al. observed that for all sizes of 
capsules, there was a gradual decrease in fill weight and increasing variability with increasing 
pellet size [104]. For all capsule sizes increasing polydispersity within a set range normally seen 
with pellets produced by extrusion and spheronisation had no effect on fill weight or weight 
variation and that for any pellet shape with aspect ratios of 1.2 and below, there was no difference 
in fill weight and weight variation [ 104]. 
The use of granules to fill hard gelatin capsules to overcome difficulties such as variations in fill 
weight due to impaired powder flow or stickiness has been shown to be beneficial [ 1 05]. 
Granules prevent fine powder segregation, which is important if the particle size of the drug 
cannot be matched to those of compatible excipients [105]. Granules can enhance homogeneity of 
powder mixtures, which is particularly important for the inclusion of low dose drugs in 
formulations [105]. 
Different capsule filling mechanisms have facilitated filling of capsules with tablets as well as 
combinations of powders, pellets and tablets [ 1 05]. 
3.4.3.2 Liquid and semi-solid fill materials for capsule filling 
Liquid and semi-solid fill materials for pharmaceutical capsules offer several advantages over 
solid fill materials, including better control of capsule fill weight and content uniformity, 
particularly for low dose drugs of relatively higher potency [ 1 06]. Furthermore liquid fill 
formulations for capsules reduce the presence of airborne particles and ensure easy containment 
of spillages when working with toxic materials [93, 1 06]. In general liquid formulations use fewer 
excipients and ensure an improvement in the dissolution of poorly water soluble drugs or control 
drug release with these relatively simple formulations [93,107]. 
Liquid fill formulations for pharmaceutical capsules are mainly thixotropic gels that undergo 
shear thinning during the filling process and gel restructuring with an apparent increase in 
viscosity once dosed into the capsule [ 1 08]. In addition thermosoftening systems that are 
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liquefied by heat to permit filling into capsules followed by rapid solidification on cooling in the 
capsules, have been used [93, 109]. 
When filling capsules using the abovementioned systems, important factors to consider include 
the apparent viscosity of the formulation as this influences the efficiency and accuracy of filling, 
the capsule shell integrity as it is important for gelatin shells to maintain their moisture content 
balance in addition to the excipients used in relation to thermal stability, rheology and capsule 
shell integrity [93,110]. 
3.4.4 Sustained-release capsule formulations 
Capsules have made an important contribution to the production of oral controlled release 
products and to date several formulation techniques have been used to produce controlled-release 
capsule formulations [ 111-116]. It is advantageous to fill pellets coated with rate retarding 
polymers into capsules as this strategy will avoid the damage that may be caused to coating 
materials during compaction of materials into tablets (93]. Enteric coating of the capsules after 
filling has been successfully applied to the intestinal targeting of drugs using HPMC capsules and 
Eudragit® polymers [99]. Formulations of powder blends of active pharmaceutical ingredients 
and sustained release polymers [93] in addition to liquid and semi solid blends, particularly with 
lipid materials as retardants of drug release [113,117-120] have been successfully used in 
capsule formulations to achieve controlled release of the active. 
3.5 MATERIALS AND METHODS 
3.5.1 Excipients 
All excipients used for formulation studies were GRAS (Generally Accepted As Safe) listed 
and/or are accepted for use as food additives in Europe and/or are included in the FDA Inactive 
Ingredients guide [121]. A summary of the trade names and sources of all excipients used in 
formulation studies is summarised in Table 3.2. 
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Table 3.2. Excipients used in formulation studies 
Name 
Minocycline hydrochloride 
Hydroxypropylmethyl cellulose 
(HPMC) 
Hydroxypropyl cellulose (HPC) 
Glyceryl behenate 
Glyceryl palmitostearate 
Microcrystalline cellulose (MCC) 
Lactose monohydrate 
USP/NF/BP/EP/JP 
Sodium starch glycolate 
Poloxamer 188 
Composition 
Trade name 
Minocycline HCL 
Metbocel® KlOOM 
Klucel® EF 
Compritol® 888 ATO* 
Precirol® ATO 5** 
Avicefl!) 102 
Super Tab<t 
Explotab® 
Lutrollf micro 68 MP *** 
Technical 
* Glyceryl dibehenate, Tribehenin, Gylceryl behenate 
** Tripalmitin, Tristearin 
*** Polyoxypropylene-Polyoxyetbylene Block Copolymer 
3.5.1.1 Hydrophilic matrix-forming polymers 
Manufacturer/Donor 
Aspen Pbarmacare, SA 
Colocorna- LTD, UK 
Aspen Pharmare, SA 
Gattefosse, Germany 
Gattefosse, Germany 
Aspen Pharmacare,SA 
Lactose Co. Hawera, NZ 
Aspen Pharmacare,SA 
BASF Corporation, USA 
Hydrophilic matrix tablets are regarded as the simplest and most cost effective means of 
formulating extended release dosage forms [122]. Various hydrophilic or water swellable 
polymers with high molecular weights, such as hydroxypropyl methylcellulose (HPMC), 
hydroxypropyl cellulose (HPC) and polyethylene oxide (PEO) have been used as sustained 
release polymeric matrices [122]. 
The mechanism of drug release from hydrophilic polymer matrices is complex but may be 
described as including three main stages viz. dissolution of the drug (if soluble), diffusion of the 
drug through a hydrated portion of a matrix and erosion of the outer hydrated polymer on the 
surface of the matrix [122]. 
Initially drug release from hydrophilic matrix systems involves the formation of a steep 
concentration gradient at the polymer/water interface resulting in water uptake into the matrix 
facilitating hydration ofthe polymer to form a 'gel layer" around the dosage form [82,122]. This 
process is a glassy-to-rubbery state transition of the polymer [122]. Except for soluble drug on the 
surface of the dosage form, which may result in an initial burst release, the core of the 
formulation is essentially comprised of drug at the initial stages of polymer hydration (122]. 
Following contact of the dosage form with water, drug diffuses out of the system along a 
concentration gradient with a substantial increase in the diffusion coefficient as water content in 
the system increases [82]. Dissolved and un-dissolved drug co-exist within the matrix in the case 
of poorly soluble drug inclusion and un-dissolved drug is not available for diffusion [82]. High 
69 
Chapter 3, Formulation development and assessment of minocycline capsule dosage forms 
initial drug loadings result in matrix systems that change significantly during the drug release 
process and they tend to become porous and less restrictive to diffusion as drug is depleted [82]. 
The final stage of drug release and which may be negligible in cases in which rapid drug release 
occurs, is the dissolution of the matrix [82, 122]. The rate of dissolution of the matrix is dependent 
on the chain length and degree of the substitution of the matrix used [82,122]. 
3.5.1.1.1 Hydroxypropyl methylcellulose (HPMC) 
Hydroxypropyl methylcellulose (HPMC) or hypromellose is commercially available as 
Methocel® and is a partly 0-methylated and 0 -(2-hydroxypropylated) cellulose [121]. HPMC is 
an odourless and tasteless, white or creamy-white fibrous or granular powder that is soluble in 
cold water forming a viscous colloidal solution on hydration [121]. Different grades of HPMC 
may be distinguished by appending a number indicative of the apparent viscosity, in megapascals 
(mPa ), of a 2% w/w aqueous solution at 20°C [121]. 
The physicochemical properties ofHPMC, such as for example its solution viscosity, are strongly 
affected by the content of methoxy and the hydroxypropoxy functional group content and the 
associated molecular weight ofthe polymer [82]. Four different types ofHPMC are distinguished 
by the USP based on their relative methoxy and hydroxylpropoxy functional group content. The 
grades reported include HPMC 1828, HPMC 2208, HPMC 2906 and HPMC 2910 where the first 
two digits denote the approximate percentage content of the methoxy functionality and the last 
two digits denote the percentage of hydroxypropoxy functionality calculated on a dried basis 
[82, 121]. 
HPMC may be classified as a coating agent, film-former, rate-controlling polymer for sustained 
release, stabilizing agent, suspending agent, tablet binder and viscosity-increasing agent [121]. 
High viscosity grades of HPMC may be used at concentrations of between 10-80% w/w to retard 
the rate ofre1ease of drugs from a matrix in tablets and capsules in which it is included [121]. 
HPMC is the most frequently used and studied hydrophilic polymer for the formulation of 
sustained release matrices [122-124]. HPMC is readily available and globally accepted as a 
pharmaceutical excipient. HPMC can be used with various drugs or in combination with other 
polymers. The stability of HPMC and its non-ionic nature allows for the development of dosage 
forms that exhibit pH-independent performance [122-124]. 
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3. 5.1.1.2 Hydroxypropy/cellu/ose (HPC) 
Hydroxypropylcellulose (HPC), also known as hyprolose or K.lucel® is a non ionic partially 
substituted poly (hydroxypropyl) cellulose ether [121]. HPC is a white or slightly yellow-
coloured, odourless and tasteless powder that is freely soluble in water below 38°C and that forms 
a smooth clear colloidal solution on hydration [ 121). 
As the molar substitution of HPC is fixed, the molecular weight is varied by controlling the 
degree of polymerization of the cellulose backbone [ 125]. The viscosity of HPC increases as the 
degree of polymerization increases [ 125]. 
HPC may be classified as a coating agent, emulsifying agent, suspending agent, tablet binder, 
thickening agent or viscosity-increasing agent [121]. Low viscosity grades of HPC are used 
mainly as tablet binders whereas high viscosity grades of HPC are used in sustained-release 
matrix formulations [125]. The release rate of drug included in HPC matrices increases with 
decreasing viscosity ofHPC that is included in the formulation [125). 
3.5.1.2 Lipophilic matrix-forming agents 
Lipid excipients, particularly solid lipids have gained popularity as matrix forming agents for 
sustained release. The advantages of using lipid or wax matrices for sustained release includes 
chemical inertness, ease of manufacturing with high reproducibility and low cost [126]. Lipid 
matrices have been used to formulate dosages forms that contain freely [127] and poorly water 
soluble [117] compounds. 
Considerable attention has been focussed on the Gelucire® family as matrix forming lipids for 
sustained release technologies. Gelucire® is derived from natural hydrogenated food grade fats 
and oils [ 117]. Gelucire® may contain pure gycerides which may be mono-, di- or triglycerides of 
saturated fatty acids, or may be comprised of mixtures of glycerides and fatty acid esters of 
polyethylene glycols in varying proportions [ 117]. 
Ge1ucire® is commercially available in different grades that are characterised by their 
hydrophilic-lipophilic balance (HLB value) and their melting points [128,117]. In vitro release 
and sustained release characteristics and mechanism of drug release are influenced by the grade 
and proportion of Gelucire® used in the matrix [ 117]. A specific grade of Gelucire® is denoted by 
two sets of digits, of which the first two digits denote the melting point of the material and the 
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last two denote the HLB value. Different grades of Gelucire® have been used pharmaceutically to 
ensure sustained release of drugs can be achieved [ 129]. Lipid matrices are prepared by 
dispersing a drug into molten lipid, after which the matrix is filled into capsules directly or left to 
solidify prior to screening through sieves and subsequent compression into granules 
[117,126,130]. Lipid matrices may also be prepared, by mechanical blending to form physical 
mixtures, which may then be compressed into tablets [ 131). Drug granulation followed by 
compression at elevated temperature has been used to prepare diprophylline sustained release 
formulations using glycerol palmitosterate lipid matrices [ 132]. 
Drug release from highly lipophilic lipid matrices has been attributed to diffusion through 
channels formed in the matrices which result from rapid dissolution of soluble drug particles 
located on the surface of the matrices [ 117]. Further penetration of aqueous media through the 
channels that are formed, facilitates further release of drug embedded deeper in the matrices 
[ 131]. Drug release from matrices may be further enhanced by the addition of water soluble 
excipients such as lactose, which promote the formation of pores through which more drug can be 
released as the excipients dissolve [13 1]. The addition of surfactants increases the rate of release 
of drugs from lipid matrices as surfactants reduce the hydrophobic interactions between lipid 
matrix materials and the drug dispersed in the matrix [ 130,131). Drug release from amphiphilic or 
water dispersible Gelucire® bases has been demonstrated to be predominantly a result of erosion 
of the matrix [ 117). 
One of the major disadvantages associated with the use oflipid matrices is the instability of lipids 
over long periods of storage and which is attributed to either the conversion of triglycerides to 
more stable polymorphic forms or conversion of amorphous to crystalline forms of the lipid bases 
[133]. Remunan et al. [120], have demonstrated a decrease in the in vitro release rate of 
nifedipine from lipid matrices over a period of six months and San Vicente et al. [ 134] showed an 
alteration of biopharmaceutic parameters of salbutamol sulphate in lipid matrices dependent of 
the type of Gelucire® and size of the dosage fom1 used. 
Glycerol palmito-stearate (Precirol® ATO 5, also known as Gelucire® 54/02) and glycerol 
behenate (Compritol® 888, also known as Gelucire® 70/02) have been widely used as glyceride 
bases for preparation of sustained release dosage forms [ 126]. The esterification of long chain 
fatty acids and the absence of PEG esters have resulted in Precirol® and Compritol® showing a 
pronounced hydrophobic character that is expressed by a low HLB value of approximately 2 
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[ 13 5] 0 The classification and physical characteristics of Precirol<1l and Compritol® are summarized 
in Table 3030 
Table 3.3o Classification of Precirol® and Compritol® [126] 
Category Lipid Melting point Description Acid value 
Fatty acid ester of Compritol"' -70 Glyceryl behenate 4> 
gycerol 
Precirol® Fatty acid ester -57 Glyceryl palmitostearate 
305010201 Glyceryl Palmitostearate (Preciro~ ATO 5) 
Glyceryl palmitostearate is a white powder with a faint odour and a melting point of 52-55°C 
[ 121). Glyceryl palmi to stearate is classified as a coating, gelling, release-modifying and 
sustained-release agent, tablet and capsule lubricant and diluent and taste masking agent [ 121] 0 
305010202 Glyceryl Behenate (Comprito~ 888 ATO) 
Glyceryl behenate is a fine white powder or hard waxy mass with a melting point of 65-77°C 
[121]. Glyceryl behenate may be classified as a coating agent, tablet binder or a tablet and 
capsule lubricant and is used as a lipophilic matrix or coating for sustained-release tablets and 
capsules when used at concentrations greater than 10% w/w [121]. 
3.5.1.3 Microcrystalline cellulose (MCC) 
Microcrystalline cellulose is commercially available as Avicel® PH or Emcocel® amongst others 
and is a purified, partially depolyrnerised cellulose that occurs as a white, odourless, tasteless, 
crystalline powder composed of porous particles [121]0 Microcrystalline cellulose is available in 
different grades based on the method of manufacture, the particle size as well as the moisture 
content of the material [121]0 The larger particle size grades exhibit greater flowability than small 
particles sizes whilst low moisture content grades have been used to formulate moisture sensitive 
drugs (121). 
Microcrystalline cellulose has been particularly useful pharmaceutically as a result of its low 
chemical reactivity and its excellent compactibility at low pressures [136]. Microcrystalline 
cellulose is used pharmaceutically as a binder or diluent in the formulation oftablets and capsules 
as well as a lubricant and disintegrant in tableting (121]. 
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3.5.1.4 Lactose Monohydrate 
Lactose monohydrate is a naturally occurring disaccharide, derived from milk and consists of a 
single galactose and glucose moiety [121]. Lactose is odourless and slightly sweet tasting and 
occurs as white to off-white crystalline particles or powder (121]. 
Several grades of lactose differentiated by different particle size distribution and flow 
characteristics are available for use as fillers or diluents for tablets and capsules [ 121]. The 
selection of suitable grades of lactose for use in the formulation of capsules is determined by the 
type of encapsulation machinery used and fine grades are regarded suitable for tableting as they 
permit adequate mixing with other formulation excipients during a wet granulation or milling 
process [ 121 ]. 
3.5.1.5 Sodium starch glycolate 
Sodium starch glycolate is described in the USP-NF23 as the sodium salt of carboxymethyl ether 
of starch [121]. Sodium starch glycolate occurs as a white to off-white, odourless, tasteless, free-
flowing powder [121]. 
Sodium starch glycolate is used pharmaceutically at concentrations of2-8% w/w as a disintegrant 
in tablet and capsule formulations [ 121]. Disintegration occurs as a result of rapid fluid uptake 
and swelling ofthe sodium starch glycolate [121]. The effectiveness of sodium starch glycolate as 
a disintegrant is determined by its physicochemical properties which are affected by the degree of 
crosslinking and extent of carboxymethylation of the polymer [121]. 
3.5.1.6 Poloxamer 188 
Poloxamers are commercially available as Lutrol®, Pluronic®, Monlan®, Supronic® or 
Synperonic®, amongst others and are block copolymers of ethylene oxide and propylene oxide 
conforming to the general formula HO(C2H40)a(C3H60)b(C2~0)aH [121]. Poloxamers are non-
ionic and are comprised of a hydrophilic polyoxyethylene segment and a hydrophobic 
polyoxypropylene segment, the compositions of which are included in their nomenclature [ 121]. 
The non-proprietary name "poloxamer" is followed by a number, the first two digits, of which 
when multiplied by 100, corresponds to the approximate average molecular weight of the 
polyoxypropylene portion of the copolymer and the third digit, when multiplied by 10, 
corresponds to the percentage by weight of the polyoxyethylene portion [ 121]. 
Poloxamers occur as white, waxy free flowing solids and are tasteless and odourless [ 121]. 
Poloxamer 188 has a melting point of 52-57°C and is freely soluble in water [121]. Poloxamers 
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are used as dispersing agents, emulsifying and co-emulsifying agents, solubilising agents, tablet 
lubricants and as wetting agents [ 121]. 
3.5.2 Formulation Composition 
Sustained release formulations based on the matrix technology were prepared. Hydrophilic and 
lipid polymeric matrices were studied. To ensure the selection of optimal formulations in terms 
of minocycline release pattern, for further studies, the following formulation variables were 
investigated during formulation development: 
i) the effect of hydrophilic polymer type 
ii) the effect of different concentrations of hydrophilic polymer 
iii) the effect of lipid type 
iv) the effect of different concentrations of lipid 
v) the effect of using different diluents/capsule fillers 
vi) the effect of adding disintegrant to the formulations 
vii) the effect of adding surfactant to the lipid formulations 
A summary of the composition of formulations manufactured in these studies is shown in Table 
3.4. 
75 
Chapter 3, Formulation development and assessment ofminocycline capsule dosage forms 
Table 3.4. Minocycline capsule formulations 
Batch# Release-retarding polymers (%w/w) Capsule 
HPMC HPC Precirol® Compritol® filler 
MIN0-01 10 MCC 
MIN0-02 20 MCC 
MIN0-03 30 MCC 
MIN0-04 50 MCC 
MIN0-05 10 MCC 
MIN0-06 20 MCC 
MIN0-07 30 MCC 
MIN0-08 50 MCC 
MIN0-09 50 MCC 
MIN0-10 50 MCC 
MIN0-11 20 LACTOSE 
MIN0-12 30 LACTOSE 
MIN0-13 20 MCC 2 
MIN0-14 20 LACTOSE 2 
MIN0-15 30 MCC 2 
MIN0-16 30 LACTOSE 2 
MIN0-17 10 10 MCC 
MIN0-18 30 MCC 
MIN0-19 30 MCC 
MIN0-20 30 LACTOSE 
MIN0-21 30 MCC 
MIN0-22 30 LACTOSE 
3.5.3 Formulation of sustained release minocycline hydrophilic matrix capsules 
SAA 
Pluronic F68 
2 
1 
1 
0.5 
0.5 
Powder formulations for capsule filling that contained minocycline hydrochloride equivalent to 
100 mg minocycline base (per capsule), 10-50% w/w of the hydrophilic polymer under 
investigation and microcrystalline cellulose or lactose monohydrate as filler were manufactured. 
The effect of sodium starch glycolate was investigated for selected formulations. Powders were 
prepared by the geometric dilution method of mixing using a mortar and pestle and passed 
through a 315 )..till sieve before manually filling into size 0 hard gelatin capsules. Each capsule 
contained 300 mg of powder fill material. A schematic representation of the procedures in the 
preparation of the formulations is summarised in Figure 3.6. The formula for each capsule is 
shown in Table 3.5 below. A sample production record for all formulations based on hydrophilic 
polymer matrix fills is located in Appendix I. 
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Weigh approprimeamount 
ofminocycline 
hydrochloride,BPMC/ 
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Pass powder 
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Mix powders by 
geometric dilution 
method of mixing 
Add additive 
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and mix 
Fill300mg/250mginto 
sm: 0 lmd gdalin 
C3pSO)cs 
Figure 3.6. Schematic representation of procedure for preparation of minocycline sustained release 
capsule formulations 
Table 3.5. Formula for hydrophilic polymer matrix sustained release minocycline capsules 
Minocycline hydrochloride 
Hydrophilic polymer (HPMC/HPC) 
Sodium starch glycolate 
Capsule filler (Microcrystalline cellulose/Lactose monohydrate) 
* I 0%, 20%, 30%, 40%, 50% w/w 
** 0, 2%w/w 
108 mg 
* 
** 
Ad 300 mg 
3.5.4 Formulation of sustained release minocycline lipid matrix filled capsules 
Powder formulations for capsule filling contained rninocycline hydrochloride equivalent to 100 
mg minocycline base (per capsule), 10-50% w/w of the lipid under investigation and 
microcrystalline cellulose or lactose monohydrate as filler. The effect of sodium starch glycolate 
and Poloxamer 188 was investigated for selected formulations. Powders were prepared by 
geometric dilution method of mixing and passed through a 315 11m sieve before filling into size 0 
hard gelatin capsules. Each capsule contained 250 mg of powder. A schematic representation of 
the preparation procedures for the formulations is illustrated in Figure 3.6. The formula for each 
capsule is shown in Table 3.6. A sample production record for all formulations based on lipid 
matrices can be seen in Appendix I. 
Table 3.6. Formula for lipid matrix sustained release minocycline capsules 
Minocycline hydrochloride 
Lipid (Compritol.r I Precirol'') 
Sodium starch glycolate 
Poloxamer 188 
Capsule filler (Microcrystaliine cellulose/ Lactose monohydrate) 
* 10%, 20%, 30%,40%,50% w/w 
** 0, 2% w/w 
** * 0, 0.5%, I%, 2% w/w 
108mg 
* 
** 
*** 
Ad 250 mg 
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3.6 DOSAGE FORM ANALYSIS 
3.6.1 Pharmacopoeial tests for capsules 
To ensure quality dosage forms are released onto the market regulatory authorities and 
pharmacopoeial bodies require that specific standards of quality are met. The British 
Pharmacopoeia (BP) requires that pharmaceutical capsules comply with the test for uniformity of 
content or uniformity of mass [22]. The BP also recommends a suitable dissolution test be used to 
demonstrate the appropriate release of active pharmaceutical ingredients. In addition the BP 
requires that hard capsules comply with the test for disintegration of tablets and capsules. 
3.6.1.1 Uniformity of mass 
The test for uniformity of mass as described in the BP requires the use of ten capsules from each 
manufactured batch [22]. The entire contents of each capsule are accurately measured after 
which, the average mass and percent deviation are calculated. For capsules containing less than 
300 mg of fill material, the percent deviation should be no more than 10 % whilst for capsules 
containing 300 mg or more, the percent deviation should not exceed 7.5% [22]. 
The exact weight for capsules manufactured in this study was obtained by calculating the 
difference in weight between the mass of the filled and empty capsules. The mean weight and 
relative standard deviations were then calculated and recorded. 
3. 6.1.2 Disintegration 
The BP requires that hard capsules conform to the disintegration test for tablets and capsules [22]. 
The disintegration apparatus is comprised of a basket rack assembly and a 1 litre low form beaker 
which measures 149 ± 11 mm in height with an inside diameter of 106 ± 9 rnm for the 
immersion fluid [22]. Present in the apparatus is a thermostatic arrangement for heating to ensure 
a temperature between 35°C and 39°C is maintained, and a device for raising and lowering the 
basket in the immersion fluid at a constant frequency rate between 29 and 32 cycles per minute, 
through a distance of 55 ± 2 mm [22]. The immersion fluid may be water and when justified, 
0.1M HCl or artificial gastric fluid [22]. The basket rack assembly moves vertically on its axis 
and there is no significant horizontal movement of the axis from the vertical [22]. 
Six dosage forms for testing are placed in each of the six tubes of the basket rack assembly (22]. 
Discs of dimensions that meet pharmacopoeial specifications may be used when permitted for 
dosage forms that float [22]. On completion of the disintegration test using the specified 
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conditions, all dosage forms must have disintegrated. If all six dosage forms have not 
disintegrated, the test should be repeated twice with twelve more dosage units [22]. To pass the 
test, sixteen of the eighteen dosage forms must have disintegrated [22]. 
Although it is not a requirement of some pharmacopoeias such as the United States 
Pharmacopoeia (USP) for tablets or capsules intended as extended-release or delayed-release 
dosage forms to comply with the disintegration test, disintegration tests were carried out to ensure 
that the capsule shell disintegrated in order to ensure that the capsule contents were exposed to 
dissolution media within a short period of time. A summary of the conditions used for the 
disintegration tests conducted in this study is shown in Table 3.7. 
Table 3.7. Conditions for disintegration test for minocycline capsule formulations 
Instrument 
Temperature of disintegration medium 
Volume of disintegration medium 
Dip rate per minute (dpm) 
3.6.1.3 Dissolution 
ERWEK.A ZT6 Disintegration Tester, Heusenstamm, Germany 
37°C 
700 ml 
30dpm 
Dissolution tests were carried out to study in vitro release characteristics of rninocycline 
formulations developed and manufactured in these studies. In vitro release profiles of 
minocycline from manufactured formulations are described in Chapter 4. 
3.6.1.4 Assay 
Assays for the powder fills were performed for each formulation. An amount of powder 
equivalent to the contents of one capsule viz., 300 mg and 250 mg for the HPMC based and 
Cornpritol® based formulations, respectively, were weighed out and dissolved in 100 rnl HPLC 
grade water and sonicated for ten minutes in a 100 rnl A-grade volumetric flask. A 1 ml aliquot of 
this solution was filtered through a Millipore Millex-HV Hydrophilic PVDF filter (0.45 )lrn) and 
diluted with 5 ml of a 250 )lg/ml solution of doxycycline hyclate solution. The solution was made 
up to volume with mobile phase and analysed using the developed HPLC method summarised in 
Table 2.5. 
3.6.2 Results 
3.6.2.1 Uniformity of mass 
A summary of the average content per capsule in addition to the relative standard deviations for 
all batches of minocycline sustained release capsules is located in Table 3.8. 
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Table 3.8. Mean mass and standard deviation for capsule formulations 
Formulation 
MIN0-01 
MIN0-02 
MIN0-03 
MIN0-04 
MIN0-05 
MIN0-06 
MIN0-07 
MIN0-08 
MIN0-09 
MIN0-10 
MIN0-11 
MIN0-12 
MIN0-13 
MIN0-14 
MIN0-15 
MIN0-16 
MIN0-17 
MIN0-18 
MIN0-19 
MIN0-20 
MIN0-21 
MIN0-22 
3.6.2.2 Disintegration 
Mean mass (mg) (n=l2) 
300.27 
299.63 
299.33 
299.87 
250.85 
249.70 
249.62 
250.58 
300.17 
250.48 
299.63 
250.45 
299.77 
299.47 
250.73 
250.15 
250.32 
250.08 
250.07 
250.11 
249.33 
250.25 
Standard deviation 
0.468 
0.887 
0.650 
1.088 
0.235 
0.754 
0.924 
0.488 
0.753 
0.652 
0.971 
0.409 
0.404 
0.231 
0.280 
0.217 
0.407 
0.232 
0.186 
0.319 
0.473 
0.383 
%RSD 
0.16 
0.30 
0.22 
0.36 
0.09 
0.30 
0.37 
0.19 
0.25 
0.26 
0.32 
0.16 
0.13 
0.077 
0.11 
0.087 
0.16 
0.093 
0.074 
0.13 
0.19 
0.15 
The disintegration of capsule shells when usmg de-ionised water as the immersion fluid 
commenced within the first three minutes of the test and was complete within ten minutes for all 
formulations tested. The disintegration of capsule shells of Formulation MIN0-06, MIN0-11 and 
MIN0-17 with O.lM HCl as immersion medium was complete within ten minutes of the 
commencement of the disintegration test. 
3. 6.2.3 Assay 
Assays of the powder fills for the capsule formulations revealed that all formulations contained 
between 95.2% and 105.5% of the stated amount of minocycline hydrochloride. Assays for 
specific formulations may be seen on specific batch record summaries in Appendix II. 
3.7 CONCLUSIONS 
Although technologies for modified-drug delivery have become more advanced over the years, 
matrix-based technologies continue to play a significant role in modified-drug delivery. The use 
oflipid matrices to produce sustained release has been extensively studied over the past few years 
and has provided an alternative means of formulating matrices, which may display some 
advantages over conventional matrix forming agents. 
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The use of capsules in the pharmaceutical and food industry has advanced over recent years, 
particularly with modernisation of capsule filling machines which have allowed for a huge variety 
of materials to be filled in capsules. Capsule formulations using powder blends are relatively 
simple to make and may provide for means of providing modified release dosage forms. 
Dosage form analysis is an important part of phannaceutical formulations, particularly to ensure 
quality of the products. The manufactured formulations in these studies were assessed according 
to pharmacopoeial requirements of the BP and the USP. The formulations were of uniform mass 
and the capsule shells disintegrated within the acceptable time as stated in the BP. The dissolution 
characteristics of the manufactured formulations are discussed in Chapter 4. 
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4 DRUG RELEASE FROM CAPSULE DOSAGE FORMS 
4.1 INTRODUCTION 
Drug absorption following administration of a solid dosage form depends on the release 
characteristics of the API from the dosage form, dissolution rate and/or solubilisation potential 
under physiological conditions and subsequent transport of the API across the membranes of the 
gastrointestinal tract [137]. As the first two steps of the process are crucial to the success of the 
absorption process, in vitro dissolution may be relevant as a predictor of in vivo performance 
[137). Dissolution testing is routinely used in Quality Control (QC) and Research and 
Development (R&D) laboratories [138]. 
In vitro dissolution test methods for quality control purposes provides information on the 
consistency of batches, homogeneity of dosage forms within a specific batch in addition to the 
impact of changes in composition, process or site of manufacture [139]. In vitro dissolution 
methods are important for the assessment of stability of pharmaceutical products [ 140] which is 
in turn important in establishing an appropriate shelf life for pharmaceutical products. 
As a tool in Research and Development, the focus of dissolution testing is geared towards 
providing some predictive estimates of drug release rates and mechanism in respect to the in vivo 
performance of a drug product [138]. In this instance, it is essential that the in vitro and in vivo 
dissolution behaviour of a drug product be similar or have a scalable relationship to each other, 
i.e. an in vitro in vivo correlation has been established [141] . In vitro dissolution test data may be 
used to evaluate and interpret any possible risk, such as for example dose dumping or food effects 
on bioavailability and the potential for an interaction with other drugs that has been associated 
with some pharmaceutical dosage forms [140]. 
The different approaches to in vitro dissolution testing for Quality Control and Research and 
Development requires that suitable dissolution media that fulfil the purpose of the dissolution test 
are selected for use in the test [138). In addition, one should select an appropriate dissolution test 
apparatus as the type of apparatus has been shown to influence drug release characteristics [ 142]. 
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Whilst highly discriminatory methods are suitable for QC purposes, they may not be suitable for 
the prediction of in vivo performance [138]. 
4.2 USP DISSOLUTION APPARATUS FOR SOLID ORAL PRODUCTS 
The United States Pharmacopoeia (USP) Chapter on dissolution testing; <711> DISSOLUTION, 
describes the use of four types of apparatus for dissolution testing of immediate-release (IR) and 
modified-release (MR) solid oral pharmaceutical products. These include Apparatus 1 (Basket 
Apparatus), Apparatus 2 (Paddle Apparatus), Apparatus 3 (Reciprocating Cylinder) and 
Apparatus 4 (Flow-Through Cell or BIODIS) [70]. 
The basket and paddle apparatus are recommended in various guidelines as the first choice for in 
vitro testing of immediate- and modified-release dosage forms as these apparatus are simple, 
robust and have been adequately standardised [140,142]. The basket apparatus is comprised of a 
vessel made of glass or other transparent and inert material, a motor, a metallic drive shaft and a 
cylindrical basket [70]. The vessel is partially immersed in a water bath of suitable dimensions 
and that is normally maintained at 37 ± 0.5° C during dissolution testing [70]. There is no 
significant motion from any part of the assembly except the controlled movement of the smoothly 
rotating stirring element attached to the basket [70]. The assembly of the paddle apparatus is 
similar to that of the basket apparatus except that a paddle formed from a blade and a shaft is used 
as the stirring element [70]. The use of a sinker for floating dosage forms is permissible although 
the use of sinkers has been shown to influence the in vitro release characteristics of drugs 
significantly [143]. In general dissolution media are of an aqueous nature and are typically 
buffers in the pH range 1- 8 and in some cases the use of water is permitted [70, 140]. The volume 
of dissolution medium used in each vessel for the basket and paddle methods should be between 
500 and 1000 ml with the use of 1000 ml recommended for new drug products or in the case of a 
revision of any existing test procedure [ 140]. The degassing of dissolution media, using a suitable 
method, prior to dissolution testing is recommended as drug release from some formulations is 
sensitive to the presence of dissolved gases in dissolution media [144,145]. Agitation in the 
basket and paddle apparatus is usually achieved by rotation of the basket or paddles at speeds of 
50 to 100 rpm and not exceeding stirring speeds of 150 rpm [1 40]. 
The basket and paddle apparatus have been criticised due to their "single-container" nature as this 
does not readily allow for changes in pH or any other changes during dissolution testing [140]. In 
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addition the use of the basket and paddle apparatus is not suitable for sparingly soluble drugs and 
aerophilic multiple unit doses that tend to float during the initial stages of testing [140]. 
A major disadvantage of using the basket or paddle apparatus is the variability of the release data 
that can be attributed to hydrodynamic artifacts or fluid flow patterns in the dissolution vessel 
[146]. Contrary to the belief that commercially available dissolution vessels all have the correct 
physical dimensions for dissolution testing, it has been observed that some commercially 
available dissolution vessels have irregular inner surfaces, such as for example deviations from 
circularity for the inner cylinder, deviation from cylindricity for the entire cylindrical shape and 
deviation from concentricity for the centre of the sphere, that result in an altered liquid flow 
dynamic or pattern that lead to variable drug release patterns throughout the dissolution test 
[147]. Furthermore, vessel contour imperfections have been reported to cause variability as a 
result of altered fluid flow within the vessel [148]. It is important to ensure that the physical 
parameters including type of dissolution apparatus (basket or paddle), paddle design, basket mesh 
size, agitation speed, fluid flow velocity and pattern, media temperature, deaeration method and 
type of sinker used, are carefully monitored and accurately reported, as they have been found to 
have a significant impact on the hydrodynamics of a dissolution test system and hence dissolution 
patterns of drug products tested in these systems [ 146]. A "dead zone" phenomenon or cone 
formation, whereby large quantities of insoluble excipients form a dense mass at the bottom of 
the vessel have been observed during dissolution testing of poorly soluble drugs when using the 
paddle apparatus [149]. Cone formation has also been observed to cause slower dissolution rates 
[150]. Several modifications to the paddle apparatus that change flow hydrodynamics in 
dissolution vessels have been proposed to minimise the variability of dissolution data attributed 
to cone formation [146]. These modifications could be either by displacing the unstirred 
disintegrated particles/excipients away from the centre of the vessel or by shortening the distance 
between the drug and the bottom of the paddle, thereby allowing for greater interaction between 
the surfaces of the drug and the moving dissolution medium. 
The shortcomings of USP Apparatus 1 and 2, particularly shaft wobble, location, centering, 
deformation of baskets and paddles and the effect of dissolved gases in dissolution media have 
brought about the need for the development of dissolution apparatus that are abie to withstand the 
physical, mechanical and hydrodynamic variations inherent in USP Apparatus 1 and 2 test 
systems [ 151]. In addition the increased interest to approach the goal of establishing an in-vitro in 
vivo correlation (IVIVC) has made it necessary to develop instruments in which the pH, molarity, 
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presence of cations and anions, buffer type, inclusion of surface active agents and degree of 
agitation can be altered sequentially during the dissolution test process [ 151]. The recognition of 
the above factors led to the development ofUSP Apparatus 3 [151]. 
USP Apparatus 3 or reciprocating cylinder apparatus (BIODIS) consists of a set of cylindrical flat 
bottomed glass vessels, a set of glass reciprocating cylinders, inert fittings and screens that are 
made of suitable non adsorbing and inert material [70]. The fittings and screens are designed to fit 
the tops and bottoms of the reciprocating cylinders [70]. USP Apparatus 3 is also fitted with a 
motor and drive assembly to reciprocate the cylinders vertically inside the vessels or horizontally 
to another row of vessels [70]. The vessels of the USP Apparatus 3 are partially immersed in a 
water bath that is usually maintained at 37 ± 0.5°C during dissolution testing [70]. USP 
Apparatus 3 allows the operator to programme the agitation rate (dips per minute) within the 
vessels, the time the dosage form spends in each row of vessels as well as the pattern of 
dissolution media changes, which is of importance when developing dissolution methodology to 
study IVIVC [151]. 
The main advantages presented by USP Apparatus 3 include the fact that variability of 
dissolution data is reduced as this apparatus is less sensitive to changes in geometry of the 
dissolution vessels and the presence of dissolved air in the dissolution media [151]. The "coning" 
effect observed in USP Apparatus 2 is absent with USP Apparatus 3 resulting in more precise 
dissolution results when using this apparatus [151]. USP Apparatus 3 may be applied as an in 
vitro predictor of bioavailability in the fed and fasted state [ 151, 152]. 
USP Apparatus 4 or flow-through cell apparatus consists of a reservoir and a pump for the 
dissolution medium, a flow-through cell and a water bath that maintains temperature at 3 7 ± 
0.5°C during dissolution testing [70]. During testing, the dosage form is placed in the flow-
through cell, which is fitted with a filter system to prevent escape of undissolved particles from 
the top of the cell [70]. The dissolution medium is continuously flushed through the cell during 
the test at a flow rate of between 4 and 16 ml per minute, providing the mechanical agitation for 
dissolution of the drug substance [70,140]. The flow-through cell may be run either as a closed or 
open system with the open system overcoming some of the problems associated with the "single 
container'' nature of the basket and paddle apparatus [140]. 
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The availability of the four compendia dissolution apparatus has ensured that dissolution testing 
of all oral solid pharmaceutical dosage forms is possible on a reasonable basis [140]. In addition, 
the use of alternate models of the above four apparatus as well as appropriate modifications are 
available for the dissolution testing of formulations that cannot be accommodated by use of 
standard USP Apparatus 1- 4 [ 140]. 
4.3 IN VITRO RELEASE STUDIES OF MINOCYCLINE FROM SUSTAINED 
RELEASE CAPSULE FORMULATIONS 
4.3.1 Procedure 
There is no pharmacopoeial method for the dissolution of modified-release minocycline in the 
USP or BP [11,153,154]. Furthermore the monograph for prolonged-release minocycline in the 
BP does not indicate the desired release pattern for minocycline from prolonged release 
formulations. The objective of this study was to formulate minocycline dosage forms that 
released minocycline through a zero-order kinetic process over a 12 hour period. At least 80% of 
the minocycline in the formulation was expected to have been released at the end of the 
dissolution test period of 12 hours. 
The USP monograph for immediate release minocycline formulations recommends the use of 
water as the dissolution medium. De-ionised water was therefore used as the dissolution medium 
for preliminary dissolution studies of minocycline sustained release formulations. The de-ionised 
water was degassed by filtration through a 0.45 !liD DuraporeQy HVLP membrane filter (Millipore 
Corporation, Bellerica, MA, USA) with the aid of an Eyela Vacuum pump (Tokyo Rikakikai Co., 
Tokyo, Japan). The in vitro release pattern for minocycline from the formulations MIN0-0 1 to 
MIN0-22 listed in Table 3.4 were assessed using a fully automated Model SR 8 PLUS 
dissolution apparatus (Hanson Research Corporation, Chatsworth, CA, USA) fitted with an 
Autoplus™ Multifill™ and a Maximizer Syringe Fraction Collector (Hanson Research 
Corporation, Chatsworth, CA, USA). The dissolution studies were conducted using USP 
Apparatus 1 [70] with USP baskets of mesh size 40 and a basket rotation speed of 50 rpm (n=6). 
Aliquots of 2 ml were withdrawn at the sampling times summarised shown in Table 4.1 without 
further replacement of the dissolution medium. Samples were analysed using a validated HPLC-
UV method described in Table 2.5 of this dissertation. A complete summary of the dissolution 
test conditions used in these studies is shown in Table 4 .1. 
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Table 4.1. Summary of dissolution test conditions 
Dissolution apparatus 
Dissolution media: 
Preliminary studies 
USP Delayed-release two-stage test 
Temperature 
Basket speed 
Basket screen size 
Filter size 
Volume withdrawn 
Volume replaced 
Sampling times 
USP Apparatus I 
900 ml de-ionised water 
750 m1 0.1 M HCI followed by addition of 250 ml 0.2 M tribasic 
sodium phosphate after 2 hr. Resultant pH of dissolution medium = 6.8 
37°C± 0.5°C 
50 rpm 
40 
0.45J.1m 
2ml 
No replacement 
I , 2, 4, 6, 8, 12 hours 
All formulations were tested within 12 hours of manufacture and the in vitro dissolution test was 
able to discriminate formulation factors that affected drug release during early formulation 
development studies of minocycline sustained release formulations. 
Several extended-release capsule formulations described in the USP have been assessed using the 
USP "two-stage" test for delayed-release dosage forms [70,153,154]. The USP "two-stage" test 
involves exposure of a dosage form to an acidic medium for two hours (usually 0.1 M 
hydrochloric acid) and then to a buffer (usually 0.2 M tribasic sodium phosphate, pH = 6.8) for 
the duration of the test [70]: The three test formulations that exhibited "near-zero order" release 
and released at least 80 % of rninocycline in the 12-hour dissolution test were then tested using 
the USP "two-stage" test to gain an understanding of the type of in vivo release pattern that could 
be expected, should the dosage form be administered to humans. 
4.3.2 Statistical Interpretation of data 
Dissolution profiles were compared using statistical and mathematical methods to better 
understand the release characteristics of rninocycline from the test formulations. A one way 
analysis of variance and the difference (fi) and similarity (h) factors were used to compare 
dissolution profiles of the formulations displaying "near-optimal" release and the release profile 
of the target formulation. Zero-order, Higuchi and Korsmeyer-Peppas mathematical models were 
used to fit data from all formulations tested in order to determine the mechanisms of drug release 
from the formulations and to establish the effect of formulation variables on the mechanism of 
minocycline release. The mathematical and statistical comparison of dissolution profiles is 
discussed in further detail in Chapter 5 of this dissertation. 
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4.4 RESULTS AND DISCUSSION 
4.4.1 The effect of type and concentration of hydrophilic polymer on the rate and extent 
of minocycline release 
The use of hydroxypropyl cellulose (HPC) at a concentration of 50% w/w resulted in almost 
complete release of minocycline within six hours whereas only 41 % minocycline was released 
from the formulation in which 50% w/w hydroxypropylmethyl cellulose (HPMC) was used, and 
these profiles are depicted in Figure 4.1. Vue be et al. [ 155] observed similar results in an 
investigation of the influence of cellulose ether polymers on drug release from hydrophilic matrix 
tablets. Almost complete release of ketoprofen was observed within eight hours from matrices 
formed using HPC whereas only 60% was released in 20 hours when HPMC was used [155]. 
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Figure 4.1. Dissolution profiles for batches MIN0-04 (SO% HPMC w/w) and MIN0-09 (50% HPC w/w) 
Several factors affecting the release of drugs from hydrophilic polymer matrices have been 
identified and include the rate of polymer hydration, polymer composition and polymer viscosity 
[ 156]. 
As previously mentioned in Section 3.5.1.1, the initial stage of drug release from hydrophilic 
matrices involves the hydration of the hydrophilic polymer used in a formulation and the 
subsequent formation of a gel layer on contact with water. Some authors have described the 
initial five (5) minutes of contact of the matrix with an aqueous medium as the most important 
time for the gel structure to form, after which if the structure has not formed, the matrix may 
erode too quickly to sustain the release of a drug dispersed in that matrix [124,157-159]. An 
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understanding of the hydration/swelling process of the polymer and factors affecting these 
phenomena is therefore essential. The important steps in polymer dissolution include the 
absorption/adsorption of water onto the surface of the material, the rupture of the polymer-
polymer linkages with the resultant formation of polymer-water linkages, separation of polymeric 
chains, swelling and dispersion of polymeric chain in dissolution medium [156]. The hydration 
rate of hydrophilic cellulose ethers such as HPC and HPMC depends on the nature of the 
substituent present on the polymer backbone and the degree of substitution of that particular 
functionality [160]. A comparison between HPMC and HPC in terms ofhydrophilicity is difficult 
to make since they are in different classes of cellulose ethers. However the hydration rate of 
cellulose ethers increases with an increase in hydroxypropyl content and decreases with an 
increase in alkyl chain length [160]. The hydrophilic hydroxymethyl group in HPMC positively 
contributes to the rate of hydration of this polymer [160]. Furthermore Methocel® K polymers 
hydrate rapidly due to the low concentration ofthe less hydrophilic methoxy groups [156]. 
The chemical composition of cellulose ethers is also an important factor that affects drug release 
from hydrophilic matrices as complex reactions with API that have aldehydes, methylol groups, 
epoxides, ethylene imine derivatives, sulfones and labile chlorine functional groups may occur 
[156]. The effect of polymer composition was not considered to be the primary reason for the 
differences observed in minocycline release as the chemical composition of HPMC and HPC 
results in similar reactions. In addition minocycline does not possess reactive functional groups 
that could potentially form complexes with HPMC or HPC and that would affect drug release. 
The use of a high viscosity grade polymer in a matrix formulation results in the formation of a 
gel layer of increased viscosity that results in a slower release rate of an API dispersed in that 
matrix [ 156]. Furthermore the more viscous gel is resistant to dilution and erosion thus producing 
a more sustained release effect [161]. As the viscosity of an HPMC K100M solution is higher 
than that ofHPC [121,162] the faster rate ofrelease observed for minocycline from HPC matrices 
can be attributed to the formation of a less coherent gel layer by HPC which permits faster 
diffusion of the minocycline in the matrix. In addition the lower viscosity will facilitate faster 
erosion of the HPC matrix further increasing the rate ofminocycline release. 
The effect of the concentration of HPMC on the release of minocycline was investigated in the 
concentration range 10 - 50% w/w. The resultant release profiles are depicted in Figure 4.2. 
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Figure 4.2. Dissolution profiles of batches MIN0-01, MIN0-02, MIN0-03 and MIN0-04 (10, 20, 30,50% 
w/w HPMC, respectively) 
As shown in Figure 4.2 the rate of minocycline release from the matrices was inversely 
proportional to the concentration of HPMC used to form the matrices. Nearly 100% minocycline 
release was observed within eight hours of dissolution for the 10% w/w HPMC formulations 
whereas only 41% of minocycline was released following 12 hours of testing for the 50% w/w 
HPMC formulation. Similar relationships have been reported where the rate of drug released is 
slower as the concentration ofHPMC used in hydrophilic matrices increases [123,163-165]. This 
decreased drug release observed with increasing concentrations of HPMC has been attributed to 
the faster hydration and formation of the gel layer [166] as the solution viscosity of HPMC 
increases with an increase in the concentration of the polymer [160]. 
4.4.2 The effect of type and concentration of lipid on the rate and extent of minocycline 
release 
The rate of release of minocycline was found to be faster from Precirol® matrices than those 
observed from Compritol® matrices when a concentration of 50% w/w of lipid was used as 
retardant and the release profiles are shown in Figure 4.3 . Minocycline was released completely 
within two hours of the commencement of dissolution testing from Precirol(jl, matrices whereas 
less than 10% minocycline was released from Compritol® matrices at the end of the 12 hour 
dissolution test. 
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Figure 4.3. Dissolution profiles for batches MIN0-08 (50% Compritol® w/w) and MIN0-10 (50% 
Prccirol® w/w) 
The effect of the lipid on drug release from lipid matrices has been observed to be of utmost 
importance [ 167]. The effect of the lipid is primarily dependent on the chemical composition of 
the lipid, physical properties of the lipid and the composition of the dissolution medium used to 
test the formulations [ 167]. 
Several parameters in particular the acid value, hydroxyl value and saponification value have 
been used to describe lipids as these relate to the chemical composition and quality of the lipid 
material [167]. The behaviour of lipids in formulation development and dissolution may be 
inferred, in part, from these parameters. In a study to evaluate the effect of wax on drug 
dissolution, Cusimano and Becker [167] observed that dissolution from the lipid matrices they 
used could be correlated to the acid and hydroxyl values of the lipid used. The release of drug 
from waxes with high hydroxyl values was observed to be faster in both acidic and alkali 
dissolution media. This effect can be attributed to the fact that hydroxyl groups in any lipid 
impart some degree of hydrophilicity to the lipid, such that the matrix as well as the drug particles 
are easily wetted thereby potentially increasing the rate of drug dissolution from these particular 
waxes [167]. Cusimano and Becker [167] also observed that dmg release from waxes with higher 
acid values and therefore a higher percentage of free fatty acids, was slower in acidic media and 
more rapid in basic media and attributed this result to the fact that fatty acids are less soluble in 
acidic media than they are in basic media. Compritol® and Precirol~ have similar hydroxyl values 
of 102.6 and 1 06.4, respectively [ 168] and similar acid values of < 4 and < 6, respectively [ 126]. 
Based on these observations it can be inferred that Compritol~ due to its lower hydroxyl value, 
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would retard the release on minocycline to a greater extent than would Precirol® as indicated by 
the results. However, the difference in hydroxyl and acid values is very small and cannot solely 
explain the large differences observed in the rate of release from MIN0-08 and MIN0-1 0. Higher 
solubility of a drug in the lipid may result in slower dissolution of the drug out of the matrix. 
However, as the lipid matrices in this study were not prepared using the fusion method, solubility 
of minocycline in the lipid matrices was expected to have a negligible effect on the release of 
minocycline from the formulations. Furthermore, solubility studies of minocycline hydrochloride 
were conducted during the course of these studies and indicated better solubility of minocycline 
in Precirol® ( 4 mg/g) than in Compritol® (2.5 mg/g). If solubility of minocycline in the lipids had 
a significant effect on minocycline release from the matrix, then release from Precirol® matrices 
would have been expected to be slower than that from Compritol® matrices. 
Ozyazici et al. [126] studied the release of metronidazole from lipid matrices and reported similar 
results to those observed by Cumimano and Becker [ 167]. The acid value and hydroxyl value of a 
lipid contributes to the overall hydrophile-lipophile balance (HLB), which ultimately determines 
how lipophilic the lipid is. Ozyazici et al. [126) observed the slowest rate of release of 
metronidazole from lipid matrices manufactured using camauba wax and the fastest rate of 
release from matrices manufactured using stearic acid. The carnauba wax is the more lipophilic 
matrix that does not permit water to penetrate the pores of the matrix structure and hence retards 
drug release. In contrast the stearic acid is not as lipophilic and permitted hydration of the matrix 
hence facilitating drug release [126]. The rate of drug release from matrices prepared from 
Compritol® and Precirol® were between those of camauba wax and stearic acid [ 126]. Compritol® 
and Precirol® have a similar hydrophobic character and identical HLB values of2 [135] and it is 
therefore expected that the rate of release from matrices formed from these two lipids would be 
similar, if all physicochemical considerations are equal. In contrast to the results observed in this 
study, Ozyazici et al. [135] observed faster drug release rates from Compritol41) than from 
Precirol® matrices that was attributed to the non-ionic surfactant nature of Compritol® [126]. 
Although other studies have demonstrated slow drug release from Precirol® matrices, 
comparisons with Compritol®were not included in those studies [127,169]. 
The in vitro release characteristics of carbamazepine (a less hydrophilic drug compared to 
minocycline hydrochloride) from lipophilic, amphiphilic and water dispersible Gelucire® matrices 
has been reported [ 11 7]. As expected, drug release was faster from water dispersible bases. 
Similar lipophilic bases in terms of hydrophobic character were studied i.e. Gelucire® 33/01 and 
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Gelucire® 39/01. Gala! et al. observed that drug release was faster from matrices of Gelucire® 
33/01 with 65% carbamazepine released in eight hours compared to only 10% released from 
Gelucire® 39/01 matrices. This difference in drug release was attributed to the difference in 
melting point of the Gelucire® bases. The higher amount of drug released from Gelucire® 33/0 l 
may be as a result of the lower melting point of this lipid which results in a high degree of 
dispersibility of the Gelucire® 33/01 base after melting, providing a large area for surface release 
of the drug [117). Wu et al. [ 170] observed a higher degree of retardation of release of potassium 
chloride (a more hydrophilic drug than minocycline hydrochloride) from matrices manufactured 
using Gelucire® bases with high melting points, indicating that the melting point of the Gelucire® 
used was the most influential factor on potassium chloride release from these bases. 
Several factors may contribute to the differences in drug release observed from matrices formed 
using different lipids. Compritol® and Precirol® have similar hydrophobic characteristics but the 
major physical difference between these two lipids is their meting points. As all other 
experimental conditions were similar it can be concluded that the most likely reason for the 
observed difference between the release profiles of minocycline from batches MTN0-08 and 
MIN0-1 0, is a consequence of the lower melting point of Precirol® (±57°C) compared to that of 
Compritol® (± 70°C). The warm dissolution medium may have caused the softening and 
consequent dispersibility of the Precirol® matrix, which resulted in the formation of a greater area 
for the surface dissolution of minocycline hydrochloride from this formulation. The high 
solubility of minocycline hydrochloride in aqueous medium may also have contributed to its 
rapid release once a greater surface area was available for dissolution of the drug. 
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The effect of concentration of Compritol® used in the formulations on the release of minocycline 
was investigated and the release profiles are depicted in Figure 4.4. 
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Figure 4.4. Dissolution profiles for MIN0-05, MIN0-06, MIN0-07 and MIN0-08 (10, 20, 30, 50% 
Compritol® w/w, respectively) 
The rate and extent of minocycline release from lipid matrices was observed to decrease as higher 
concentrations of Compritol® were used in the formulation as shown in Figure 4.4. This 
observation was consistent with that observed by Li et al. [131] who reported a decrease in the 
rate and extent of sodium ferulate release from Compritol®-based directly compressed tablets as 
the concentration of Compritol® used was increased. Saraiya and Bolton [127] also observed a 
correlation between the rate and extent of theophylline release and concentration of lipid used in 
the matrices. As the concentration of lipid used to form the matrix was increased, the rate and 
extent of release of theophylline decreased. 
As the release of drugs from lipid matrices is largely dependent on the concentration of aqueous 
medium that penetrates the matrices, the decrease in rate and extent of minocycline release at 
higher concentrations of Compritol® can, in part be attributed to the fact that more hydrophobic 
systems result when higher concentrations of Compritol® are used to manufacture formulations. 
As a consequence it becomes increasingly difficult for the aqueous dissolution medium to 
penetrate the lipid matrices resulting in minimal dissolution of drug and hence a slower drug 
release rate. Alternatively, one may view Compritol® as having the ability to "coat" drug particles 
[131] and therefore infer that at higher concentrations of Compritol® the drug particles are 
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"coated" to a greater degree with lipid and dissolution in an aqueous medium is thus slower as 
there is a slower rate of wetting of the drug particles. 
4.4.3 The effect of diluent type on the rate and extent of minocycline release 
The use of different diluents in the formulation of minocycline sustained release capsules was 
found to have an impact on the rate of release of minocycline from both the HPMC and 
Compritol® matrices manufactured and tested in these studies. The rate of release from HPMC 
matrices with lactose as a diluent was observed to be faster than when microcrystalline cellulose 
(MCC) was used as a diluent and these profiles are depicted in Figure 4.5 . 
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Figure 4.5. Dissolution profiles for batches MIN0-02 (20% HPMC w/w - MCC) and MIN0-11 (20% 
HPMC w/w- Lactose) 
Almost 100 % of minocycline was released from HPMC matrices in which lactose was added 
whereas < 80% minocycline was released when MCC was used as a diluent. Similar results were 
observed by Lapidus and Lordi [ 171] who reported that the rate of release of chlorpheniramine 
was shown to increase when a hydrophilic diluent such as lactose was used in a formulation in 
place of calcium phosphate that is less soluble [ 171]. Sako et al. [ 172] showed that although the 
addition or substitution of hydrophilic diluents did not influence the release of drugs from HPMC 
matrices in vitro they had a profound effect in vivo and reported an increased rate of drug release 
from the matrices following administration to volunteers. 
The use of lactose as a diluent in place of MCC had the opposite effect for Compritol>li> matrices 
to that observed for HPMC matrices. The rate of minocycline release was faster from Compritol® 
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matrices when MCC rather than lactose was used as a diluent and the release profiles are depicted 
in Figure 4.6. These data are similar to those reported by Malamataris et a1.[132] who observed 
that the release of diprophylline from Precirol® matrices was faster when MCC was used as a 
diluent than when lactose was used. 
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Figure 4.6. Dissolution profiles for batches MTN0-07 (30% Compritol® w/w- MCC) and MIN0-12 (30% 
Compritol® w/w- Lactose) 
Furlanetto et al. [173] in studies designed to identify formulation variables that affect drug release 
from hydrophilic polymeric and lipid matrices showed that the overall drug release rates from 
matrices was as a result of the combined effect of the diluent type, matrix forming polymer 
diluent ratio, type of matrix and the solubility of drug to be included in the formulation. The use 
of lactose as a diluent in both hydrophilic and lipid matrices has been observed to increase the 
rate of drug release due to the hydrophilic nature of lactose which permits dissolution of the 
carbohydrate in water, producing pores and channels in the matrices through which drug may 
diffuse and be released [ 131, 165]. However, it has been noted that the use of a hydrophilic diluent 
with a freely soluble drug may reduce drug release as a result of a competitive effect for 
dissolution in an aqueous medium in the dosage form [ 173]. Although MCC is Jess hydrophilic 
than lactose and is therefore expected to cause a slower rate of drug release, it has been observed 
that MCC may actually increase drug release rates due to its ability to swell and draw additional 
water into the matrix, thereby promoting dissolution of the drug [132, 174]. 
The increased rate of release for minocycline observed when using lactose as a diluent in HPMC 
matrices can be attributed to more porous matrix being formed following the dissolution of 
lactose. In contrast the faster release rates observed with the use of MCC as a diluent in 
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Compritol<~> base formulations may be attributed to the ability of MCC to draw water into the 
matrix thereby permitting faster drug dissolution and subsequent release. 
4.4.4 The effect of additives on minocycline release 
Excipients such as surfactants [130,131 ,175] and hydrophilic channelling agents [117, 169,175-
179] have been widely applied in formulation development to optimize the rate of drug release 
from both hydrophilic and lipid matrices. The effect of incorporating disintegrant on the release 
of minocycline from both HPMC and Comprito!'t> matrices was investigated. In addition the 
effect of addition of surfactant on the release of minocycline from Compritol® matrices was 
studied. 
4.4.4.1 The effect of disintegrant on minocycline release 
The effect of disintegrant on minocycline release from HPMC and Compritol® based 
formulations was investigated by incorporating 2% w/w sodium starch glycolate to the 
formulations. The resultant dissolution profiles are shown in Figure 4. 7 to Figure 4.1 0. 
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Figure 4.7. Dissolution profiles for batches MIN0-02 (20% HPMC w/w - MCC) and MIN0-13 (20% 
HPMC w/w + 2% w/w Sodium starch glycolate- MCC) 
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Figure 4.8. Dissolution profiles for batches MIN0-11 (20% HPMC w/w - Lactose) and MIN0-14 (20% 
HPMC w/w + 2% starch glycolate- Lactose) 
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Figure 4.9. Dissolution profiles for batches MIN0-07 (30% Compritol® w/w- MCC) and MIN0-15 (30% 
Compritol~ w/w + 2% w/w Sodium starch glycolate- MCC) 
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Figure 4.10. Dissolution profiles for batches MIN0-12 (30% Compritol® w/w - Lactose) and MIN0-16 
(30% Compritol® w/w + 2% w/w Sodium starch glycolate- Lactose) 
The rate of release of minocycline from HPMC matrices did not improve when sodium starch 
glycolate was incorporated in the formulation irrespective of the diluent used and these data are 
depicted in Figures 4.7 and 4.8. However the rate and extent of minocycline release increased 
when sodium starch glycolate was incorporated into Compritol® matrices irrespective of the 
diluent used and these data are shown in Figures 4.9 and 4.1 0. 
Drug release has been found to increase [175,176,180] or show no improvement [180] with the 
incorporation of disintegrant into HPMC matrices. Disintegrants are incorporated into matrix 
formulations in an effort to increase the rate of release of the API in that formulation [ 17 6]. The 
rapid uptake of water by the disintegrant followed by its swelling leave the matrix highly porous 
and weak leading to the disintegration of that matrix and subsequent release of the drug 
formulated into that delivery system [ 124, 176]. In some instances, particularly when lower 
concentrations of hydrophilic polymers are used, the rapid swelling of the disintegrant on initial 
contact with water may prevent the formation of a coherent gel structure on the surface of the 
matrix leading to faster drug release rates [ 180]. In this study, the addition of disintegrant to the 
formulation showed no improvement in the rate of release of minocycline. In fact a slightly 
negative effect on drug release was observed which may be due to the initial rapid uptake of 
water by the disintegrant thereby permitting faster hydration of HPMC and a more rapid 
formation of a gel layer which results in a greater degree of retardation of minocycline release. 
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Galal et a!. [ 117] observed an increase in the rate of drug release from Gelucire® based matrices 
when disintegrants such as croscarmellose sodium (1-10% w/w) were added to Gelucire~ 53/10 
and that resulted in an increase in the release of carbamazepine [117]. This increase in drug 
release was attributed to the increased penetration of dissolution medium into the matrix resulting 
in the rapid disruption and erosion of the matrices with a subsequent rapid rate of release of the 
drug. The observed increase in minocycline release from Compritol® matrices with the addition 
of sodium starch glycolate in our study was attributed to the increase in water uptake by the 
matrix as a result of rapid swelling of sodium starch glycolate. The presence of additional water 
in the matrix resulted in faster dissolution of minocycline thereby causing an increase in the 
overall release of minocycline from the matrix. 
4.4.4.2 The effect of surfactant on minocycline release 
The effect of surfactant on the release of minocycline from Compritol® based fonnulations was 
investigated by incorporation of concentrations of 0.5% and 1% w/w of Poloxamer 188 to the 
formulations. Dissolution profiles of minocycline from formulations incorporating surfactant are 
depicted in Figures 4.11 and 4.12. 
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Figure 4.11. Dissolution profiles for batches MIN0-07 (30% Compritol® w/w- MCC), MIN0-19 (30% 
Compritol® w/w + 1% w/w Poloxamer 188 - MCC) and MIN0-21 (30% Compritol® w/w + 0.5% w/w 
Poloxamer 188- MCC) 
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Figure 4.12. Dissolution profiles for batches MIN0-12 (30% Compritol® w/w- Lactose), MIN0-20 (30% 
Compritol<l9 w/w + 1% w/w Poloxamer 188 - Lactose) and MIN0-22 (30% Compritol® w/w + 0.5% w/w 
Poloxamer 188 -Lactose) 
As shown in Figure 4.11 and 4.12, the rate and extent of minocycline release from Compritol~ 
based fmmu1ations increased with the addition of poloxamer 188 to the formulation. As is more 
clearly illustrated in Figure 4.12, this increase in the rate and extent of release could be correlated 
to the concentration of the surfactant added, with higher surfactant concentrations resulting in 
faster drug release. 
The results generated in these studies are consistent with those reported by Li et a!. [ 131 ], who 
observed an increase in sodium ferulate release from Compritol® based matrices when 
polysorbate-SO or poloxamer 188 were added to the formulation. Jannin et a!. ( 130] also observed 
an increase in theophylline release from Precirol® matrices with the addition of Lutrol® F68 and 
Lutrol~ F127 to the formulation. 
The HLB value of a formulation is a major determinant of the degree to which water will 
penetrate that matrix and allow drug dissolution. The addition of surfactant to a lipid matrix 
increases the HLB value of the formulation thus facilitating the penetration of additional water to 
the matrix with a resultant faster dissolution rate of drug [ 130]. Three types of interactions may 
affect the rate of drug release from matrices and include electrostatic interactions, hydrogen 
bonding and hydrophobic interactions [131, 181]. Hydrophobic interactions and textural 
properties of matrices are the most important interactions that determine drug release from a lipid 
matrix (181]. The interface between hydrophobic lipid carrier and hydrophilic drug is thought to 
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hinder the release of the drug from the matrix [ 131]. The addition of a surfactant to a formulation 
is believed to adjust hydrophobic interactions between the drug and lipid matrix resulting in an 
increased rate of release of the drug [ 131]. The observed increase in the rate and extent of 
minocycline release from formulations MIN0-19, MIN0-20, MIN0-21 and MTN0-22 in which 
poloxamer 188 was incorporated may be attributed to the resultant increase in the HLB of the 
system. This may have resulted in an increased uptake of water by the formulation with the 
consequent faster dissolution and faster diffusion of minocycline into the dissolution medium. 
Careful consideration of the type of surfactant to be added to formulations is important so as to 
attain the desired rate of drug release from a specific formulation. As the overall HLB value of a 
formulation is a major determinant of drug release from such formulations in aqueous medium, it 
is therefore easy to assume that surfactants with higher HLB values will promote the rate of drug 
release from lipidic matrices. However Jannin et al. [ 130] observed that at surfactant 
concentrations greater than 25% w/w, the less hydrophilic Lutrol® F127 produced a more 
pronounced increase in theophylline release from Precirol® based matrices than the more 
hydrophilic Lutrol® F68 (Poloxamer 188). This result was attributed to the fact that Lutrol® Fl27, 
as it is less water-soluble swelled to a greater extent than Lutrol® F68, creating pores in the 
matrix through which more drug could be dissolved [ 130). At surfactant concentrations of 2% 
w/w, Li et al. [ 131] observed a more pronounced increase in the release of sodium ferulate from 
Compritol® based matrices using the less hydrophilic surfactant polysorbate-80 as compared to 
that from the more hydrophilic surfactant, Poloxamer 188. This difference in effect was attributed 
to the higher solubility of polysorbate-80 in the lipid matrix which may have aided the diffusion 
of dissolved drug out of hydrophobic pores or channels in that matrix [ 131]. 
4.4.5 The effect of drug release from a matrix combination of HPMC and Compritol® 
The addition of hydrophilic polymers to lipid matrices has been applied in formulation 
development to optimise drug release rates. Parab et al. [ 169] observed that the rate and 
mechanism of release of theophylline from Precirol® based matrices differed when both mannitol 
and HPMC were added to the formulation, from when either one of the two was used separately 
in the formulation. As shown in Figure 4.13 the combination of Compritol® and HPMC had an 
additive effect on the retardation of minocycline release although this effect was small. The 
combination ofHPMC and Compritol® resulted in less variable release ofminocycline from these 
dosage forms. 
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Figure 4.13. Dissolution profiles for batches MIN0-01 (10% w/w HPMC- MCC), MIN0-05 (10% w/w 
Compritol®- MCC) and MIN0-17 (10% Compritol® w/w + 10% HPMC- MCC) 
4.4.6 USP Delayed-release dissolution test for selected formulations 
Resultant dissolution profiles of minocycline from formulations MIN0-06, MIN0-11 and 
MIN0-17 that released at least 80% of minocycline following "near-zero order'' kinetics based on 
visual analysis were tested using the USP conditions for delayed release formulations and the 
profiles are depicted in Figures 4.14 to 4.16. 
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Figure 4.14. Dissolution profiles for batches MIN0-06 (20% Compritol®- MCC) under study dissolution 
conditions and USP delayed-release test dissolution conditions 
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Figure 4.15. Dissolution profiles for batches MIN0-11 (20% HPMC- Lactose) under study dissolution 
conditions and USP delayed-release test dissolution conditions 
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Figure 4.16. Dissolution profiles for batches MIN0-17 (10% Compritol® + 10% HPMC- MCC) under 
study dissolution conditions and USP delayed-release test dissolution conditions 
The use of the USP two-stage test conditions for dissolution testing of delayed release 
formulations, revealed that the minocycline formulations developed in these studies and based on 
lipidic matrices did not adequately sustain drug release. Batch MIN0-06 was comprised of 20% 
w/w Compritoi'E yet 95% of the drug was released within two hours of the commencement of 
dissolution testing as shown in Figure 4.14. Similarly for Batch MIN0-17 that was comprised of 
10% w/w of each of Compritol® and HPMC revealed that 95% of the minocycline was released 
within four hours as shown in Figure 4.16. 
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Drug release from formulations based on lipid or wax matrices has been observed to be 
dependent on the pH of the dissolution medium due to the chemical composition of the lipid 
bases [ 167]. Compritol® is an ester of behenic acid [ 121] and may undergo hydrolysis in aqueous 
acid media [ 182]. Hydrolysis of the ester yields a less hydrophobic product, thereby facilitating 
the penetration of water into the lipid matrices promoting the subsequent dissolution and faster 
release rates of minocycline. As formulation MIN0-17 was comprised of both Compritol® and 
HPMC the release of minocycline was less rapid than that of MIN0-06 which was comprised 
only of Compritol® as the retardant, as the HPMC swells and provides a sustaining effect despite 
the hydrolysis of Compritol® in the acid medium. 
The rate and extent of drug release from MIN0-11 that was comprised of 20% w/w HPMC and 
lactose as the diluent was slower when tested using the USP two-stage test conditions than with 
water as the dissolution medium and as is shown in Figure 4.15. HPMC and lactose are pH-
independent materials [ 172] and any change in drug release can be attributed to other formulation 
variables. The ionic state of a drug in matrix formulations is an important factor in in vitro testing 
of drugs (124,183). Drug molecules that exist in their ionised state are more soluble in aqueous 
dissolution media than unionised species, resulting in faster in vitro release rates from matrices 
[183]. Minocycline has four reported pKa values or dissociation constants of 5 and 9.5 for the 
amine functional groups and 2.8 and 7.8 for the hydroxyl groups as reported in Chapter 1. The 
overall slower rate of release of minocycline under the USP two-stage test conditions may be 
attributed to the ionisation state of minocycline which may be less favourable for its dissolution 
under the pH ranges used in the USP "two-stage" dissolution test. 
4.5 CONCLUSIONS 
The objective of preliminary dissolution studies was to determine the effect of formulation 
variables on the development of minocycline sustained release dosage forms. The use of the USP 
Apparatus 1 and de-ionised water as dissolution medium was successfully applied to these 
assessments and provided a means to discriminate between the different minocycline 
formulations manufactured. Following dissolution testing a hydrophilic polymer matrix 
comprised of 20% w/w HPMC and a lipid matrix of 30% w/w Compritol® were identified for 
further optimisation. The target profile for minocycline release was that drug release was to 
follow zero-order kinetics and that at least 80% of the minocycline in the formulation was to be 
released in a 12 hour period. 
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The optimisation of minocycline release from the lipid and hydrophilic matrices was achieved by 
using different diluents and the addition of different hydrophilic excipients to the formulations. 
The use of different diluents and the addition of disintegrant and surfactant was found to affect 
minocycline release from both hydrophilic and lipophilic matrices. 
The three formulations with dissolution profiles similar to that of the target dissolution profile 
were tested using the USP "two-stage" test for delayed-release dosage forms. This test gave a 
better indication of the potential in vivo release behaviour of the dosage forms as it is comprised 
of an acid stage with a pH similar to that found in the stomach and a buffer stage with a pH 
similar to that found in the intestines. All formulations behaved differently in this test due to the 
different chemical characteristics of the excipients and the ionic state of minocycline in the 
different dissolution media. Based on this information it may be beneficial to conduct preliminary 
dissolution investigations using the USP delayed release conditions as opposed to water to avoid 
such situations in which formulations that showed optimal release patterns fail in media that are 
better indicative of the conditions in vivo. 
Based on the obtained results, HPMC based formulations may be more appropriate for further 
investigation of minocycline sustained release dosage forms as they are more resistant to changes 
in pH of dissolution media. However, Compritol® was successfully used to sustain minocycline 
when water as used as the dissolution indicating its potential for use as a polymer for sustaining 
drug release. Further studies focussing on protecting fatty esters from extremes of pH may be of 
benefit for the successful application oflipids as sustained release polymers. 
106 
CHAPTER FIVE · 
5 MATHEMATICAL MODELING AND COMPARISON OF IN VITRO 
DISSOLUTION PROFILES 
5.1 INTRODUCTION 
The comparison of dissolution profiles plays an important role in the course of product 
development [184,185]. The comparison of dissolution profiles provides a basis for establishing 
the final dissolution specifications for a pharmaceutical dosage form for the purposes of quality 
control and to demonstrate the batch to batch consistency of a product [ 184, 185). Furthermore the 
comparison of dissolution profiles provides a basis for establishing the similarity of 
pharmaceutical dosage forms for which the composition, manufacturing site, scale of 
manufacture and manufacturing processes may have changed within specifically defined limits 
[ 186). The methods used for the comparison of dissolution profiles may be classified as 
exploratory data analysis, statistical, model-independent and model-dependent methods and/or 
models [ 184]. 
5.2 EXPLORATORY DATA ANALYSIS 
Exploratory data analysis methods are useful as initial means of assessing dissolution data from a 
graphic or numerical perspective [ 184]. Graphically the dissolution curves to be compared, i.e. a 
test and reference(s) product or formulations are plotted on the same set of axes with error bars at 
the same time points and that extend to twice the standard error of estimates [184]. As the 
standard error bars are considered to represent an approximate 95% confidence interval, the 
formulations can be considered to be significantly different to a reference formulation if the error 
bars for the time points under consideration do not overlap [184). 
Graphical comparisons of dissolution profiles may be complemented by presenting the mean and 
standard deviation of dissolution data for a test and reference formulation at each time point, 
numerically [ 184]. Dissolution profiles may be considered significantly different at a 5% level of 
significance if the 95% confidence interval for the mean difference (reference- test) at a 
specific time point does not represent a numerical value of zero [ 184]. 
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The use of exploratory methods of data analysis is not comprehensive due to the difficulty of 
concluding if dissolution profiles are different in cases where the error bars for measurements 
overlap at some of the times data are accumulated (184]. Furthermore, it is challenging to 
interpret results when comparing more than two formulations as graphical depiction or 
illustration of the data becomes cluttered and the summary table for that data becomes too large 
[184]. 
5.3 STATISTICAL METHODS 
The comparison of in vitro dissolution profiles has been conducted using statistical methods 
based on the analysis of variance (ANOVA-based methods) [184,187,188]. Statistical methods 
test the statistical difference between dissolution profiles in terms of the shape and size of the 
curves and provide probability values related more to statistical equivalence than to 
pharmaceutical similarity [ 177]. 
ANOVA-based methods may be further differentiated as one way analysis of variance (ANOVA) 
and multivariate analysis of variance (MANOV A) methods [ 189, 190]. One way analysis of 
variance methods execute separate statistical comparisons of mean dissolution data at each time 
point and are equivalent to t-tests when dissolution data for only two formulations are compared 
[184]. In cases of the comparison of more than two data sets, posteriori comparisons such as 
Tukey's Multiple Range Test, Scheffe Method, Newman-Keuls Test and Dunnett's Test may be 
used to establish where, if any, differences arise [191). Multivariate analysis of variance methods 
assess the difference between the mean of dissolution data sets in multiple time point dissolution 
tests [ 189]. 
One way analysis of variance methods have been criticised as they ignore the correlation between 
the data at the sample time points within a single dissolution profile [ 184]. The risk of incurring a 
Type I error is relatively high when using one way analysis of variance methods and when 
statistical differences are observed at some but not all time points, it is difficult to conclude if the 
profiles are different [184]. Despite the criticisms of one way analysis of variance methods they 
provide more informative and easier to interpret data compared to MANOV A methods of data 
analysis [187]. 
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ANOVA-based methods have also been reported to be overly discriminating and not useful for 
the analysis of pharmaceutical data [190]. The use of ANOVA-based methods is not 
recommended and there in no mention of these methods in FDA guidance documents [184]. 
5.4 MODEL-INDEPENDENT METHODS 
Model-independent methods used for comparison of dissolution profiles do not require the use of 
a preconceived or fitted model [ 177]. Model independent models may be further divided into 
ratio tests and pair-wise procedures [189]. 
5.4.1 Ratio tests 
Ratio tests involve the comparison of parameters obtained at the same time point from the release 
profiles of a test and reference and formulation [ 189]. The comparison may be expressed as the 
ratio of the percent drug released from each formulation at specific time points, (tx%), as a ratio 
of the area under the curve (AUC) of the two fonnulations or the ratio of the mean dissolution 
time (MDT) for each formulation [189]. The mean dissolution time may be calculated using 
Equation 5.1: 
Where, 
j =sample number 
n = number of dissolution sample times 
ti =time at midpoint between ti and tj_1 
!J.Mj = additional amount of drug dissolved between ti and ti_1 
Equation 5.1 
Ratio tests, particularly the time point approach, (txo/o) have been criticised for their inadequacy to 
completely characterise dissolution profiles as they do not take into account profiles that do not 
follow a single path or which cross over [192]. Although such a cross over may be insignificant 
for immediate release products as the time scale of release is short, such occurrences with 
controlled release products may have significant implications for quality assurance and the 
establishment of in-vitro-in-vivo correlations [192]. 
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5.4.2 Pair-wise procedures 
Two commonly used pair-wise procedures used for the comparison of dissolution profiles are the 
difference (f1 ) and similarity ([2) factors [193], and the Rescigno index [194]. 
5.4.2.1 The difference and similarity factor 
The difference and similarity factors, first described by Moore and Flanner [ 193], constitute the 
most widely known model-independent approach for the comparison of dissolution profiles 
[177]. The difference factor, [1 , is the sum ofthe absolute values of vertical distances between the 
mean values for a test and reference product at each dissolution time point and is expressed as the 
percentage of the sum of the mean fraction released from the reference formulation at each time 
point as depicted in Equation 5.2 (184]. The similarity factor, [ 2 , is a logarithmic transformation 
of the average of the squared vertical distances between the mean test and the reference 
dissolution time points, which may be multiplied by an appropriate weighting factor, usually set 
as 1 and is calculated us ing Equation 5.3 [ 184]. 
Where, 
n = number of dissolution time points 
Rt = percent dissolved of reference product at each time point, t 
'0 =percent of dissolved of test product at each time point, t 
Wt =optional weight factor 
Equation 5.2 
Equation 5.3 
The difference and similarity factors have been adopted by the Center for Drug Evaluation (FDA) 
and may be used for the comparison of dissolution profiles if at least three dissolution time points 
are available for use in computing the factors [1 37,186,195]. The similarity factor in particular 
has been widely recognised as a valid criterion to assess the similarity between two dissolution 
profiles and should ideally be used following testing of at least twelve individual dosage form 
units [137]. Values of [1 between 0 and 15, and of fz between 50 and 100 indicate similarity or 
sameness of the two dissolution profiles under comparison. 
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It has been recommended that only one data point after 80% of the drug has been released 
should be included in the calculation of the difference and similarity factors, as the region of 
interest for comparability normally lies between 0 and 80% of dissolution, i.e. before the plateau 
region ofthe dissolution profile is reached [185]. 
The main advantage of using the difference and similarity factors for the companson of 
dissolution of profiles is that they are easy to compute and provide a single number to describe 
the comparison of dissolution profiles [ 184]. 
Despite the useful nature of the difference and similarity factors for the comparison of dissolution 
profiles there are several limitations. In particular, interchanging the reference and test 
formulations in the calculation for the difference factor will result in a different value for the 
difference factor being calculated [184,189]. The similarity factor is insensitive to the shape of 
the dissolution profile and does not take into account information relating to unequal spacing 
between sampling points ( 196]. Furthermore as the similarity factor is a function of the mean 
difference between curves, it does not take into account variability within the test or reference 
formulations, making careful interpretation of data for batches with high inter-batch variability, 
necessary (197]. As the similarity factor is a sample statistic that cannot be used to formulate a 
statistical hypothesis for assessment of dissolution similarity, it is difficult to access the Type I 
and Type II error rates that may be associated with its use [196,197]. 
5.4.2.2 Rescigno Index 
The Rescigno indices, first described by Rescigno [194] as bioequivalence indices to measure the 
difference between a test and reference product based on blood plasma concentration functions 
may also be applied to the comparison of dissolution profiles based on drug concentrations in 
dissolution samples [184,189]. The Rescigno indices are denoted by ~i (i = 1,2), and may be 
calculated using Equation 5.4 [ 184]. 
Where, 
Rt =mean percent drug dissolved for reference product at time (t) 
Tt =mean percent drug dissolved for test product at time (t) 
tn = final dissolution time point 
t =time 
Equation 5.4 
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A high value of i for the Rescigno index, implies a higher weighting of the magnitude of change 
in concentration than in the duration of that change [ 189]. The indices which may take up values 
between 0 and 1 inclusively measure the difference between two dissolution profiles [189]. A 
value of 0 or close to 0 indicates similarity between the mean dissolution profiles being compared 
and a value of 1 is obtained if one of the two mean dissolution profiles is zero at each dissolution 
time point [ 184]. The Rescigno indices, ( 1 and ( 2 are approximately analogous to the difference 
and similarity factors, respectively [184]. 
An advantage of using the Rescigno indices is that unlike the difference factor the value of the 
indices remains unchanged if the test and reference dissolution profiles are interchanged [ 184]. 
However the Rescigno indices are more difficult to compute compared to the difference and 
similarity factors and it is not clear how close their values should be to 0 in order for one to 
conclude that the mean dissolution profiles for the test and reference products are similar [ 184]. 
The use of the Rescigno indices is not included in any of the guidance documents published by 
the FDA [184]. 
5.5 MODEL-DEPENDENT METHODS 
5.5.1 Zero order model 
Zero-order kinetics can be used to model dissolution data from pharmaceutical dosage forms that 
do not disaggregate and release drug slowly over an extended period of time [ 189]. The 
dissolution profiles of pharmaceutical formulations that follow zero-order kinetics release the 
same amount of drug per unit time and are ideal for ensuring a prolonged action of the drug in the 
dosage form [189]. The zero-order model can be expressed using Equation 5.5: 
Where, 
Q1 = amount of drug dissolved in time t 
Q0 = initial amount of drug in the solution 
K0 = zero-order release constant 
t =time 
Equation 5.5 
Zero-order kinetics have been successfully used to describe drug release from modified-release 
dosage forms based on matrices manufactured using polyethylene oxide and polyethylene glycol 
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polymers of various molecular weights [199,200]. Zero order kinetics are usually the preferred 
release kinetics for sustained release dosage forms. 
5.5.2 First order model 
First order kinetics were first applied to the evaluation of dissolution data by Gibaldi and 
Feldman [201] and can be expressed mathematically using Equation 5.6: 
Where, 
Qt = amount of drug released in timet 
Q0 = initial amount of drug in the solution 
K1 = first order release constant 
t =time 
Equation 5.6 
Pharmaceutical dosage forms that display first order kinetics, particularly those with water 
soluble drugs in porous matrices [202] release the API in proportion to the amount of drug 
remaining in the dosage form and the rate of drug release declines as the amount of drug 
remaining in the dosage form diminishes [ 189]. The release of hydrophilic drugs from modified-
delivery systems manufactured by poly-(ethylene glycol-b-(DL-lactic acid-co-glycolic acid)-b-
ethylene glycol) has been shown to follow first order kinetics [203]. 
5.5.3 The Higuchi model 
The Higuchi model was developed to study the release of water soluble and low solubility 
compounds incorporated in semi-solid and/or solid matrices [204,205]. Although the model was 
initially used to describe the dissolution of drugs in suspension in an ointment, it is now applied 
to other types of dissolution from other pharmaceutical dosage forms [ 189]. The Higuchi model is 
based on Fick's first law of diffusion where the fraction of drug released is proportional to the 
square root of time [82, 189]. A simplified expression of the Higuchi model is shown in Equation 
5.7 [189]. 
Where, 
Q t = amount of drug release at time t 
KH =Higuchi dissolution constant 
t =time 
Equation 5.7 
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5.5.4 Korsmeyer-Peppas model 
The Korsmeyer-Peppas model or power law [206] is an empirical expression that relates the 
fraction of drug released over time as an exponential. The model incorporates a constant, k, that 
takes into account the structure and geometry of the dosage form and a release exponent, n, that is 
indicative of the mechanism of drug release [189]. A simplified expression of the Korsmeyer-
Peppas model is shown in Equation 5.8 and in the log-transfonned state in Equation 5.9: 
log (;J =log k + n logt 
Where, 
.!!.!.. = released fraction of drug at time t 
Moo 
Equation 5.8 
Equation 5.9 
k = constant incorporating structural and geometric characteristics of the dosage form 
t =time 
n = release exponent indicating drug release mechanism 
The use of the release exponent, n, to characterise drug release mechanisms from dosage forms of 
different geometries was described by Peppas [207]. For a slab, Peppas concluded that values of n 
=== 0.5 indicated Fickian diffusion and values of 0.5 < n < 1.0 indicated mass transfer following a 
non-Fickian model. For a cylinder it was concluded that values of n === 0.45 indicated Fickian 
diffusion whilst values of 0.45 < n < 0.89 represent drug release via non-Fickian diffusion 
mechanisms. A summary of the interpretation of the release exponent, n for release mechanisms 
from a slab is summarised in Table 5 .1. 
Table 5.1. Interpretation of the release exponent 
Release exponent (n) 
0.5 
0.5 < n < 1.0 
1.0 
> 1.0 
Drug transport mechanism 
Fickian diffusion 
Anomalous transport 
Case-II transport 
Super Case-II transport 
Rate as a function of time 
I ·0.3 
r·l 
Zero-order release 
I'"' 
The Korsmeyer-Peppas model is generally used to characterise drug release from polymer based 
dosage forms in addition to dosage forms that display more than one type of release mechanism 
[ 189]. The· Korsmeyer-Peppas model has been extensively used to model drug release from 
hydrophilic [82,208,209] and lipid matrices [210]. 
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The application of the Korsmeyer-Peppas model requires that only the portion of the curve that 
displays up to a maximum of 60% drug release be used for model fitting [ 189]. 
5.5.5 Weibull model 
The Weibull function was first adapted to model drug release processes and dissolution by 
Langenbucher [211] and is an empirical model that can be used for the characterisation of drug 
dissolution from a variety of dosage forms [212]. The log transformed expression of the Weibull 
model is shown in Equation 5.10: 
log[ -ln(1- m)] = b log(t- Tt)- log a Equation 5.10 
Where, 
- m = accumulated fraction of drug in solution at time t 
a= scale parameter definitive of the time scale of the process 
b = shape parameter 
Tt = location parameter representative of the lag time before the onset of the release process 
t =time 
From the expression in Equation 5.10 a linear relationship can be obtained for a log-log plot of 
-ln(l- m) versus time (t) . The shape parameter, b is obtained from the slope of the line and 
may be equal to, greater than or less than 1 depending on the shape of the curve as summarised in 
Table 5.2 [189]. The ordinate value, a, is estimated from the ordinate value (1/a) at time t = 1 
[ 189]. 
Table 5.2. Interpretation of shape parameter, bin Weibull model 
Value of b 
b = l 
b > l 
b < l 
Curve description 
Case (1 ), exponential 
Case (2), sigmoid, S-shaped, with an upward curvature followed by a turning point 
Case (3), parabolic with higher initial slope and after that consistent with exponential 
The Weibull model lacks any kinetic basis and as a result has several limitations, particularly in 
that it does not adequately characterise the dissolution kinetics or intrinsic dissolution of a drug 
[189,213]. 
Despite the criticisms of the Weibull method it has been used successfully to describe drug 
release from fractal matrices [214]. The Weibull function is linearly related to the exponent, n of 
the power law derived from the analysis of the first 60% of dissolution profiles [214]. The value 
of b, can be used as an indicator of drug release from the matrices with values of b ~ 0.75 
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indicating that Fickian diffusion drives drug release. Values of b in the range 0. 75 < b < 1 
indicate that drug release is a combination of Fickian diffusion and Case-ll transport and values 
of b > 1 indicate that a complex release mechanism predominates [214]. 
5.6 SELECTION OF BEST -FIT MATHEMATICAL MODEL 
Although the Higuchi, zero order, Weibull and Korsmeyer-Peppas models are the most widely 
used models to describe drug release [189], it is important that an analyst selects a model that best 
fits and describes their data. 
A commonly used method to determine the 'best fit" model for the description of in vitro release 
data is the coefficient of determination, R2 [ 189]. The value of R2 tends to increase as the number 
of model parameters increases, posing a problem of inconsistency in selecting the "best fit" 
model [ 189). The use of an adjusted coefficient of determination (R~djusted ) is regarded as more 
meaningful when comparing fitting models with different numbers of parameters to experimental 
data [189]. The adjusted coefficient of correlation is calculated using Equation 5.11 [189]: 
2 - (n-1) ( 2) 
Radjusted - 1 - (n-p) 1 - R 
Where, 
n =number of dissolution data points 
p = number of parameters in the model 
R 2 = coefficient of determination 
Equation 5.11 
Several other methods may be used to assess the suitability of a mathematical model to fit 
experimental data. These methods include using the sum of squares of residuals (SSR), the mean 
square error (MSE), the Alaike's Information Criterion (AIC) and the F-ratio probability [189]. 
As only one parameter for all mathematical models used i.e. time (t) was manipulated in the 
dissolution studies, the coefficient of determination, R2 was adequate for determining the model 
that best fitted minocycline dissolution profiles generated from formulations manufactured in 
these studies . Values of R2 greater than 0.950 were considered acceptable for the comparisons 
investigated and higher values of R2 indicated that the mathematical model used fitted the data 
better. 
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5.7 MATHEMATICAL TREATMENT OF IN VITRO RELEASE DATA 
The pnmary objective of these studies was to manufacture formulations that released 
approximately 80% of minocycline at a constant rate over a 12 hour period. In order to elucidate 
if manufactured dosage forms followed this pattern of release, the difference and similarity 
factors [193] were used to compare all dissolution profiles of minocycline for all prepared 
formulations to the reference profile described in Section 4.3.1. Formulations with dissolution 
profiles similar to the reference profile based on the difference and similarity factors were further 
analysed using one way analysis of variance to elucidate the specific points at which differences 
and similarities occurred in the dissolution profile. Furthermore formulations MIN0-06, MIN0-
11 and MIN0-17 with dissolution profiles which appeared visually, to be similar to the target 
dissolution profile, were analysed using the one way analysis of variance method to determine if 
the profiles were indeed similar to the reference profile. 
All in vitro dissolution profiles obtained in Section 4.4 were modelled by the Korsmeyer-Peppas 
model which was used as the primary mathematical model to investigate the effect of formulation 
variables i.e. polymer concentration, diluent type, addition of disintegrant and surfactant on the 
mechanism(s) of minocycline release. The zero order and the Higuchi model were also used to 
establish which model best described drug release from these formulations. 
5.8 RESULTS AND DISCUSSION 
5.8.1 Difference and similarity factors 
The in vitro release profiles for minocycline obtained in the dissolution studies in Section 4.4 
were compared to a target dissolution profile described in Section 4.3.1 using the difference (f1 ) 
and similarity (f2 ) factors. The results showed that only three of the formulations were similar to 
that of the target profile and the results are summarised in Table 5.3. 
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Table 5.3. Difference and similarity factors values for minocyclinc batches using the target profile 
(Section 4.3.1) as a reference 
Batch# Fit Factors 
I 
MIN0-01 125 21.7 
MIN0-02 11 71.5 
MIN0-03 15 59.5 
MIN0-04 41.6 39.2 
MIN0-05 * * 
MIN0-06 52.5 42.0 
MIN0-07 30.2 44.1 
MIN0-08 * * 
MIN0-09 169.8 17.2 
MIN0-10 * * 
MIN0-11 83.1 24.2 
MIN0- 12 55.9 33.7 
MIN0-13 24.1 54.7 
MIN0-14 9.8 76.2 
MIN0-15 113.3 22.5 
MIN0-16 31.8 52.5 
MIN0-17 52.7 41.1 
MIN0-18 * * 
MIN0-19 * * 
MIN0-20 * * 
MIN0-21 30.5 45.6 
MIN0-22 32.3 51.7 
* The difference and similarity factors were not applicable as the amount of minocycline released was 
greater than 80% before the second sampling point 
The target minimum amount of minocycline to be released from the manufactured dosage forms 
was set at 80% within or at 12 hours. Visual analysis of the dissolution profiles of MIN0-06, 
MIN0-11 and MIN0-17, indicated that the amount of minocycline released from these 
formulations was greater than 80% at 12 hours. Furthermore, a significant portion of each of the 
dissolution profiles appeared to follow zero order kinetics resulting in the selection of these 
dosage forms for further dissolution testing under the USP "two-stage" test for the assessment of 
delayed-release formulations. However, the importance of using statistical methods for the 
comparison of dissolution profiles was emphasised when the difference and similarity factors 
indicated that MIN0-06, MIN0-11 and MIN0-17 were in fact different to the target release 
profile. MIN0-02, MIN0-03 and MIN0-14 which were not selected for further dissolution 
studies as the release of minocycline from these formulations was less than the required minimum 
of 80% in 12 hours were the only profiles that were regarded similar to the target profile when 
using the similarity and difference factors. Whilst MIN0-06, MIN0-11 and MIN0-17 were 
selected for further dissolution testing as they released more than 80% of rninocycline, the 
similarity and difference factors considered only the closeness of minocycline release from 
MIN0-02, MIN0-03 and MIN0-14 to 80% regardless of whether this was above or below 80%. 
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Furthermore, the value of the similarity and difference factors is influenced by the actual pattern 
of drug release. It is therefore of utmost importance that a formulation scientist understands the 
factors that influence the results generated using different statistical methods of analysis, in 
particular the extent and pattern of release. The selection of an appropriate reference profile is 
vital, as it should allow the formulation scientist to generate reliable results relating to the desired 
pattern and extent of release from test formulations. 
5.8.2 Analysis of variance 
Although the interpretation of the similarity and difference factors is easier than other analyses as 
these factors are a single value that describes the similarity or difference between any two 
profiles, ANOV A-based methods may be more informative in formulation development studies 
in order to match a reference product as closely as possible since they show the exact point(s) of 
difference between two formulations [ 187]. 
The one way analysis of variance results for dissolution profiles of minocycline obtained for 
MIN0-02, MIN0-03 and MIN0-12 and MIN0-06, MIN0-11 and MIN0-17 in Section 4.4 were 
tested against the target profile and are summarised in Table 5.4 and 5.5, respectively. 
One of the challenges of ANOV A-based methods is the overall conclusions of similarity or 
difference between any two profiles when the difference is significant at some but not all 
dissolution points. As observed in Table 5.4, the difference between the target profile and MIN0-
02 is significant at three of the six sampling points, whereas the difference between the target 
profile and MIN0-03 is significant at only two of the six sampling points. The differences 
between the target profile and MIN0-14 is significant at four out of six sampling points. Based 
on these observations it is clear that formulations that are similar (based on the similarity and 
difference factors) may in reality be different when using ANOVA-based methods for data 
analysis. Such scenarios highlight the need for regulatory bodies to stipulate which methods take 
precedence over others. These results indicate the over-discriminatory power of ANOVA-based 
methods which may explain their lack of suitability for data analysis in the pharmaceutical 
sciences [190]. 
Using ANOV A analysis to compare MlN0-06, MIN0-11 and MIN0-17 to the target profile, it 
can be clearly observed that the release of minocycline from these formulations was significantly 
119 
Chapter 5, Mathematical modeling and comparison of in vitro dissolution profiles 
different from that of the target profile as significant differences in minocycline release were 
observed at all but one dissolution time point for MIN0-11. 
120 
"-'''"-' }Jf'-1 -'t •r.-L.-rt.ti~H f "-'1'·._ ... , .. IIIV'-A "-" 1.•"6 WIHA \JV II IJ-'"" HIVII VJ 1·11 V III V &AhJUV'-t.-l i.IVII J-'1 Vj l l-f;.o) 
Table 5.4. Summary of ANOVA analysis for in vitro release profiles of MIN0-02, MIN0-03 and MIN0-14 versus the reference profile 
Time (hours) Comparison Mean difference 95% Confidence interval to mean difference P value Summary 
MIN0-02 3.097 -2.302 0.2810 p > 0.05 Not signifi cant 
MIN0-03 2.707 -2.175 0.4081 p > 0.05 Not significant 
MIN0-14 5.758 0.5873 3.1 71 p < 0.01 Significant 
2 MIN0-02 5.740 -4.540 -0.8341 p < 0.01 Significant 
MIN0-03 2.764 -3. 147 0.5590 p > 0.05 Not significant 
MIN0 -14 2.137 -2.853 0.8527 p > 0.05 Not significant 
4 MIN0-02 4.491 -4. 117 -0.2597 p < 0.05 Significant 
MTN0-03 2.040 -0.9344 2.923 p > 0.05 Not significant 
MIN0-14 10.28 -6.938 -3.080 p < 0.001 Significant 
6 MIN0-02 2.80 1 -8.403 1.439 p > 0.05 Not significant 
MIN0-03 3.738 -0.2730 9.568 p > 0.05 Not significant 
MIN0- 14 8.400 - 15.36 -5.522 p < 0.001 Significant 
8 MTN0-02 2.092 -10. 19 3.143 p > 0.05 Not significant 
MIN0-03 4.790 L.402 14.74 p < 0.05 Significant 
MIN0-14 5.513 -15.96 -2.619 P < O.OI Significant 
12 MIN0-02 4.598 1.216 16.25 p < 0.05 Significant 
MIN0-03 8.853 9.295 24.33 p < 0.00 1 Significant 
MIN0-14 2.687 -2.412 12.62 p > 0.05 Not significant 
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Table 5.5. Summary of ANOV A analysis for in vitro release profiles of MIN0-06, MIN0-11, MIN0-17 versus the target release profile 
Time (hours) Comparison Mean difference 95% Confidence interval to mean difference P value Summary 
Lower limit Upper limit 
1 MIN0-06 15.83 -12.32 -7.390 p < 0.001 Significant 
MIN0-11 0.06097 -2.426 2.502 p > 0.05 Not significant 
MIN0-17 17.13 -1 3. 12 -8.197 p < 0.001 Significant 
2 MIN0-06 17.26 -24.09 -15.10 P < O.OI Significant 
MIN0-1 I 5.756 -11.03 -2.042 p < 0.001 Significant 
MIN0-17 18.62 -25.64 -16.65 p < 0.001 SignHicant 
4 MIN0-06 11.76 -38.92 -19.32 p < 0.001 Significant 
MJN0 - 11 8.067 -29.78 -10. 17 p < 0.001 Significant 
MJN0-17 12.54 -40.85 -21.25 p < 0.001 Significant 
6 MIN0-06 10.98 -39.61 -18.61 p < 0.001 Significant 
MIN0-11 11.15 -40.08 -19.08 p < 0.001 Significant 
MIN0-17 12.14 -42.70 -21.70 p < 0.001 Significant 
8 MlN0-06 12.54 -34.54 -17.97 p < 0.00 1 Significant 
MIN0-11 16.26 -42.33 -25.75 p < 0.001 Significant 
MIN0-17 13.57 -36.71 -20.13 p < 0.001 Significant 
12 MIN0-06 11.78 -1 5.09 -7.498 p < 0.001 Significant 
MIN0- 11 16.69 -19.79 -1 2.21 p < 0.001 Significant 
MIN0-17 7.554 - I 1.03 -3.447 p < 0.001 Significant 
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5.8.3 Application of Korsmeyer-Peppas model 
Several drug delivery devices in which HPMC has been used exhibit different mechanisms that 
control API release including polymer swelling and subsequent erosion, drug dissolution, drug 
diffusion or a combination of these [82]. Important factors that influence drug release from 
hydrophilic polymer matrices such as HPMC include the water solubility of the drug dispersed in 
the dosage form [123,161,161,215,216] and/or drug loading in the system [215). The release of 
water soluble drugs from hydrophilic matrices is predominantly a consequence of the dissolution 
of the drug in the aqueous medium that penetrates the matrix and the subsequent diffusion of the 
drug from the matrix system [38]. In contrast the release of poorly water soluble compounds 
occurs predominantly as a result of the erosion of the matrix [217). Formulation variables such as 
the shape of the matrix device [123) and the addition of diluents such as lactose may alter the 
penetration rate of water into the matrix system and therefore may influence the mechanism of 
drug release from these hydrophilic matrix systems [123, 161]. 
Although several mathematical models have been used to describe the release mechanisms of 
drugs from hydrophilic matrices, the most frequently used methods have been the Higuchi 
[204,205] model and the Korsmeyer-Peppas [207] model [82,161,215,216,218]. 
Several mechanisms of drug release from lipid matrices may be observed and are dependent on 
the HLB value and composition of the lipid [219,220]. As with hydrophilic matrices, drug release 
from lipid matrices may be due to drug diffusion across the matrix into the dissolution medium, 
or following erosion of the matrix or as a result of the combination of both mechanisms 
[219,220]. Drug release from Gelucire® bases with low HLB values occurs as a result of a simple 
diffusion mechanism whilst drug release from Gelucire® bases with high HLB values occurs 
predominantly as a result of lipid erosion [219,221). The mechanisms of drug release from lipid 
matrices may also be influenced by formulation variables such as the concentration of lipid used 
in the matrix or by the addition of hydrophilic additives [220). In addition, drug release from lipid 
matrices may be affected by the temperature and the pH of the dissolution medium used to 
monitor drug release [220]. 
Several mathematical models such as the first-order and Higuchi models have been applied in 
describing release mechanisms of drugs from lipid matrices [222]. In addition modifications of 
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the Korsmeyer-Peppas and Higuchi models have been used to demonstrate the contribution of 
both diffusion and erosion mechanisms to drug release from lipid matrices [219,221]. 
As the release of drugs from both hydrophilic and lipid matrices is mainly a consequence of 
diffusion of the drugs from, or erosion of matrices or as a result of both mechanisms, the 
Korsmeyer-Peppas model is an ideal model to use to evaluate the effects of formulation variables 
on the release of minocycline from the manufactured dosage forms. The exponent, n, has a value 
of 0.5 when applied to Higuchi ( Vtime ) kinetics or a value of 1.0 for a zero-order kinetic model 
[123). It is therefore possible to identify the predominant mechanism of drug release from the 
matrices judging by how close to 0.5 or 1.0 the release exponent is after modeling experimental 
data. A slab geometry was assumed in these studies for the interpretation of the release exponent. 
In vitro release profiles of minocycline obtained in Section 4.4 for all prepared formulations 
were modelled using the Korsmeyer-Peppas model and are summarised in Table 5.6. 
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Table 5.6. Summary of Korsmeyer-Peppas best-fit parameters 
Batch # Mt N K (%/min) R 
Moo 
MIN0-01 0.6376 0.6864 0.252872 0.9906 
MIN0-02 0.5952 0.9542 0.08213 0.9987 
MIN0-03 0.4793 0.8594 0.081077 0.9987 
MIN0-04 0.4116 0.9656 0.046644 0.9511 
MIN0-05 * * * * 
MIN0-06 0.571161 0.8804 0.173061 0.9944 
MIN0-07 0.497627 0.7562 0.079013 0.9926 
MIN0-08 0.05361 0.6495 0.009849 0.9814 
MIN0-09 * * * * 
MIN0-10 * * * * 
MIN0-11 0.479745 1.3923 0.072377 0.9952 
MIN0-12 0.30044 0.6634 0.056494 0.994 
MIN0-13 0.643351 0.7614 0.104978 0.9834 
MIN0-14 0.524427 1.2869 0.054967 0.9935 
MIN0-15 0.627994 0.9083 0.181009 0.9983 
MIN0-16 0.57197 0.7757 0.14983 0.9888 
MIN0-17 0.590479 0.8707 0.181677 0.9935 
MIN0-18 * * * * 
MIN0-19 * * * * 
MIN0-20 * * * * 
MIN0-21 0.524017 0.9931 0.051487 0.9578 
MIN0-22 0.627029 0.8265 0.146487 0.8265 
* The Korsmeyer-Peppas model was not applicable as the amount ofminocycline released was greater than 
60% before the second sampling point 
5.8.3.1 Effect of HPMC and Comprito~ concentrations on mechanism of drug release 
In order to elucidate the impact of concentration of rate retarding polymers on the mechanism of 
drug release, the change in value of the release exponent, n, was monitored as the concentration 
of the polymer in the formulation changed. A plot of the release exponent versus concentration of 
HPMC and Compritol® in the formulation is depicted in Figure 5.1. 
125 
Chapter 5, Mathematical modeling and comparison of in vitro dissolution profiles 
12~------------------------------------------~ 
0.8 
1 I I 0.61 
~ ~ , ----------------------~ 
0.4 ~ 
I 
02 i 
O +-----~~----~-------r------,-------~-----4 
0 10 20 30 so 60 
Figure 5.1. Effect of polymer concentration on the value of the release exponent 
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The value of n at all concentrations of HPMC used was found to be between 0.5 and 1.0 
incticating that the mechanism of minocycline release was a result of both diffusion and erosion. 
Minocycline release occurred by anomalous transport kinetics at all concentrations of HPMC. 
Similar results indicating the somewhat independence of the release exponent from HPMC 
concentration were observed by Fu et al. when tablets containing water soluble and slightly water 
soluble drugs comparable to minocycline, particularly theophylline were tested [216]. Although 
the overall release kinetics were unchanged over the HPMC concentration range studied the value 
of n increased from a 0.6864 when 10% w/w HPMC was used in the formulation to a value of 
0.9656 when the polymer content was increased to 50% w/w. It is important for a pharmaceutical 
scientist to consider the solubility of the drug, the coherence of the matrix in addition to the 
extent of drug release when interpreting the value of the release exponent n. A value of n of 
0.9656 at 50% w/w HPMC is very close to 1.0 and thus indicates minocycline release follows a 
zero-order kinetic model. Although the release kinetics using 50% w/w HPMC were ideal it is 
important to note that only 41% (versus the targeted minimum of 80%) of minocycline was 
released from these delivery systems. At the other extreme, a value of n of 0.6864 using 10% w/w 
HPMC was an indication that diffusion was the predominant mechanism controlling release. At a 
concentration of 10% w/w HPMC, a gel layer formed by HPMC is not as coherent as when 
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higher concentration of HPMC are used and tbis layer is more likely to erode than at the higher 
HPMC concentrations. Consequently erosion is likely to be the more dominant mechanism of 
release. However, minocycline hydrochloride is readily soluble in water and can diffuse through 
channels of the matrix into the dissolution medium at a faster rate than matrix can erode. As a 
result the overall dominant mechanism of release observed when this concentration of polymer 
was used is diffusion as is clearly indicated by the value of n. 
Similarly the overall mechanism of minocycline release from the lipid matrices at the 
concentrations of Compritol® studied was found to be independent of the concentration of 
Compritol® used in the formulation. Minocycline release occurred as a result of both diffusion 
and erosion mechanisms. It was observed as is clearly depicted in Figure 5.1 that the value of n 
decreased as the concentration of Compritol® used in the matrix increased with the lowest value 
of n (0.6495) observed when a Compritol® concentration of 50% w/w was used in the 
formulation. As the concentration of Compritol® used in the formulation increases, diffusion 
became the more dominant mechanism of drug release. Similar results were observed by Kopcha 
et al. [220]. As a higher concentration of Gelucire® with a low HLB value was added to the lipid 
matrix drug release using anhydrous theophylline and D&C Yellow No.10 as model drugs, was 
observed to be predominantly diffusion controlled (220]. Furthermore drug release from more 
hydrophobic lipids ~as been observed to be controlled predominantly by diffusion [219,221]. As 
the concentration of Compritol® used in these studies increased ~be formulation became more 
hydrophobic resulting in minocycline release becoming predominantly diffusion controlled. 
The impact of concentration of the polymer used on the rate of release was evaluated by 
monitoring the change in the kinetic constant, k, as the concentration of polymer changed. Plots 
of the kinetic constant versus concentration of HPMC and Compritol® in the formulations are 
depicted in Figure 5.2. 
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Figure 5.2. Effect of polymer concentration on the kinetic constant 
The kinetic constant k was observed to decrease as the concentration of HPMC used in the 
formulation increased although this observation was less significant between polymer 
concentrations of 20% w/w and 30% w/w. A correlation between the release constant and the 
rate and extent of minocycline released was observed. When lower kinetic constants were 
generated correspondingly lower rates and extents of minocycline release were observed. Ku et 
al. [216] observed similar results in their investigation of the release of water soluble and slightly 
water soluble drugs from HPMC matrices. 
As the concentration of Compritol® used in the formulation increased, the value of k decreased in 
an almost linear manner as can be seen in Figure 5.2. It is interesting to note that there is a clearly 
defined relationship between the concentration of Compritol® used and the value of k and n in 
addition to the rate and extent of minocycline release. The values for of k and n in addition to the 
rate and extent of minocycline release decrease as the concentration of Compritol® used in the 
formulation increases. 
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5.8.3.2 Effect of diluent type on mechanism of drug release 
To investigate the influence of diluent type on the mechanism of minocycline release from the 
test formulations, microcrystalline cellulose (MCC) and lactose representing a slightly soluble 
and a freely soluble diluent, respectively, were studied. A plot of n versus the diluent used is 
depicted in Figure 5.3. 
15 ~---------------------------------------
1 
i 
c 
0 ADoamlaos i 
• 
tnDipalt 
I 
-; 
~ 
05 FicDan 
-+-HPMC 
0 
j MCC 
--Campritol 
Figure 5.3. Effect of diluent type on release exponent 
As can be seen in Figure 5.3, the mechanism of minocycline release from HPMC matrices was 
affected by the type of diluent used in the test formulations. When MCC was used as a diluent, 
the mechanism of release of minocycline from the matrix was readily described by an anomalous 
transport mechanism with both erosion and diffusion playing an integral part in the release of 
minocycline. However, when lactose was used as the diluent, the release of minocycline from test 
formulations could be easily explained by Super Case II transport mechanisms. Super Case II 
diffusion mechanisms, in most cases display a phenomenon in which the concentration fronts are 
sharp with a flux into the phase change boundary less than the flux out of the phase change 
boundary [223]. Similar Super Case II release mechanisms have been observed for the release of 
theopylline from alginate capsule formulations [224] and for the release of diclofenac sodium 
from natural gum capsule formulations [225]. This change in release mechanism from the HPMC 
matrices was associated with an increase in the rate of release of minocycline when lactose was 
used as a diluent than when MCC was used as a diluent. 
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Unlike the effect of diluent type on minocycline release mechanisms from the HPMC matrices, 
there was no change in the release mechanism from Compritol® matrices. The release of 
minocycline from HPMC matrices followed anomalous transport mechanisms when either of the 
two diluents, MCC or lactose was used in the formulations. However, when lactose was used as 
the diluent in the Compritol® based formulations, minocycline release occurred primarily as a 
result of diffusion rather than erosion. The diffusional release was associated with a lower extent 
of minocycline release after the 12 hour dissolution period, with a release of approximately 30% 
observed versus 49% when MCC was used as the diluent. As mentioned is Section 4.4.3, this 
may be explained by the more dominant "water-drawing" effect of MCC than the "channel-
creating" effect of lactose in the Compritol~~> matrices. When MCC was used as a diluent the 
release of minocycline was predominantly controlled by erosion due to the greater uptake of 
water by the formulation that increased the dispersibility and hence deformation of the matrix. 
5.8.3.3 Effect of addition of disintegrant on mechanism of drug release 
The effect of disintegrant addition on the mechanism of minocycline release from the 
manufactured formulations was investigated by studying the release of minocycline from 
formulations with and without sodium starch glycolate. A plot of the release exponent versus the 
amount of sodium starch glycolate added to the HPMC matrix based formulations is shown in 
Figure 5.4. 
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Figure 5.4. Effect of disintegrant on release exponent for HPMC matrix formulations 
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The addition of disintegrant to HPMC matrices using either MCC or lactose as a diluent had no 
significant effect on the mechanism of release of minocycline in both instances. When MCC was 
used as a diluent the release of minocycline was controlled by anomalous transport kinetics with 
or without the addition of disintegrant whereas the release of minocycline from formulations 
incorporating lactose as the diluent were better described by Super Case II kinetics with or 
without the addition of disintegrant. In both cases the inclusion of disintegrant, with MCC or 
lactose resulted in a decrease in the release exponent from 0.9542 to 0.7614 for MCC and from 
1.3923 to 1.2869 for lactose formulations. This decrease in the value of the release exponent was 
associated with a decrease in the extent of minocycline release after a twelve hour dissolution 
period indicating that erosion contributed to faster drug release when MCC was used as the 
diluent. The addition of disintegrant when MCC was used as the diluent resulted in an immediate 
and increased water uptake by the formulation which may have caused the formation of a 
coherent HPMC gel layer more rapidly, as discussed in Section 4.4.4. 1, thereby decreasing the 
contribution of erosion to minocycline release from the test formulations and making diffusion 
more dominant. The faster formation of a coherent HPMC gel layer with the addition of 
disintegrant to test f01mulations with lactose may have contributed to the decrease in the value of 
the release exponent observed. 
A plot of the release exponent versus the amount of sodium starch glycolate added to Compritol® 
based formulations is shown in Figure 5.5. 
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Figure 5.5. Effect of disintegrant on release exponent for Compritol® matrix formulations 
As was observed for the HPMC matrix based formulations the addition of disintegrant had no 
effect on the general mechanism of minocycline release from Compritol~ based formulations. 
The release of minocycline with or without the addition of disintegrant, using MCC or lactose 
occured via anomalous transport mechanisms. However, the addition of disintegrant to the 
Compritol® based formulations had an effect opposite to that observed in the HPMC based 
formulations in terms of the change in value for the release exponent. When either MCC or 
lactose was used the value of the release exponent increased with the addition of disintegrant. In 
both instances the release of minocycline from the formulations was controlled by erosion, 
approaching zero-order release, particularly for the formulations with lactose as the diluent. As 
discussed in Section 4.4.1 , the addition of disintegrant increased the water uptake into the 
formulation which may have resulted in a higher dispersibility/erosion of the Compritol® matrix. 
It was observed during dissolution studies that the Compritol'ts. matrix maintained its integrity i.e. 
a shape similar to that of the capsule shell was retained throughout the twelve hour duration of the 
dissolution test. The integrity of the matrix was not observed when disintegrant was added to the 
formulations. The resultant increase in the value of the release exponent corresponding to the 
predominance of erosion of the mechanism of release was associated with a higher extent of 
minocycline release. The addition of disintegrant resulted in an increase in release from 49% -
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91% for formulations containing MCC and from 30% - 79% for formulations containing lactose. 
From these observations, it may be concluded that erosion resulted in a higher release of water 
soluble drugs at a more constant rate from lipid matrices. 
5. 8.3. 4 Effect of addition of surfactant on mechanism of drug release 
The effect of surfactant on the mechanism of release of minocycline from lipid matrices was 
investigated by comparing dissolution profiles of formulations with and without Poloxamer 188 
added. A plot of the release exponent versus the concentration of Poloxamer 188 added into the 
formulations is depicted in Figure 5.6. 
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Figure 5.6. Effect of surfactant on the release exponent for Compritol® formulations 
The addition of 0.5% w/w Poloxamer 188 to the Compritol® based formulations had no effect on 
the overall release ofminocycline from the formulations and release was controlled by anomalous 
mechanisms with or without the addition of 0.5% w/w Poloxamer 188 for formulations 
containing lactose or MCC as the diluent. The addition of surfactant to the CompritoliiY based 
formulations had similar effects to the addition of disintegrant to the Compritol® based 
formulations. The addition of surfactant to the test formulations increased the water uptake by the 
formulations. Following the addition ofthe surfactant, the value of the release exponent increased 
from 0.7562 to 0.9931 and from 0.6634 to 0.8265 for formulations with MCC and lactose, 
respectively, indicating the predominance of erosion as the controlling mechanism of drug 
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release. It is particularly interesting to note that Case Il or zero-order kinetics were observed for 
formulation MIN0-21, which had MCC as a diluent and 0.5% w/w Poloxamer 188 with a 
resultant high value of 0.9931 for n . Similar to the effects observed when disintegrant was 
included erosion predominated as the release controlling mechanism and a greater rate and extent 
and rate of release of minocycline was observed, albeit at a constant rate. 
5.8.4 Application of other mathematical models 
As the mechanism of release from the matrix systems tested in these studies occurs by diffusion, 
erosion or a combination of both, it was necessary to further evaluate the release mechanisms 
using other models, viz., Higuchi and a Zero-order model. The results obtained using the Higuchi 
and the zero-order models are summarised in Table 5.7. 
Table 5.7. Summary of mathematical model parameters 
Batch # Zero-order model Higuchi model 
Rz Ko Rz KH 
MIN0-01 0.8384 8.2249 0.9712 32.196 
MIN0-02 0.9831 6.9662 0.9473 24.87 
MIN0-03 0.9938 5.9705 0.9479 21.206 
MIN0-04 0.9398 3.8464 0.9604 14.142 
MIN0-05 0.3412 5.1141 0.6222 25.115 
MIN0-06 0.9101 8.5013 0.982 32.117 
MIN0-07 0.974 4.37 0.9749 15.901 
MIN0-08 0.9761 0.4452 0.9604 1.6061 
MIN0-09 0.6535 8.0174 0.8832 33.896 
MIN0-10 0.294 4.3449 0.5654 21.914 
MIN0-11 0.9363 9.8753 0.9344 35.875 
MIN0-12 0.9737 2.5668 0.9765 9.3488 
MIN0-13 0.9597 5.6954 0.9797 20.928 
MIN0-14 0.9647 7.6335 0.935 27.331 
MIN0-15 0.8364 8.4732 0.9505 32.849 
MIN0-16 0.9276 7.0225 0.9869 26.342 
MIN0-17 0.8715 8.2348 0.9715 31.62 
MIN0-18 0.4027 5.4133 0.692 25.809 
MIN0-19 0.2858 4.8246 0.5623 24.612 
MIN0-20 0.3059 4.7046 0.5753 23.465 
MIN0-21 0.9788 4.7969 0.9532 17.216 
MIN0-22 0.9403 7.9279 0.9797 29.431 
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As shown in Table 5.7, most formulations fitted better to the Higuchi model compared to the 
zero-order model indicating the predominance of diffusion as the overall mechanism of drug 
release from the manufactured formulations. However some formulations i.e. MIN0-02, MIN0-
03, MIN0-11, and MIN0-14 with HPMC as the release retarding polymer and MIN0-08 and 
MIN0-21 with Compritol® as the release retarding polymer were better modelled by the zero-
order model. Minocycline release from these formulations was less than 80% after twelve hours 
of dissolution; hence the portion of the dissolution profile that was mathematically modelled 
would be expected to follow zero order kinetics than Higuchi kinetics, as the drug release plateau 
that deviates from zero order kinetics had most likely not been reached. 
5.9 CONCLUSIONS 
Using statistical, model-independent and model-dependent mathematical models the comparison 
of dissolution profiles and the elucidation of mechanism of minocycline release from the 
manufactured dosage forms was achieved. 
The comparison of dissolution profiles against a target or reference profile was successfully 
performed using the difference and similarity factor approach and a one way analysis of variance. 
When using the difference and similarity factors, three formulations, viz., MIN0-02, MIN0-03 
and MIN0-14 were identified to be similar to the target release profile. On further analysis of 
these formulations using one way analysis of variance, differences were observed at some 
dissolution points indicating the highly discriminative nature of ANOVA based methods. The 
importance of setting limits and selecting methods for comparing dissolution profiles cannot be 
overlooked as different methods may result in different conclusions being drawn. 
The Korsmeyer-Peppas model was successfully used to elucidate the mechanisms involved in the 
release of minocycline from the test formulations. The release mechanism for most formulations 
was a combination of erosion and diffusion. The contribution of diffusion and erosion to the 
release of minocycline was influenced by the type of diluent used and the addition of disintegrant 
or surfactant to the formulations. Super Case IT transport mechanisms were observed when 
lactose was used as the diluent for HPMC matrix based formulations. In all cases it was noted 
that as the value of the release exponent increased, an associated higher overall rate and extent of 
minocycline release was observed. 
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By means of application of the Higuchi and the zero-order models to investigate mechanisms of 
release, it was noted that diffusion was the more dominant controlling mechanism than erosion 
for the release of minocycline from the manufactured test formulations. 
The formulations that displayed similar release profiles to that of the target profile viz. MIN0-02, 
MIN0-03 and MIN0-14, were all based on hydrophilic matrices. This may be an indication of 
the relative ease with which drug release from hydrophilic matrices can be manipulated compared 
to lipid matrices. 
Based on the information obtained, the insight gained from mathematical and statistical modeling 
in formulation development cannot be undermined. Mathematical modeling forms a crucial 
component in formulation development particularly when an appropriate reference product is 
available. It is however vital that the formulation scientist has an understanding of the 
assumptions of each model as well as its limitations to ensure that information gained is 
bene~cial in the formulation process. 
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6 CONCLUSIONS 
Minocycline is a tetracycline antibiotic that is indicated for the treatment of a broad range of 
systemic infections. The broad spectrum of activity of minocycline can, in part, be attributed to 
the physicochemical properties of the compound, in particular its lipophilicity at physiological 
pH. The use of minocycline has been associated with vestibular side effects that are likely to 
reduce adherence to treatment by patients. Sustained release formulations of minocycline that 
ensure slower dissolution of the API, once administered, may be beneficial in improving 
adherence to minocycline therapy by a patient. 
A sensitive, selective and accurate HPLC method for the analysis of minocycline in 
pharmaceutical dosage forms was developed and validated following ICH guidelines. The 
method was linear over the range 5 - 140 flg/ml. Furthermore the method was accurate and 
precise with % Bias and % RSD values of less that 5% for accuracy, intra-day and inter-day 
precision, which was within the limits set in our laboratory. In addition, the method was stability 
indicating as chromatographic analysis of minocycline samples exposed to stress conditions of 
extreme pH, temperature, light and exposure to a 3% v/v solution of hydrogen peroxide, revealed 
appropriate resolution ofminocycline from degradant peaks. 
Sustained release capsule formulations of minocycline were manufactured using hydroxypropyl 
methylcellulose (HPMC) and Compritol® as rate retarding polymers. Following initial studies, the 
use of hydroxypropyl cellulose (HPC) and Precirol® was discontinued as HPC and Precirol® 
containing formulations failed to exhibit extended release profiles for minocycline even when 
used at concentrations as high as 50% w/w. Hydrophilic and lipophilic powder fill materials for 
formulati?ns were manufactured using the geometric dilution method for powder mixing. 
To investigate the effect of polymer concentration on the rate and extent of minocycline release 
the composition ofHPMC and Compritol® in fill formulations was varied within the range of 10-
50 % w/w. Furthermore the use of other excipients was also investigated to optimise the release 
of minocycline from the capsule formulations that bad been manufactured. These studies were 
conducted to establish the impact of diluent and disintegrant on formulation performance. 
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Furthermore the impact of incorporating different concentrations of Poloxamer 188 on 
Compritol® based formulation performance, was also investigated. 
Uniformity of mass and capsule shell disintegration tests were conducted on all formulations and 
the results confirm that the dosage forms complied with BP specifications. In addition, the 
analysis of hydrophilic and lipop~ilic capsule fill material was conducted and all dosage forms 
were found to contain 95.2 - 105.5% of the stated 108 mg of minocycline hydrochloride, 
equivalent to 100 mg minocycline base. 
In vitro dissolution testing was performed on all capsules using USP Apparatus I with water as 
the dissolution medium. The dissolution method was used to differentiate the dissolution rate 
profiles of experimental minocycline formulations tested. The rate and extent of rninocycline 
release was influenced by the concentration of polymer used in the formulations with faster rates 
and greater extents of drug release being observed when low concentrations of polymer were 
incorporated into formulations . Formulation MIN0-02 in which 20% w/w HPMC and MIN0-07 
in which 20% w/w Compritol® were used, released approximately 75.3% and 49.8% 
minocycline after twelve hours, respectively. These formulations were also used to investigate the 
effects of other excipients on the performance of formulations in order to further optimise 
minocycline release from these dosage forms. 
Microcrystalline cellulose (MCC) and lactose were evaluated as potential diluents during further 
formulation optimisation studies. For HPMC based formulations minocycline release was faster 
when lactose (Batch MIN0-11) as opposed to MCC (Batch MIN0-02) was used as the diluent. 
Less than 80% minocycline release was observed from Batch MIN0-02 whereas almost 100% 
release was observed for Batch MIN0- 11 after twelve hours. This difference was attributed to the 
hydrophilic nature of lactose which promoted the uptake of water by the formulation resulting in 
faster dissolution and subsequent diffusion of rninocycline through the polymeric matrix. In 
contrast for Compritol® based formulations faster release of minocycline was observed when 
MCC (Batch MIN0-07) as opposed to lactose (Batch MIN0-12) was used as the diluent. Whilst 
approximately 50% minocycline was released from Batch MIN0-07 only 30% was released from 
Batch MIN0-12. The greater extent of release of minocycline from Batch MIN0-07 was 
attributed to the significant ability ofMCC, due to its hygroscopicity, to draw water into the lipid 
matrix thereby enhancing the dissolution of the API with a consequent faster diffusion of 
minocycline through the matrix. 
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The inclusion of sodium starch glycolate to formulations in which HPMC was used, resulted in 
slower release of minocycline, whereas for Compritol® based formulations faster release of 
minocycline from the formulations was observed. The resultant slower release of minocycline 
from HPMC based formulations was attributed to a higher initial uptake of water by the 
formulation, which resulted in the early formation of a more coherent HPMC gel layer that 
impedes minocycline release more effectively. Formulations in which Compritol1J) was used do 
not include polymers that form gels on contact with water. Consequently an increased uptake of 
water may enhance dissolution and subsequent diffusion of minocycline through the matrix and 
hence faster release is observed. 
The addition of Poloxamer 188 at concentrations of 0.5 and 1% w/w to Compritol® based 
formulations was investigated. An increased rate of minocycline release was observed following 
addition of surfactant. This increased release was attributed to the overall increase in the HLB 
value of formulations which would have resulted in greater water uptake thereby promoting 
dissolution and subsequent release, of minocycline. Furthermore the addition of surfactant to the 
formulation may reduce hydrophobic interactions between minocycline and Compritol® thereby 
increasing the rate of minocycline release. 
The effect of combining hydrophilic and lipid polymers was investigated and 10% w/w HPMC 
and 10% w/w Compritol® were included in a formulation (Batch MIN0-17). The dissolution 
results generated indicate that there is no significant advantage in the use of this combination as 
the release pattern of minocycline was similar to that observed for Batch MIN0-0 1, in which 
10% w/w HPMC was used. However, further investigations using different proportions of 
hydrophilic and lipophilic polymers in combination are necessary to allow for adequate 
characterisation of such formulations. 
Three formulations, viz., Batches MIN0-06, MIN0-11 and MIN0-17 released more than 80% 
minocycline after twelve hours and, based on visual analysis, displayed "near zero order" release 
kinetics. Consequently these formulations were subjected to further in vitro dissolution testing 
using the USP test for delayed release dosage forms. The test is comprised of two stages, viz., a 
two hour acid exposure (pH= 1.2) stage followed by a second stage in which the dosage form is 
exposed to buffer (pH=6.8) for the duration of the dissolution test. For Batches MIN0-06 and 
MIN0-17, in which Compritol® was used as the polymer, sustained release of minocycline was 
not observed and 95% was released within four hours of the commencement of dissolution 
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testing. Compritol® is comprised of fatty acid esters that undergo hydrolysis in acid conditions 
rendering Compritol® less lipophilic thereby reducing the capability for sustaining drug release. 
Minocycline release from Batch MIN0-11 occurred at a slower rate than when water was used as 
the dissolution medium most likely as a result of a change in the ionisation state of minocycline, 
which in tum may have altered its solubility and hence its dissolution characteristics. 
The disparity in dissolution results observed when different dissolution media are used raises 
important questions as to which medium is suitable for dissolution testing of experimental dosage 
forms, in general and for modified release delivery systems, in particular. As both the USP and 
BP do not specify dissolution test conditions for modified release dosage forms of minocycline, 
water was selected as the dissolution medium as it is recommended for use for immediate release 
dosage forms of minocycline. In addition water is recommended as a dissolution medium of 
choice for several modified release capsule dosage forms listed in the USP, including phenytoin 
sodium, phenylpropanolamine hydrochloride, pseudoephedrine, diltiazem hydrochloride and 
trihexyphenidyl hydrochloride. As modified release dosage forms will be exposed to different 
conditions in the gastro-intestinal tract (GIT) the use of dissolution media of pH similar to those 
likely to be encountered in the GIT would be more appropriate than water for preliminary 
formulation development studies. Furthermore the use of USP Apparatus 3 should also be 
considered as it may be possible to establish in vitro in vivo correlations (IVIVC) relatively easily 
more so than when using other official dissolution apparatus. Moreover, it is important to 
consider excipient properties when selecting dissolution test apparatus and conditions as several 
excipients are sensitive to pH changes. 
Statistical, model-dependent and model-independent mathematical tests were used to analyse the 
in vitro dissolution profiles generated following testing of minocycline formulations. The 
difference and similarity factors, f 1 and [ 2 , were used for the comparison of all experimental 
formulations to a target or reference profile. Only three formulations, MIN0-02, MIN0-03 and 
MIN0-14 were identified as being similar to the target profile. One way analysis of variance 
(ANOV A) studies indicated that there were several differences, at specific dissolution points, 
between experimental formulations and the reference formulation. Formulations MIN0-06, 
MIN0-11 and MIN0-14 that had been observed to show optimal release patterns following 
visual inspection of dissolution profiles were regarded as different from the target profile when 
tested using the difference and similarity factors and ANOV A analysis. The use of mathematical 
models for comparing dissolution profiles is thus an important step during formulation 
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development studies. However, formulation scientists should have a deep understanding of the 
limitations of such methods and in particular the discriminatory potential and nature of each 
model prior to using them. Furthermore it is important that reference profiles that show the 
required pattern of release in addition to an appropriate extent of drug release are selected for the 
companson. 
Mathematical models were used to elucidate the mechanism(s) of drug release and determine 
whether the use of additional excipients in formulations had an impact on the release mechanism 
for the formulations manufactured in these studies. The Korsmeyer-Peppas model was used as the 
primary model to describe minocycline release from formulations. The Korsmeyer-Peppas release 
exponent, n, indicated that minocycline release occurred as a consequence of diffusion and 
erosion based mechanisms, in most cases. The value of n increased or decreased indicating a 
change in the dominant mechanism of release from a formulation as water uptake by the matrix 
system changed. In addition the uptake of water by matrix formulations was influenced by the 
excipients incorporated in those formulations. 
Despite the fact that only three formulations were regarded as being similar to the target or 
reference profile and that most formulations followed Higuchi type release kinetics as compared 
to zero order kinetics, this study forms a strong basis for further formulation development of 
minocycline sustained release dosage forms. The study has shown the applicability of lipids as 
potential polymers for sustaining the release of minocycline as Compritol® was able to sustain 
release when water was used as the dissolution medium. As sustained release formulations are 
subjected to pH conditions in which lipid esters may be susceptible to hydrolysis, further studies 
that include an investigation into the use of acid-resistant coatings when lipids are included as 
sustained release polymers may be beneficial. Furthermore, it is important to investigate 
manufacturing variables such as for example the use of the fusion method to manufacture 
matrices when lipids are incorporated as sustained release polymers in dosage forms. In addition 
the compression of lipophilic powder material into tablets may well be an important approach for 
the optimization of such formulations. Furthermore a comparison of dissolution methods is 
crucial to determine the most appropriate approach and conditions to evaluate minocycline 
release from sustained release formulations accurately. 
Based on these studies formulations MIN0-02 and MIN0-14 may be considered as appropriate 
starting compositions for minocycline sustained release dosage forms as 75% and 78% 
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minocycline was released from these formulations in twelve hours using water as the dissolution 
medium. Furthermore the release profiles are better fitted to a zero order kinetic model, which is 
an important consideration when formulating sustained release dosage forms. 
The research undertaken has highlighted the importance of selecting the appropriate composition 
and test conditions for the development and assessment of sustained release dosage forms and 
lays the foundation for the further development of a minocycline sustained release formulation 
that may well improve adherence through side-effect minimisation. 
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SAMPLE PRODUCTION RECORDS 
Only a sample of one production record for a hydrophilic matrix based formulation and one of a 
lipophilic based matrix formulation are included. The production records for the other 
formulations manufactured and assessed in these studies are available on request. 
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Formulator 
Product 
Batch # 
Batch size 
Date of Manufacture 
RHODES UNIVERSITY 
FACULTY OF PHARMACY 
BATCH PRODUCTION RECORD 
Tinotenda Sachikonye 
Minocycline hydrochloride Capsules 
MIN0-02 
6g 
20 August 2009 
ORIGINAL AND WORKING FORMULAE 
Name Original Working RM# 
Formula ~mg) Formula (mg~ 
Minocycline 108 2 160 RM000225 
hydrochloride 
Methocel® Kl OOM 60 1 200 RM000062 
Microcrystalline 132 2 640 X061882 
cellulose (MCC) 
EQUIPMENT VERIFICATION 
Description Type Verified By 
Balance Mettler Toledo Model AG 135 --r:=; 
Mortar and pestle 
Sieve 
Porcelain IS 
315 J..Lm IS 
MANUFACTURING PROCEDURE 
Step 
2 
3 
4 
5 
6 
Procedure 
Weigh appropriate amounts ofminocycline 
hydrochloride and actives: 
-Minocycline hydrochloride 
-Methocel® Kl OOM 
-MCC 
Mix powders by geometric dilution method 
of powder mixing using a mortar and pestle 
Pass powder fill material through 315 J..Lm 
sieve 
Weigh empty capsule body and cap ] 
Weigh 300 mg of powder fill material and fill 
into capsule body and cover with cap 
Weigh filled capsule -
Time Done Bl 
C\: D:f TS 
q -_, t> 
'1-S 
~'.1'2- 1 -S 
c~ ·.J.~ \S 
q ·. '11- \..) 
I 0 '. ?:, Gj T S 
SIGNATURE AND INITIAL REFERENCE 
Full Name 
Tinotenda Sachikonye 
Faith Chaib·:a 
Signature Initials 
Dispensed Checked 
Bl By 
1.5 
.ft. 
""""i""Z:") r-c_ 
i,S F'C 
Confirmed By 
CheckedBl 
Date 
0-vf f;./~ 
ZO . 08. ZCC.1=J 
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Formulator 
Product 
Batch# 
Batch size 
Date ofManufacture 
RHODES UNIVERSITY 
FACULTY OF PHARMACY 
BATCH PRODUCTION RECORD 
Tinotenda Sachikonye 
Minocycline hydrochloride 
MIN0-06 
5g 
26 August 2009 
ORIGINAL AND WORKING FORMULAE 
Name Original Working RM# Dispensed Checked By 
Minocycline 
hydrochloride 
Compritol® 
Microcrystalline 
cellulose 
Description 
Balance 
Mortar and pestle 
Sieve 
Formula (mg) Formula (mg) By 
108 2 160 RM000225 ~~ 
50 1 000 RM000201 IS 
92 1 840 X061882 T.S 
EQUIPMENT VERIFICATION 
TYPe Verified By 
Mettler Toledo Model AG 135 
Porcelain 
315 fliD 
MANUFACTURING PROCEDURE 
Fe 
FL. 
FC 
Confirmed By 
Step Procedure Time Done By Checked By 
1 
2 
3 
4 
5 
6 
Weigh appropriate amounts of rninocy_cline 
hydrochloride and actives: 
-Minocycline hydrochloride 
-Compritol® Kl OOM 
-MCC 
Mix powders by geometric dilution method of 
powder mixing using a mortar and pestle 
Pass powder flll material through 315 f!m sieve 
Weigh empty capsule body and cap J 
Weigh 250 mg of powder fill material and fill 
into capsule body and cover with cap 
Weigh filled capsule 
9 ;3. 1., TS 
0\, '-~c\ \S 
(\ '. 't- \ 'T~ 
C\:5~ IS 
C\ ·.51- IS 
I 0•. 4- q \ .S 
SIGNATURE AND INITIAL REFERENCE 
Full Name 
Tinotenda Sachikonye 
Faith Chaibva 
Signature Initials 
R: 
Fe.. 
Fe 
fC_ 
FC 
Fe.-
Date 
?--b I fS I C1 
ZG-Og-09 
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BATCH RECORD SUMMARIES 
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Formulator 
Product 
Batch # 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Methocel® Kl OOM 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-01 
6g 
19 August 2009 
Original Formula 
(m) 
108 
30 
162 
Working Formula 
(m ) 
2 160 
600 
3 240 
Rhodes Batch Number 
RM000225 
RM000062 
X061882 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
300. 27 ± 0.47 
95.79± 0.29 
IN VITRO RELEASE PROFILE AND COMMENTS/OBSERVATIONS 
120 
100 
"ii 
• 
so 
i 60 
.. 
<! r A 40 
"#. 
T' 
20 ,l 
! 
0 
0 2 
r/+· I---
6 8 10 
TUDe (Ills) 
·-I 
- MINO..Ol 
12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Methocel® Kl OOM 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-02 
6g 
20 August 2009 
Original Formula 
(mg) 
108 
60 
132 
Working Formula 
(m 
2 160 
1 200 
2 640 
Rhodes Batch Number 
RM000225 
RM000062 
X061882 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
120 
100 
'i so i! 
~ 60 
"" ~ 40 ~ 
20 
0 
0 2 
299.63 ± 0.89 
95.87 ± 0.61 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
6 
Tm-=(lmo) 
T~ 
l 
s 10 12 
--MIN0-02 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Methocel® Kl OOM 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-03 
6g 
21 August 2009 
Original Formula 
(m ) 
108 
90 
102 
Working Formula 
(m ) 
2 160 
1 800 
2 040 
Rhodes Batch Number 
RM000225 
RM000062 
X061882 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
120 
100 
"'il so I! 
c;: 
..: 60 
.. 
2 
A 4U #. 
20 
_,. 
0 
0 2 
299.33 ± 0.65 
100.44 ± 0.48 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
6 
TIIIIC(lm;) 
I 
• 
• 
• 
10 12 
Fine pale yellow-coloured powder fill 
material 
No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
F ACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-04 
6g 
24 August 2009 
Name Original Formula 
(m) 
Working Formula 
(m ) 
Rhodes Batch Number 
Minocycline hydrochloride 
Methocelil- K1 OOM 
Microcrystalline cellulose 
108 
150 
42 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
299.87 ± 1.089 
96.77± 0.28 
2 160 
3 000 
840 
RM000225 
RM000062 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
~0 -
. I • Fine pale yellow-coloured powder fill 40 material 
"B r No white specs in powder fill I 3o Jy • ~ ./ material indicating homogenous 
.. / J tS 20 
-MIN0-04 mixing of excipients 
"#. r • Satisfactory powder flowability 10 / 
= 
0 -- - -
0 2 4 6 B 10 12 
Tlmc(bn) 
150 
Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-05 
5g 
25 August 2009 
Original Formula 
(m ) 
108 
25 
117 
Working Formula 
(mg) 
2 160 
500 
2 340 
Rhodes Batch Number 
RM000225 
RM000201 
X061882 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
120 
100 
"i 
I so 
~ 
..: 60 
.. 
,s 40 ~ 
20 
0 
0 2 
250.85 ± 0.24 
98.47± 0.50 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
4 6 
TUDe (Ins) 
- MJNO.OS 
10 12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Fonnulator 
Product 
Batch# 
Batch size 
Date ofManufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-06 
5g 
26 August 2009 
Name Original Formula 
(m ) 
Working Formula 
(m ) 
Rhodes Batch Number 
Minocycline hydrochloride 
Compritolq;, 
Microcrystalline cellulose 
108 
50 
92 
Target capsule ILII weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
249.70 ± 0.75 
96.37 ± 0.90 
2 160 
1 000 
1 840 
RM000225 
RM000201 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
• Fine pale yellow-coloured powder fill 100 
---·-
I material 
II 80 
_,. I,- --I No white specs in powder fill ! • 60 1 material indicating homogenous "" lS 41J - MIN0-06 mixing of excipients ~ r' • Satisfactory powder flowability 
20 / ;r 
0 
0 2 
" 
6 I 10 12 
TUDC(IIIs) 
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Formulator 
Product 
Batch # 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-07 
5g 
27 August 2009 
Name Original Formula 
(mg) 
Working Formula 
(mg) 
Rhodes Batch Number 
Minocycline hydrochloride 
Compritol® 
Microcrystalline cellulose 
108 
75 
67 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight(mg) 
Assay(%) 
249.62 ± 0.92 
95.20 ± 0.79 
2 160 
1 500 
1 340 
RM000225 
RM000201 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
110 
• Fine pale yellow-coloured powder fill so 
...- I 
material 
II 40 :r ... • No white specs in powder fill II 
0 ...... materials indicating homogenous llG 30 -I 
... 
2 
-I - MIN0-07 mixing of excipients A 20 ~ 
_I / • Satisfactory powder flowability 
10 1 ' 
0 
0 2 4 6 8 10 12 
TIIDI::{brl} 
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Formulator 
Product 
Batch# 
Batch size 
Date ofManufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Microcrystalline cellulose 
RHODES UNIVERSITY 
F ACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-08 
5g 
28 August 2009 
Original Formula 
(m ) 
108 
125 
17 
Working Formula 
(m) 
2 160 
2 500 
340 
Rhodes Batch Number 
RM000225 
RM000201 
X061882 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
10 
s 
2 
0 
0 2 
250.58 ± 0.49 
104.03 ± 0.87 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
4 6 
TIDIC(Ins) 
8 10 12 
• 
• 
• 
Fine pale yellow-coloured powder fill 
material 
No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-09 
6g 
31 August 2009 
Name Original Formula 
(m ) 
Working Formula 
(m ) 
Rhodes Batch Number 
Minocycline hydrochloride 
Hydroxypropyl cellulose 
Microcrystalline 
108 
150 
42 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
300.17 ± 0.75 
101.19 ± 1.63 
2 160 
3 000 
820 
RM000225 
X054558 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
11 so r . I 
... 
e.: 60 
.1 .. 
~ 40 1/ #. 
·1 20 
0 
0 2 
1/- - - --
• 6 g 10 
TIIIIC(Ius) 
-
- MIN().()9 
12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-10 
5g 
1 September 2009 
Name Original Formula 
m) 
Working Formula 
m) 
Rhodes Batch Number 
Minocycline hydrochloride 
Precirol® 
Microcrystalline cellulose 
108 
125 
17 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.48 ± 0.65 
102.63 ± 1.17 
2 160 
2 500 
340 
RM000225 
RM000200 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
1 so 
~ 60 
.. 
tS 40 
'# 
20 
I -r - - :J;-----'1: - - --- -
I 
0 ----------
0 2 6 
Tmx:(llls) 
10 12 
- MIN0-10 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-11 
6g 
2 September 2009 
Name Original Formula 
(m ) 
Working Formula 
(m ) 
Rhodes Batch Number 
Minocycline hydrochloride 
Methocel® Kl OOM 
Lactose monohydrate 
108 
60 
132 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
299.63 ± 0.97 
105.50 ± 1.11 
2 160 
1 200 
2 640 
RM000225 
RM000062 
RM000013 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
• Fine pale yellow-coloured powder fill 100 
- I 
,.-I - -- material 
0 
i 80 f / • No white specs in powder fill 1) 
material indicating homogenous ~ 60 / .. 
lS 
40 J - MIN0.11 mixing of excipients 
'I! 
• Satisfactory powder flowability 
20 I" 
,. 
0 
0 2 4 6 10 12 
Ttme(lns) 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Lactose monohydrate 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sacbikonye 
Minocycline hydrochloride capsules 
MIN0-12 
5g 
3 September 2009 
Original Formula 
(m ) 
108 
75 
67 
Working Formula 
(m ) 
2 160 
I 500 
I 340 
Rhodes Batch Number 
RM000225 
RM000062 
RM000013 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
0 
0 2 
250.45 ± 0.4I 
101.36 ± 0.55 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
6 
TIDIC{hrs) 
8 
- MIN0-12 
10 12 
• 
• 
• 
Fine pale yellow-coloured powder fill 
material 
No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date ofManufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-13 
6g 
4 September 2009 
Name Original Formula 
(m ) 
Working Formula 
(m) 
Rhodes Batch Number 
Minocycline hydrochloride 
Methocel® Kl OOM 
Sodium starch glycolate 
Microcrystalline cellulose 
108 
60 
6 
126 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
299.77 ± 0.40 
101.27 ± 1.12 
2 160 
1 200 
120 
2 520 
RM000225 
RM000062 
X070074 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
80 
70 
60 
11 i '0 
0 
"' 40 
"" ~ 30 
#. 20 r/ 
' 10 ) 
0 --
0 2 
r 
T /' }-
.--1 
-- ·--·- -
4 6 8 
TIDIC{III¥) 
--
I 
10 12 
- :uiN0-13 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Methocel~~~. K1 OOM 
Sodium starch glycolate 
Lactose monohydrate 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-14 
6g 
7 September 2009 
Original Formula 
(mg) 
108 
60 
6 
126 
Working Formula 
(mg) 
2 160 
I 200 
120 
2 520 
Rhodes Batch Number 
RM000225 
RM000062 
X070074 
RM000013 
Target capsule fill weight: 300 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
100 
110 
i! 
i! 
"il 
0:: 
60 
.. 
tS 40 
"#. 
20 
~ 
. .J 
0 -· 
0 2 
/ 
299.47 ± 0.23 
103.00 ± 0.40 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
6 
Tlllll:(lm;) 
g 
- MIN0-14 
10 12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Sodium starch glycolate 
Microcrystalline cellulose 
RHODES UNIVERSITY 
F ACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-15 
5g 
8 September 2009 
Original Formula 
(m ) 
108 
75 
5 
62 
Working Formula 
(m ) 
2 160 
1 500 
100 
1 240 
Rhodes Batch Number 
RM000225 
RM000201 
X070074 
X061882 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.73 ± 0.28 
100.26 ± 0.62 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
11 so j 
... 60 
¥ 40 
20 
I 
0 - - '- -
0 2 4 
- - :urN0-15 
s 10 12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-16 
5g 
9 September 2009 
Name Original Formula 
(mg) 
Working Formula 
(mg) 
Rhodes Batch Number 
Minocycline hydrochloride 
Compritol® 
Sodium starch glycolate 
Lactose monohydrate 
108 
75 
5 
62 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.15 ± 0.22 
104.65 ± 0.71 
2160 
1 500 
100 
1 240 
RM000225 
RM000201 
X070074 
RM000013 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
100 
so 
-g 
i 60 ~ 
.. 
~ 40 
~ J/ 
20 
,.( I 
' 0 --
0 2 
t.. -
. l 
- I---
;y' 
6 
TUDC(Ius) 
s 
-I 
-
--MIN0-16 
10 12 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Methocel® Kl OOM 
Compritol<b 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-17 
5g 
10 September 2009 
Original Formula 
(m) 
108 
25 
25 
92 
Working Formula 
m) 
2 160 
500 
500 
I 840 
Rhodes Batch Number 
RM000225 
RM000062 
RM000201 
X061882 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
120 
100 
-g 10 i 
~ 60 g 
~ 40 
20 
0 --
0 2 
550.32 ± 0.40 
105.45 ± 1.03 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
r 
•J. 
6 
Tma:(.lmo) 
- - l 
10 12 
-MIN~17 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-18 
5g 
11 September 2009 
Name Original Formula 
(mg) 
Working Formula 
(mg) 
Rhodes Batch Number 
Minocycline hydrochloride 
Compritol® 
Poloxamer 188 
Microcrystalline cellulose 
108 
75 
5 
62 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.08 ± 0.23 
99.97 ± 0.25 
2 160 
1 500 
100 
1 240 
RM000225 
RM000201 
RM000196 
X061882 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
r · = - =---1 - - --= 
"i sa il I ~ 60 r .. 
,5 
40 ~ 
20 
0 -- - - - - -
D 2 s 10 12 
- :MINO-U 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Poloxamer 188 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-19 
Sg 
14 September 2009 
Original Formula 
(mg) 
108 
75 
2.5 
64.5 
Working Formula 
(mg) 
2 160 
1 500 
50 
1 290 
Rhodes Batch Number 
RM000225 
RM000201 
RM000196 
X061882 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.07 ± 0.19 
104.78 ± 0.85 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
1J 
i! 10 
"0 
"' 
60 
2 Q 40 
"$. 
20 
0 
0 
-/ - -- :::-- I -
2 4 6 
Tma:(lml) 
-« - - I 
- - MIN0-19 
s 10 12 
• 
• 
• 
Fine pale yellow-coloured powder fill 
material 
No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
Satisfactory powder flowability 
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Formulator 
Product 
Batch # 
Batch size 
Date of Manufacture 
Formula: 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-20 
5g 
15 September 2009 
Name Original Formula 
(m ) 
Working Formula 
(mg) 
Rhodes Batch Number 
Minocycline hydrochloride 
Compritol® 
Poloxamer 188 
Lactose monohydrate 
108 
75 
2.5 
64.5 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.11 ± 0.32 
102.21 ± 0.78 
2 160 
1 500 
50 
I 290 
RM000225 
RM000201 
RM000196 
RM000013 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
• Fine pale yellow-coloured powder fill 100 
- - material 
11 80 +- ------~ No white specs in powder fill i • 
~ 60 material indicating homogenous 
"" mixing of excipients 8 40 --MIN~20 ~ • Satisfactory powder flowability 
20 
0 -· - - -
0 2 4 6 8 10 12 
TIIIIC{Im) 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol® 
Poloxamer 188 
Microcrystalline cellulose 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Saclllkonye 
Minocycline hydrochloride capsules 
MIN0-21 
5g 
16 September 2009 
Original Formula 
(mg) 
108 
75 
1.25 
65.75 
Working Formula 
(mg) 
2 160 
1 500 
25 
1 315 
Rhodes Batch Number 
RM000225 
RM000201 
RM000196 
X061882 
Target capsule flU weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
60 
so . 
] 40 . 
t: 
~ 30 
... 
t5 20 ~ 
10 . 
0 
0 2 
249.33 ± 0.47 
103.85 ± 1.16 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
6 
T"UDC(bD) 
8 10 12 
- :t.mro-21 
• Fine pale yellow-coloured powder fill 
material 
• No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
• Satisfactory powder flowability 
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Formulator 
Product 
Batch# 
Batch size 
Date of Manufacture 
Formula: 
Name 
Minocycline hydrochloride 
Compritol~ 
Poloxamer 188 
Lactose monohydrate 
RHODES UNIVERSITY 
FACUTLY OF PHARMACY 
BATCH RECORD SUMMARY 
Tinotenda Sachikonye 
Minocycline hydrochloride capsules 
MIN0-22 
Sg 
17 September 2009 
Original Formula 
(mg) 
108 
75 
1.25 
65.75 
Working Formula 
(mg) 
2 160 
1 500 
25 
1 315 
Rhodes Batch Number 
RM000225 
RM000201 
RM000196 
RM000013 
Target capsule fill weight: 250 mg 
Tests performed: 
Weight (mg) 
Assay(%) 
250.25 ± 0.38 
105.08 ± 0.84 
IN VITRO RELEASE AND COMMENTS/OBSERVATIONS 
120 
100 
'B j so 
~ 60 g 
"/( 40 
20 
0 - · -
0 2 4 6 
Tma:(lm;) 
10 12 
• 
• 
• 
Fine pale yellow-coloured powder fill 
material 
No white specs in powder fill 
material indicating homogenous 
mixing of excipients 
Satisfactory powder flowability 
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